

09899322

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssspta1626kas

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

Enter NEWS followed by the item number or name to see news on that.

09899322

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 07:23:20 ON 22 NOV 2002

FILE 'REGISTRY' ENTERED AT 07:23:39 ON 22 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 NOV 2002 HIGHEST RN 474043-36-2
DICTIONARY FILE UPDATES: 20 NOV 2002 HIGHEST RN 474043-36-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See **HELP CROSSOVER** for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END) :end

=> screen 1006

L1 SCREEN CREATED

=>
Uploading C:\Program Files\Stnexp\Queries\09899322.str

L2 STRUCTURE UPLOADED

=> que L2 AND L1

L3 OUE L2 AND L1


09899322

=> d

L3 HAS NO ANSWERS

L1 SCR 1006

L2 STR



Structure attributes must be viewed using STN Express query preparation.

L3 QUE ABB=ON PLU=ON L2 AND L1

=> s l2 full

FULL SEARCH INITIATED 07:24:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3229 TO ITERATE

100.0% PROCESSED 3229 ITERATIONS
SEARCH TIME: 00.00.01

755 ANSWERS

L4 755 SEA SSS FUL L2

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
---------------------	------------------

FULL ESTIMATED COST

140.28 140.49

FILE 'CAPLUS' ENTERED AT 07:24:24 ON 22 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

09899322

FILE COVERS 1907 - 22 Nov 2002 VOL 137 ISS 22
FILE LAST UPDATED: 21 Nov 2002 (20021121/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

```
=> s 14
L5      32 L4

=> s 15 and py<2000
      19717769 PY<2000
L6      28 L5 AND PY<2000


=> d ibib abs hitstr tot
```

)


Kamal Saeed

L6 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1999:6319899 CAPLUS
 DOCUMENT NUMBER: 131:331751
 TITLE: Structure-activity relationships of biphenyl
 tetrazoles as metallo- β -lactamase inhibitors
 AUTHOR(S): Toney, Jeffrey H.; Cleary, Kelly A.; Hammond, Gail
 G.; Yuan, Xiling; May, Walter J.; Hutchins, Steven M.;
 Ashton, Wallace T.; Vanderwall, Diane E.
 CORPORATE SOURCE: Departments of Biochemistry, Merck Research
 Laboratories, Rahway, NJ, 07065-0900, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1999
), 9(18), 2741-2746
 CODEN: BMCLB8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Resistance to carbapenem antibiotics in Gram-neg. bacteria is due, in
 part, to expression of a wide spectrum metallo- β -lactamase, which
 renders the drug inactive. Biphenyl tetrazoles contg.
 3-n-butyl-1-phenylpyrazole-5-carboxylates or the corresponding 5-Et
 esters
 were found to inhibit metallo- β -lactamases as well as renal
 dehydropeptidase I to a lesser extent.
 IT 138717-62-1 138717-63-3 138717-64-3
 138717-65-4 138717-66-5 138717-67-6
 138717-69-8 138717-70-1 138717-71-2
 138733-00-3 138733-01-4 150282-42-1
 150282-43-2 150282-44-3 150282-45-4
 150282-46-5 150282-47-6 152713-35-4
 152713-43-4 152713-44-5 152713-45-6
 152713-46-7 152713-47-8 152713-48-9
 152713-49-0
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);
 USES
 (Uses)
 (structure-activity relationships of biphenyl tetrazoles as
 metallo- β -lactamase inhibitors)
 RN 138717-62-1 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-chlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)


L6 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 138717-63-2 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-phenyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 138717-64-3 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-phenyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 138717-65-4 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-chlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)


L6 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 138717-66-5 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-methylphenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 138717-67-6 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-methylphenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 138717-69-8 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2,6-dichlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)


L6 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 138717-70-1 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-(2-(trifluoromethyl)phenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 138717-71-2 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-(2-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)




RN 138733-00-3 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-nitrophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 138733-01-4 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-nitrophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 150282-42-1 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2,4-dichlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 150282-43-2 CAPLUS


L6 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2,5-dichlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 150282-44-3 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-(2,4,6-trichlorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 150282-45-4 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(3-chlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 150282-46-5 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(4-chlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 150282-47-6 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2,3-dichlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 152713-35-4 CAPLUS


L6 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
 CN 1H-Pyrazole-5-carboxylic acid, 1-[1,1'-biphenyl]-2-yl-3-butyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 152713-43-4 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(3-chlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 152713-44-5 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(4-chlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 152713-45-6 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2,3-dichlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 152713-46-7 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2,4-dichlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 152713-47-8 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2,5-dichlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 152713-48-9 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-1-(2,4,6-trichlorophenyl)- (9CI) (CA INDEX NAME)




RN 152713-49-0 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 1-[1,1'-biphenyl]-2-yl-3-butyl-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L6 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 19951494397 CAPLUS
 DOCUMENT NUMBER: 122:239722
 TITLE: Pyrazolo[1,2-a]pyridazinone derivatives as angiotensin II antagonists
 INVENTOR(S): Koh, Keiko; Taniguchi, Mikio; Kushida, Hiroshi; Morita, Osamu; Yamada, Hiroyoshi; Munegada, Kiyotaka; Kunihara, Mineo; Fujita, Yoshiji
 PATENT ASSIGNEE(S): Upjohn Co., USA
 SOURCE: PCT Int. Appl. 158 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9417069	A1	19940804	WO 1993-US12447	19931230 <<
W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
JP 07002859	A2	19950106	JP 1993-239827	19930927 <<
CA 2151930	AA	19940729	CA 1993-2151930	1993100 <<
AU 9459571	A1	19940815	AU 1994-59571	19931230 <<
EP 681582	A1	19951115	EP 1994-909468	19931230 <<
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08506572	T2	19960716	JP 1993-517014	19931230
PRIORITY APPLN. INFO.:				
OTHER SOURCE(S):	MARPAT 122:239722		WO 1993-US12447	19931230
GI				




AB Novel pyrazole derivs. I [R = H, (un)substituted Ph, (biphenyl)alkyl, etc.; R1 = H, alkyl, aryl, etc.; Z = bond, NH, oxygen, sulfur; P forms fused ring] were disclosed which are useful for preventing or treating hypertension, congestive heart failure, renal failure, glaucoma and hyperuricemia and have high activity, provide rapid onset of action upon

L6 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
 i.v. injection, can be administered orally, have low toxicity, and have a long duration of action. A claimed example compd.,


3-butyl-5,8-dihydro-5,6-ethano-1H-pyrazolo[1,2-a]pyridazin-1-one (II) was prep'd.

IT 162313-72-6 162313-74-89
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

IT 162313-72-6 CAPLUS
 RN 162313-72-6 CAPLUS
 CN 3H-Pyrazol-3-one, 5-butyl-4-[(2'-(1-(triphenylmethyl)-1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 162313-74-8 CAPLUS
 CN 3H-Pyrazol-3-one, 5-butyl-4-chloro-4,5-dihydro-4-[(2'-(1-(triphenylmethyl)-1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]- (9CI) (CA INDEX NAME)




L6 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1995:36731 CAPLUS
 DOCUMENT NUMBER: 122:150872
 TITLE: In vivo receptor occupancy of the angiotensin II receptor by nonpeptide antagonists: relationship to in vitro affinities and in vivo pharmacologic potency
 AUTHOR(S): Beauchamp, Holly T.; Chang, Raymond S. L.; Siegl, Peter K. S.; Gibson, Raymond E.
 CORPORATE SOURCE: Department of Pharmacology and New Lead Pharmacology, Merck Research Laboratories, West Point, PA, USA
 SOURCE: Journal of Pharmacology and Experimental Therapeutics (1995), 272(2), 612-18
 PUBLISHER: Williams & Wilkins
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The affinities of 13 angiotensin II antagonists for the AT1 sub-type detd.
 in vitro with tissue homogenates were shown not to correlate well with in vivo pharmacol. potency. The addn. of human serum albumin to the in vitro assay to mimic in vivo plasma protein interactions reduced the measured affinity by reducing the effective free concns. of antagonists, but the resulting affinities were not predictive of the in vivo effects. Using an in vivo radioligand competition assay, in which receptor occupancy is demonstrated via competitive blockade of the in vivo binding of [¹²⁵I][Sar1,Ile8]angiotensin II to AT1 receptors in rat kidney cortex, we demonstrated that the in vivo pharmacol. potencies reflect receptor occupancy. By comparing the effects of rat plasma and bovine serum albumin on the in vitro affinity of two antagonists, we suggest that the use of plasma would alter free plasma concns. in a manner more consistent with in vivo measures of potencies.
 IT 138733-06-9, L 161274 152713-48-9, L 161276
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (in vivo receptor occupancy of angiotensin II receptor by nonpeptide antagonists: relationship to in vitro affinities and in vivo pharmacol. potency)
 RN 138733-06-9 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-(2,4,6-trichlorophenyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 152713-48-9 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-(2,4,6-trichlorophenyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1995:296274 CAPLUS
 DOCUMENT NUMBER: 122:290769
 TITLE: Synthesis and angiotensin II receptor antagonist activity of C-linked pyrazole derivatives
 AUTHOR(S): Nicolai, Eric; Cure, Gerard; Goyard, Joel; Kirchner, Maud; Teulon, Jean-Marie; Versigny, Annie; Cazes, Michele; Vironne-Odoss, Angela; Caussade, Francois; Clearec, Alix
 CORPORATE SOURCE: CARIBEM, Rueil Malmaison, 92500, Fr.
 SOURCE: Chemical & Pharmaceutical Bulletin (1994), 42(8), 1617-30
 PUBLISHER: CODEN: CPBTAL; ISSN: 0009-2363
 DOCUMENT TYPE: Pharmaceutical Society of Japan
 LANGUAGE: Journal
 GI English




AB The synthesis and pharmacol. activity of new nonpeptide angiotensin II (AT1) receptor antagonists are presented. These 5-O-substituted and 5-C-substituted 3-alkylpyrazole derivs. represent a new series of antagonists and have led to the discovery of compds. with potent oral antihypertensive activity in a renal artery-ligated rat model. In vitro, they displayed a high affinity for rat adrenal AT1 receptors. In vivo structure-activity relationship study has shown the importance of the 4-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl] moiety for oral activity and the crit. role of alkyl substituents at the 1- or 2-position. In the case of oral administration, 5-C derivs. were found to be, on the whole, more potent than 5-O derivs. UP 221-78 (I) displayed antihypertensive activity equiv. to the well known antagonist Losartan at 3 mg/kg p.o. in renal artery-ligated rats, with maximal decreases in mean arterial pressure of 60 and 63 mmHg for Losartan and UP 221-78, resp.
 IT 137645-78-4P 137661-22-4P 137661-80-4P 161463-22-5P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PRP (Preparation); RACT (Reactant or reagent) (synthesis and angiotensin II receptor antagonist activity of C-linked pyrazole derivs.)

RN 137645-78-4 CAPLUS
 CN 1H-Pyrazole-5-methanol, 3-butyl-1-methyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)


L6 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 137861-22-4 CAPLUS
 CN Acetic acid, [(1-methyl-3-propyl-4-[(4-((2-sulfobenzoyl)amino)phenyl)methyl]-1H-pyrazol-5-yl)oxy]-, 1-ethyl ester (9CI) (CA INDEX NAME)




RN 137861-80-4 CAPLUS
 CN 1H-Tetrazole, 5-[(2-((2-sulfobenzoyl)amino)phenyl)methyl]-1-ethyl-1H-pyrazol-4-yl-methyl- (9CI) (CA INDEX NAME)



L6 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)

RN 161463-22-5 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-methyl-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)



IT 137645-50-2P 137645-65-9P 137646-20-9P

137861-03-1P 137861-05-3P 137861-06-4P
137861-07-5P 137861-08-6P 137861-09-7P
137861-15-5P 137861-21-3P 137861-23-5P
137861-27-9P 137861-28-0P 137861-30-4P
137861-31-5P 137861-32-6P 137861-34-8P
137861-35-9P 137861-38-2P 137861-44-0P
137861-45-1P 137861-46-2P 137861-47-3P
137861-48-4P 137861-49-5P 137861-51-9P
137861-52-0P 137861-53-1P 137861-54-2P
137861-55-3P 137861-56-4P 137861-57-5P
137861-58-6P 137861-61-1P 137861-62-2P
137861-63-3P 137861-64-4P 137861-65-5P
137861-66-6P 137861-68-8P 137861-69-9P
137861-70-2P 137861-77-9P 137861-78-0P
137861-79-1P 137861-81-5P 137861-82-6P
137882-25-8P 137882-26-9P 137882-29-2P
138733-08-1P 161463-15-6P 161463-16-7P
161463-17-8P 161463-18-9P 161463-19-0P
161463-20-3P 161463-21-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and angiotensin II receptor antagonist activity of C-linked pyrazole derivs.)

RN 137645-50-2 CAPLUS

CN 1H-Tetrazole, 5-[4'-(3-butyl-5-(methoxymethyl)-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)

Chemical structure: 1H-pyrazole-5-carboxylic acid derivative. It features a pyrazole ring with a methyl group at position 1 and a butyl group at position 3. The 5-position is substituted with a carboxylic acid group (-CH₂OMe) and a (2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl group.

RN 137645-65-9 CAPLUS

CN 1H-Pyrazole-5-methanol,
3-butyl-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]- (9CI) (CA INDEX NAME)

Chemical structure: 1H-pyrazole-5-carboxylic acid derivative. It features a pyrazole ring with a methyl group at position 1 and a butyl group at position 3. The 5-position is substituted with a carboxylic acid group (-CH₂OH) and a (2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl group.

RN 137646-20-9 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-methyl-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]- (9CI) (CA INDEX NAME)

Chemical structure: 1H-pyrazole-5-carboxylic acid derivative. It features a pyrazole ring with a methyl group at position 1 and a butyl group at position 3. The 5-position is substituted with a carboxylic acid group (-CO₂H) and a (2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl group.

RN 137861-03-1 CAPLUS

CN 1H-Tetrazole,
5-[4'-(5-(methoxymethyl)-3-propyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)

Chemical structure: 1H-pyrazole-5-carboxylic acid derivative. It features a pyrazole ring with a methyl group at position 1 and a butyl group at position 3. The 5-position is substituted with a carboxylic acid group (-CH₂OMe) and a (2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl group.

RN 137861-05-3 CAPLUS

CN Piperazine,
1-(2-methoxyphenyl)-4-[(1-methyl-3-propyl-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-1H-pyrazol-5-yl)oxy]acetyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)

RN 137861-06-4 CAPLUS

CN Ethanamine, N,N-dimethyl-2-[(1-methyl-3-propyl-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-1H-pyrazol-5-yl)oxy]- (9CI) (CA INDEX NAME)

Chemical structure: 1H-pyrazole-5-carboxylic acid derivative. It features a pyrazole ring with a methyl group at position 1 and a butyl group at position 3. The 5-position is substituted with a carboxylic acid group (-CH₂CH₂NH₂) and a (2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl group.

RN 137861-07-5 CAPLUS

CN Thiomorpholine, 4-[(3-propyl-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-1H-pyrazol-5-yl)oxy]acetyl]- (9CI) (CA INDEX NAME)

Chemical structure: 1H-pyrazole-5-carboxylic acid derivative. It features a pyrazole ring with a methyl group at position 1 and a butyl group at position 3. The 5-position is substituted with a carboxylic acid group (-CH₂CH₂SC₂H₅) and a (2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl group.

RN 137861-08-6 CAPLUS

CN Carbamic acid, diethyl-,
1-methyl-3-propyl-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-1H-pyrazol-5-yl ester (9CI) (CA INDEX NAME)

Chemical structure: 1H-pyrazole-5-carboxylic acid derivative. It features a pyrazole ring with a methyl group at position 1 and a butyl group at position 3. The 5-position is substituted with a carboxylic acid group (-CH₂CH₂OC₂H₅) and a (2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl group.


PAGE 1-A

PAGE 2-A


Kamal Saeed

09899322

L6 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137861-09-7 CAPLUS
CN Ethanol,
2-[(3-butyl-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)oxy]- (9CI) (CA INDEX NAME)



RN 137861-15-5 CAPLUS
CN Benzenesulfonic acid, 2-[(4-[(3-butyl-5-(2-hydroxyethoxy)-1-methyl-1H-pyrazol-4-yl)methyl]phenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137861-21-3 CAPLUS
CN 1H-Pyrazole-1-acetic acid, 4-[(4-((2-carboxy-3,6-dichlorobenzoyl)amino)phenyl)methyl]-5-(2-ethoxy-2-oxoethoxy)-3-propyl-, .alpha.-ethyl ester, compd. with N-cyclohexylcyclohexanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 137861-20-2
CMF C29 H31 Cl2 N3 O8


L6 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




L6 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 1-A



PAGE 2-A



CM 2
CRN 101-83-7
CMF C12 H23 N




RN 137861-27-9 CAPLUS
CN Benzoic acid, 2-[(4-[(3-butyl-5-hydroxy-1-methyl-1H-pyrazol-4-yl)methyl]phenyl)amino]carbonyl]-3,6-dichloro- (9CI) (CA INDEX NAME)

RN 137861-23-5 CAPLUS
CN 1H-Pyrazole-1-acetic acid, 4-[(4-((2-carboxy-3,6-dichlorobenzoyl)amino)phenyl)methyl]-5-hydroxy-3-propyl-, .alpha.-ethyl ester (9CI) (CA INDEX NAME)


Kamal Saeed

09899322

L6 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137861-28-0 CAPLUS
CN Acetic acid, 1-[1-methyl-3-propyl-4-[(4-[(2-sulfonylbenzoyl)amino]phenyl)methyl]-1H-pyrazol-4-yl]oxy - (9CI) (CA INDEX NAME)




RN 137861-30-4 CAPLUS

L6 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
CN Benzoic acid, 2-[[4-[(5-(2-methoxy-2-oxoethoxy)-3-propyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl]phenyl]amino]carbonyl - (9CI) (CA INDEX NAME)



RN 137861-31-5 CAPLUS
CN Benzoic acid, 3,6-dichloro-2-[[4-[(5-(2-methoxy-2-oxoethoxy)-3-propyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl]phenyl]amino]carbonyl - (9CI) (CA INDEX NAME)


L6 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137861-32-6 CAPLUS
CN Benzoic acid, 3,6-dichloro-2-[[4-[(5-(2-methoxy-2-oxoethoxy)-1-methyl-3-propyl-1H-pyrazol-4-yl)methyl]phenyl]amino]carbonyl - (9CI) (CA INDEX NAME)

L6 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)

CM 1
CRN 137861-33-7
CMF C26 H27 Cl2 N3 O6




CM 2
CRN 101-83-7
CMF C12 H23 N




RN 137861-35-9 CAPLUS
CN Benzoic acid, 2-[[4-[(5-(2-ethoxy-2-oxoethoxy)-1-methyl-3-propyl-1H-pyrazol-4-yl)methyl]phenyl]amino]carbonyl - (9CI) (CA INDEX NAME)

RN 137861-34-8 CAPLUS
CN Benzoic acid, 3,6-dichloro-2-[[4-[(5-(2-ethoxy-2-oxoethoxy)-1-methyl-3-propyl-1H-pyrazol-4-yl)methyl]phenyl]amino]carbonyl -, compd. with N-cyclohexylcyclohexanamine (1:1) - (9CI) (CA INDEX NAME)


Kamal Saeed




RN 137861-38-2 CAPLUS
CN Benzenesulfonic acid, 2-[[4-[(5-(methoxymethyl)-1-methyl-3-propyl-1H-pyrazol-4-yl)methyl]phenyl]amino]carbonyl- (9CI) (CA INDEX NAME)




RN 137861-44-0 CAPLUS
CN Benzenesulfonic acid, 2-[[4-[(5-(2-hydroxyethoxy)-3-propyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl]phenyl]amino]carbonyl- (9CI) (CA INDEX NAME)




RN 137861-45-1 CAPLUS
CN Acetic acid, 1-[1-methyl-3-propyl-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]-1H-pyrazol-5-yl]oxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 137861-46-2 CAPLUS
CN 1H-Pyrazol-5-ol, 1-methyl-3-propyl-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137861-47-3 CAPLUS
CN 1H-Pyrazol-5-ol, 3-butyl-1-methyl-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137861-48-4 CAPLUS
CN 1H-Pyrazol-5-ol, 3-propyl-1-methyl-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 137861-49-5 CAPLUS
CN Ethanol, 2-[(3-butyl-1-methyl-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]-1H-pyrazol-5-yl)oxy]- (9CI) (CA INDEX NAME)




RN 137861-51-9 CAPLUS
CN Carboximic acid, dimethyl-, 3-butyl-1-methyl-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl ester (9CI) (CA INDEX NAME)




RN 137861-52-0 CAPLUS
CN Carbamic acid, dimethyl-, 3-butyl-1-methyl-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]-1H-pyrazol-5-yl ester (9CI) (CA INDEX NAME)




RN 137861-53-1 CAPLUS
CN Acetic acid, [(3-propyl-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 137861-54-2 CAPLUS
 CN Carbamic acid, dimethyl-, 1-methyl-3-propyl-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]-1H-pyrazol-5-yl ester (9CI) (CA INDEX NAME)




RN 137861-55-3 CAPLUS
 CN Ethanol, 2-[(1-methyl-3-propyl-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]-1H-pyrazol-5-yl)oxy]- (9CI) (CA INDEX NAME)




RN 137861-56-4 CAPLUS
 CN Acetic acid, [(3-butyl-1-methyl-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]-1H-pyrazol-5-yl)oxy]ethyl ester (9CI) (CA INDEX NAME)




RN 137861-57-5 CAPLUS
 CN Ethanol, 2-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl oxy- (9CI) (CA INDEX NAME)




RN 137861-58-6 CAPLUS
 CN Benzenesulfonic acid, 2-[[4-[(3-(methoxymethyl)-5-propyl-1H-pyrazol-4-yl)methyl]phenyl]amino]carbonyl- (9CI) (CA INDEX NAME)




RN 137861-61-1 CAPLUS
 CN Morpholine, 4-[(1-methyl-3-propyl-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]-1H-pyrazol-5-yl)oxy]acetyl- (9CI) (CA INDEX NAME)



RN 137861-62-2 CAPLUS
 CN 1H-Pyrazole-5-methanol, 3-propyl-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 137861-63-3 CAPLUS
 CN 1H-Pyrazole-5-methanol, 1-methyl-3-propyl-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137861-64-4 CAPLUS
 CN Piperazine, 1-[(3-butyl-1-methyl-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]-1H-pyrazol-5-yl)oxy]acetyl-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)







RN 137861-65-5 CAPLUS
 CN Thiomorpholine, 4-[[[1-methyl-3-propyl-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-pyrazol-5-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)




L6 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
 RN 137861-66-6 CAPLUS
 CN Morpholine,
 4-[[[3-butyl-1-methyl-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-pyrazol-5-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)




RN 137861-68-8 CAPLUS
 CN 1H-Pyrazol-5-ol, 3-butyl-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 137861-69-9 CAPLUS
 CN Morpholine, 4-[[[3-propyl-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)




RN 137861-70-2 CAPLUS
 CN Piperazine, 1-(2-methoxyphenyl)-4-[[[3-propyl-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)




RN 137861-77-9 CAPLUS
 CN Ethanol,
 2-[[3-(2-methylpropyl)-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 137861-78-0 CAPLUS
 CN Acetic acid,
 [[1-methyl-3-(2-methylpropyl)-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-pyrazol-5-yl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 137861-79-1 CAPLUS
 CN Acetic acid,
 [[3-(2-methylpropyl)-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 137861-81-5 CAPLUS
 CN 1H-Tetrazole, 5-[(5-(methoxymethyl)-1-methyl-3-propyl-1H-pyrazol-4-yl)methyl] [1,1'-biphenyl]-2-yl]- (9CI) (CA INDEX NAME)




RN 137861-82-6 CAPLUS
 CN Benzenesulfonic acid, 2-[[4-[(3-(hydroxymethyl)-5-propyl-1H-pyrazol-4-yl)methyl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 137882-25-8 CAPLUS
 CN Benzoic acid, 2-[[4-[(2-methoxy-2-oxoethoxy)-1-methyl-3-propyl-1H-pyrazol-4-yl)methyl]phenyl]amino]carbonyl]-, compd. with N-cyclohexylcyclohexanamine (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 137882-24-7
 CMF C25 H27 N3 O6




CM 2


CRN 101-83-7
 CMF C12 H23 N




RN 137882-26-9 CAPLUS
 CN Benzoic acid, 2-[[4-[(3-butyl-5-(2-ethoxy-2-oxoethoxy)-1-methyl-1H-pyrazol-4-yl)methyl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 137882-29-2 CAPLUS
 CN Benzenesulfonic acid, 2-[[4-[(5-(hydroxymethyl)-1-methyl-3-propyl-1H-pyrazol-4-yl)methyl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 138733-08-1 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-propyl-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-(2,2,2-trifluoroethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 161463-15-6 CAPLUS
 CN Benzoic acid, 2-[[4-[[3-(carboxymethoxy)-5-propyl-1H-pyrazol-4-yl]methyl]phenyl]amino]carbonyl- (9CI) (CA INDEX NAME)




RN 161463-16-7 CAPLUS
 CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[[5-(2-hydroxyethoxy)-1-methyl-3-propyl-1H-pyrazol-4-yl]methyl]- (9CI) (CA INDEX NAME)




RN 161463-17-8 CAPLUS
 CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[[3-butyl-5-hydroxy-1-methyl-1H-pyrazol-4-yl]methyl]- (9CI) (CA INDEX NAME)




RN 161463-18-9 CAPLUS
 CN Acetic acid, [(3-butyl-4-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 161463-19-0 CAPLUS
 CN Morpholine, 4-[[3-[(1-methyl-3-propyl-4-[[2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1H-pyrazol-5-yl]oxy]-1-oxopropyl]- (CA INDEX NAME)



RN 161463-20-3 CAPLUS
 CN Benzenesulfonic acid, 2-[[4-[[3-(methoxymethyl)-1-methyl-5-propyl-1H-pyrazol-4-yl]methyl]phenyl]amino]carbonyl- (9CI) (CA INDEX NAME)




RN 161463-21-4 CAPLUS
 CN 1H-Tetrazole, 5-[[4-[[3-(methoxymethyl)-1-methyl-5-propyl-1H-pyrazol-4-yl]methyl]1,1'-biphenyl]-2-yl]- (9CI) (CA INDEX NAME)




IT 137860-03-8P 137860-04-9P 137860-10-7P
 137860-20-9P 137860-27-6P 137860-33-4P
 137860-39-0P 137860-40-3P 137860-43-6P
 137860-44-7P 137860-74-3P 137860-78-7P
 137860-98-1P 137860-99-2P 137861-19-9P
 137861-36-0P 137861-37-1P 137882-21-4P
 161463-14-5P 161463-23-6P 161463-24-7P
 161463-25-8P 161463-27-0P 161463-28-1P
 161463-29-2P 161463-30-5P 161463-31-6P
 161463-32-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (synthesis and angiotensin II receptor antagonist activity of C-linked pyrazole deriv.)


RN 137860-03-8 CAPLUS
 CN 1H-Pyrazol-5-ol, 3-butyl-1-methyl-4-((4-nitrophenyl)methyl)- (9CI) (CA INDEX NAME)




RN 137860-04-9 CAPLUS
CN 1H-Pyrazol-5-ol, 1-methyl-4-[(4-nitrophenyl)methyl]-3-propyl- (9CI) (CA INDEX NAME)




RN 137860-10-7 CAPLUS
CN Acetic acid, [(1-methyl-4-[(4-nitrophenyl)methyl]-3-propyl-1H-pyrazol-5-yl)oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 137860-20-9 CAPLUS
CN Ethanol, 2-[(3-butyl-1-methyl-4-[(4-nitrophenyl)methyl]-1H-pyrazol-5-yl)oxy]- (9CI) (CA INDEX NAME)




RN 137860-27-6 CAPLUS
CN Acetic acid, [(4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1-methyl-3-propyl-1H-pyrazol-5-yl)oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 137860-33-4 CAPLUS
CN Carboximide, dimethyl-, 4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1-methyl-3-propyl-1H-pyrazol-5-yl ester (9CI) (CA INDEX NAME)



RN 137860-39-0 CAPLUS
CN 1H-Pyrazole, 3-(methoxymethyl)-4-[(4-nitrophenyl)methyl]-5-propyl- (9CI) (CA INDEX NAME)




RN 137860-40-3 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 4-[(3-(methoxymethyl)-5-propyl-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137860-43-6 CAPLUS
CN 1H-Pyrazole, 3-(methoxymethyl)-1-methyl-4-[(4-nitrophenyl)methyl]-3-propyl- (9CI) (CA INDEX NAME)

09899322

L6 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137860-44-7 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 4'-(5-(methoxymethyl)-1-methyl-3-propyl-1H-pyrazol-4-yl)methyl- (9CI) (CA INDEX NAME)




RN 137860-74-3 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 4'-(5-(methoxymethyl)-3-propyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137860-78-7 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 4'-(5-(hydroxymethyl)-1-methyl-3-propyl-1H-pyrazol-4-yl)methyl- (9CI) (CA INDEX NAME)




RN 137860-98-1 CAPLUS
CN Acetic acid, [(4-(4-aminophenyl)methyl)-1-methyl-3-propyl-1H-pyrazol-5-yl]oxy-, ethyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137860-99-2 CAPLUS
CN Acetic acid, [(4-(4-aminophenyl)methyl)-1-methyl-3-propyl-1H-pyrazol-5-yl]oxy-, methyl ester (9CI) (CA INDEX NAME)




RN 137861-19-9 CAPLUS
CN Ethanol, 2-[(4-(4-aminophenyl)methyl)-3-butyl-1-methyl-1H-pyrazol-5-yl]oxy- (9CI) (CA INDEX NAME)

L6 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137861-36-0 CAPLUS
CN Benzenamine, 4-(5-(methoxymethyl)-1-methyl-3-propyl-1H-pyrazol-4-yl)methyl- (9CI) (CA INDEX NAME)




RN 137861-37-1 CAPLUS
CN Benzenamine, 4-[(3-(methoxymethyl)-5-propyl-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)


Kamal Saeed




RN 137882-21-4 CAPLUS
 CN [1,1'-Biphenyl]-2-carbonitrile, 4'-'-[(5-hydroxy-1-methyl-3-propyl-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 161463-14-5 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-'-[(5-hydroxy-1-methyl-3-propyl-1H-pyrazol-4-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 161463-23-6 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-'-[(5-(2-hydroxyethoxy)-1-methyl-3-propyl-1H-pyrazol-4-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 161463-24-7 CAPLUS
 CN 1H-Pyrazole, 3-((methoxymethyl)-1-methyl-4-[(4-nitrophenyl)methyl]-5-propyl- (9CI) (CA INDEX NAME)




RN 161463-25-8 CAPLUS
 CN 1H-Pyrazole-3-methanol, 1-methyl-4-[(4-nitrophenyl)methyl]-5-propyl- (9CI) (CA INDEX NAME)



RN 161463-27-0 CAPLUS
 CN [1,1'-Biphenyl]-2-carbonitrile, 4'-'-[(3-(methoxymethyl)-1-methyl-5-propyl-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 161463-28-1 CAPLUS
 CN Benzenamine, 4-[(3-(methoxymethyl)-1-methyl-5-propyl-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 161463-29-2 CAPLUS
 CN 1H-Pyrazole, 5-((trimethylenesilyl)-1-methyl-3-propyl-4-[(2'-(4-(trimethylsilyl)-1,3-tetrazadienyl)methyl]-[1,1'-biphenyl]-4-yl)methyl)- (9CI) (CA INDEX NAME)

09899322

L6 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 161463-30-5 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[5-[(acetoxy)methyl]-1-methyl-3-propyl-1H-pyrazol-4-yl]methyl- (9CI) (CA INDEX NAME)




RN 161463-31-6 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1-methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 161463-32-7 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1-methyl-, ethyl ester (9CI) (CA INDEX NAME)




IT 137860-05-0P 137860-06-1P 137860-07-3P
137860-09-4P 137860-28-7P 137860-49-3P
137860-50-5P 161463-13-4P 161463-26-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis and angiotensin II receptor antagonist activity of C-linked pyrazole deriv.)
RN 137860-05-0 CAPLUS
CN 3H-Pyrazol-3-one, 1,2-dihydro-4-[(4-nitrophenyl)methyl]-5-propyl- (9CI) (CA INDEX NAME)

L6 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137860-06-1 CAPLUS
CN 1H-Pyrazole-1-acetic acid, 5-hydroxy-4-[(4-nitrophenyl)methyl]-3-propyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 137860-07-2 CAPLUS
CN 1H-Pyrazol-5-ol, 4-[(4-nitrophenyl)methyl]-3-propyl-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137860-09-4 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile,
4-[(3-butyl-5-hydroxy-1-methyl-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137860-28-7 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 4-[(5-hydroxy-3-propyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137860-49-2 CAPLUS
 CN [1,1'-Biphenyl]-2-carbonitrile,
 4'-(5-hydroxy-1-methyl-3-(2-methylpropyl)-
 1H-pyrazol-4-yl)methyl] - (9CI) (CA INDEX NAME)




RN 137860-50-5 CAPLUS
 CN [1,1'-Biphenyl]-2-carbonitrile,
 4'-(5-hydroxy-3-(2-methylpropyl)-1-(2,2,2-
 trifluoroethyl)-1H-pyrazol-4-yl)methyl] - (9CI) (CA INDEX NAME)



RN 161463-13-4 CAPLUS
 CN [1,1'-Biphenyl]-2-carbonitrile, 4'-(3-butyl-5-hydroxy-1-(2,2,2-
 trifluoroethyl)-1H-pyrazol-4-yl)methyl] - (9CI) (CA INDEX NAME)




RN 161463-26-9 CAPLUS
 CN 1H-Pyrazole-3-methanol, 4-[(4-aminophenyl)methyl]-1-methyl-5-propyl-
 (9CI) (CA INDEX NAME)



L6 ANSWER 5 OF 28 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1995:234856 CAPLUS
 DOCUMENT NUMBER: 122:31549
 TITLE: Preparation of heterocycl compds. as angiotensin II
 receptor antagonists
 INVENTOR(S): Weinstock, Joseph
 PATENT ASSIGNEE(S): Smithkline Beecham Corp., USA
 SOURCE: PCT Int. Appl., 31 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9422830	A1	19941013	WO 1994-US3478	19940330 <<
W: JP, US				
RN: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRIORITY APPLN. INFO.: US 1993-40733				19930331
OTHER SOURCE(S): MARPAT 122:31549				
GI				




AB Title compds. I (R1 = (substituted) Ph, (substituted) naphthyl; n = 0-4; A1 = C, N when X = covalent bond, or C when X is other than a covalent bond; A2 = R2C, R14C, R3:C wherein R2 substituted vinyl, R3 = O, H-H, H-C1-4 alkyl, R14 = halo; A3 = HC, N, HN, etc.; A4 = HC, N, H2N, etc. A5 = N, HC, etc., nill; A6 = C2-8 alkyl-C, etc.) or a salt thereof, useful as angiotensin II receptor antagonists (no data), are prep'd. I are claimed for treatment of hypertension, congestive heart failure, renal failure and glaucoma. NaH in glyme was added to tri-Me 3-(2-thienyl)-2-phosphonopropionate followed by 5-n-butyl-1-((4-carboxymethoxyphenyl)methyl)pyrrole-2-carboxaldehyde to give Me (E)-5-n-butyl-1-((4-carboxyphenyl)methyl)pyrrole-2-(2-thienyl)methyl-2-propenoate which was treated with NaOH to give (E)-II. Pharmaceutical formulations comprising I are given.

IT 159958-95-99
 RL: BAC (Biological activity or effector, except adverse); BU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L6 ANSWER 5 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
(prepn. of heterocycl compds. as angiotensin II receptor antagonists)
RN 159558-95-9 CAPLUS
CN 2-Thiophene-propanoic acid,
.alpha.-[(3-butyl-4-[(4-carboxyphenyl)methyl]-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)methylene]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




L6 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1995:230091 CAPLUS
DOCUMENT NUMBER: 122:23227
TITLE: Derivation of a 3D pharmacophore model for the angiotensin-II site one receptor
AUTHOR(S): Prendergast, Kristine; Adams, Kym; Greenlee, William J.; Nachbar, Robert B.; Patchett, Arthur A.; Underwood, Dennis J.
CORPORATE SOURCE: Mol. Systems Dep., Merck Res. Lab., Rahway, NJ, 07065,
USA
SOURCE: Journal of Computer-Aided Molecular Design (1994), 8(5), 491-512
PUBLISHER: ESCOM
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A systematic search has been used to derive a hypothesis for the receptor-bound conformation of A-II antagonists at the AT1 receptor. The validity of the pharmacophore hypothesis has been tested using COMPA, which included 50 diverse A-II antagonists, spanning four orders of magnitude in activity. The resulting cross-validated R2 or 0.64 (conventional R2 of 0.76) is indicative of a good predictive model of activity, and has been used to est. potency for a variety of non-peptidyl antagonists. The structural model for the non-peptide has been compared with respect to the natural substrate, A-II, by generating peptide to non-peptide overlays.

IT 138733-04-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(derivation of a 3D pharmacophore model for the angiotensin-II site one receptor)
RN 138733-04-7 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(phenylmethyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




L6 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1995:227811 CAPLUS
DOCUMENT NUMBER: 122:105706
TITLE: Discovery of nonpeptide, potent conformationally restricted angiotensin II receptor antagonists
AUTHOR(S): Huang, Horng-Chih; Chamberlain, Timothy S.; Olines, Gillian M.; Corpus, Valerie M.; Chen, Susan T.; McMahon, Ellen G.; Palomo, Maria A.; Blaine, Edward H.; Manning, Robert E.
CORPORATE SOURCE: Dept. of Chemistry and Cardiovascular Diseases Research, Searle R&D, St. Louis, MO, 63198, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (1994), 4(21), 2591-6
CODEN: BMCLB8; ISSN: 0960-894X
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A series of potent, selective, conformationally restricted angiotensin II (AII) receptor antagonists has been discovered. Two classes of conformationally restricted analogs were prep'd.: triazolone-based and imidazole-based biphenyl derivs. The most active compd., an imidazole-based analog, has an IC50 of 11 nM and a pA2 of 8.8.
IT 160561-29-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of conformationally restricted angiotensin II receptor antagonists)
RN 160561-29-5 CAPLUS
CN 3H-Pyrazol-3-one, 2-butyl-2,4-dihydro-5-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 8 OF 28 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1994:534131 CAPLUS
DOCUMENT NUMBER: 121:134131
TITLE: Heterocyclic compounds having angiotensin ii antagonistic activity and use thereof
INVENTOR(S): Kubo, Keiji; Inada, Yoshiyuki; Naka, Takehiko
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: Eur. Pat. Appl., 40 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 603712	A2	19940629	EP 1993-120135	19931214 <--
EP 603712	A3	19940713		
EP 603712	B1	20010816		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE AT 204276	E	20010915	AT 1993-120135	19931214
JP 07070118	A2	19950314	JP 1993-318151	19931217 <--
CA 2112050	AA	19940623	CA 1993-2121050	19931221 <--
US 5496835	A	19960305	US 1993-171164	19931222 <--


PRIORITY APPN. INFO.: JP 1992-342917 A 19921222
OTHER SOURCE(S): MARPAT 121:134131
GI




AB Heterocyclic compd. I (A = heterocyclic ring; R1 = substituent; R2 = substituent group capable of liberating proton in a living body or a group convertible thereto; R3 = heterocyclic group; X = bond, alkanediyl, etc.; n = integer) were disclosed. I are angiotensin II antagonistic agents. An example compd. .

09899322

L6 ANSWER 8 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
 thiadiazol-3-yl)-4-(biphenyl)methyl]-5-pyrazolecarboxylic acid (II) was
 prep. II inhibited binding of angiotensin II to angiotensin receptor.
 IT 157169-90-9P 157169-91-0P 157169-92-1P
 157169-93-2P 157169-94-3P 157169-95-4P
 157169-96-5P
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prep. of, as angiotensin II antagonist)
 RN 157169-90-9 CAPLUS
 CN 1H-Pyrazole-3-carboxylic acid, 5-butyl-4-[(2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 157169-91-0 CAPLUS
 CN 1H-Pyrazole-3-carboxylic acid, 5-butyl-4-[(2'-(2,5-dihydro-5-oxo-1,2,4-thiadiazol-3-yl)[1,1'-biphenyl]-4-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 157169-92-1 CAPLUS
 CN 1H-Pyrazole-3-carboxylic acid, 5-butyl-4-[(2'-(2,5-dihydro-5-oxo-1,2,4-thiadiazol-3-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)


L6 ANSWER 8 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 157169-93-2 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-chlorophenyl)-4-[(2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 157169-94-3 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-chlorophenyl)-4-[(2'-(2,5-dihydro-5-oxo-1,2,4-thiadiazol-3-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




L6 ANSWER 8 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)

RN 157169-95-4 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-chlorophenyl)-4-[(2'-(2,5-dihydro-5-oxo-1,2,4-thiadiazol-3-yl)[1,1'-biphenyl]-4-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 157169-96-5 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-chlorophenyl)-4-[(2'-(2,5-dihydro-5-oxo-1,2,4-thiadiazol-3-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




IT 152713-68-3P 157169-87-4P 157169-88-5P
 157169-89-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prep. of, as intermediate for
 [(biphenyl)methyl]pyrazolecarboxylate
 angiotensin antagonist)

RN 152713-68-3 CAPLUS
 CN 1H-Pyrazole-3-carboxylic acid, 5-butyl-4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)


L6 ANSWER 8 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 157169-87-4 CAPLUS
 CN 1H-Pyrazole-3-carboxylic acid, 5-butyl-4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 152713-68-3P 157169-87-4P 157169-88-5P
 157169-89-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prep. of, as intermediate for
 [(biphenyl)methyl]pyrazolecarboxylate
 angiotensin antagonist)




RN 157169-89-6 CAPLUS
 CN 1H-Pyrazole-3-carboxylic acid, 5-butyl-4-[(2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)(1,1'-biphenyl)-4-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




L6 ANSWER 9 OF 28 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1994:508820 CAPLUS
 DOCUMENT NUMBER: 121:108820
 TITLE: Preparation of antihypertensive pyrazolopyrimidines
 INVENTOR(S): Kuroki, Yoshiaki; Tamura, Shinji; Ueno, Hitoshi;
 Nakakoshi, Ichiro; Fujisawa, Hiroshi; Kimura, Tomio
 PATENT ASSIGNEE(S): Ube Industries, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 20 pp.
 CODEN: JKKXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06009638	A2	19940118	JP 1992-201733	19920619 <--
OTHER SOURCE(S):		MARPAT 121:108820		GI




AB The title compds. I [R1 = H, SH, alkenyl, alkynyl, cycloalkyl, alkylthio, alkoxy, (un)substituted alkyl, Ph; R2-R4 = H, halo, OH, SH, lower alkoxy, lower alkylthio, (lower alc.-esterified) CO2H, (lower alkyl-substituted) NH2, carbamoyl, (un)substituted lower alkyl, Ph; R5 = cyano, (lower alc.-esterified) CO2H, (un)substituted tetrazol-5-yl], useful as angiotensin II antagonists, are prep'd. Refluxing 3-amino-5-propyl-4-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]pyrazole hydrazine with acetylacetone and piperidine in EtOH for 3 h gave 89% I (R1 = Pr, R2 = R4 = Me, R3 = H, R5 = 1H-tetrazol-5-yl).
 IT 156872-86-5P 156872-87-6P 156872-88-7P
 156872-89-8P 156872-91-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and reaction of)
 RN 156872-86-5 CAPLUS
 CN [1,1'-Biphenyl]-2-carbonitrile, 4'-(3-amino-5-butyl-1H-pyrazol-4-yl)methyl- (9CI) (CA INDEX NAME)




RN 156872-87-6 CAPLUS
 CN 1H-Pyrazol-3-amine, 5-ethyl-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 156872-88-7 CAPLUS
 CN 1H-Pyrazol-3-amine, 5-propyl-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 156872-89-8 CAPLUS
 CN 1H-Pyrazol-3-amine, 5-butyl-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 156872-91-2 CAPLUS
 CN [1,1'-Biphenyl]-2-carbonitrile, 4'-(3-amino-5-propyl-1H-pyrazol-4-yl)methyl- (9CI) (CA INDEX NAME)



L6 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1994:409397 CAPLUS

DOCUMENT NUMBER: 121:9397

TITLE: Preparation of pyrazoles as angiotensin II antagonists

INVENTOR(S): Tomyama, Takeshi; Tomyama, Itaru; Yanagisawa, Takashi;

PATENT ASSIGNEE(S): Kawai, Tomoyuki; Nishimura, Hajime

Kotobuki Seiyaku Co Ltd, Japan

Jpn. Kokai Tokkyo Koho, 10 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:




PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06032782	A2	19940208	JP 1992-187085	19920714 --

OTHER SOURCE(S): MARPAT 121:9397

GI





AB The title compds. I [A = O (linked to carbon atom of pyrazole ring by double bond), OR4 (linked to carbon atom of pyrazole ring by single bond);
 R1 = hydroxycarbonyl, tetrazole; R2 = H, Me, etc.; R3 = H, Me, Ph; R4 = H, Me, propionyl] are prepnd. I are useful as cardiovascular agents.
 3-Butyl-4-[2'-(hydroxycarbonyl)-biphenyl-4-yl]methylpyrazol-5-one (II) was prepnd. in several steps from 4-bromomethyl-2'-methoxycarbonylbiphenyl. In an in vitro test for angiotensin II antagonistic activity, II showed PA2 value of 6.2.
 IT 155589-66-5P 155589-66-7P 155589-69-8P
 155589-70-1P 155589-71-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); (prepn. and reaction of, in prepn. of cardiovascular agent)
 RN 155589-66-5 CAPLUS

L6 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(5-butyl-2,3-dihydro-3-oxo-1H-pyrazol-4-yl)methyl-, methyl ester (9CI) (CA INDEX NAME)RN 155589-68-7 CAPLUS
 CN 3H-Pyrazol-3-one, 5-butyl-1,2-dihydro-4-[(2'-(1-(triphenylmethyl)-1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)RN 155589-69-8 CAPLUS
 CN 3H-Pyrazol-3-one, 5-butyl-1,2-dihydro-1-methyl-4-[(2'-(1-(triphenylmethyl)-1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




L6 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)

RN 155589-70-1 CAPLUS

CN 1H-Tetrazole, 5-[4'-(5-butyl-3-methoxy-1-methyl-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)


RN 155589-71-2 CAPLUS
 CN 1H-Pyrazol-3-ol, 5-butyl-1-(1-oxopropyl)-4-[(2'-(1-(triphenylmethyl)-1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, propanoate (ester) (9CI) (CA INDEX NAME)IT 155589-56-3P 155589-57-4P 155589-58-5P
 155589-59-6P 155589-60-9P 155589-61-0P
 155589-62-1P 155589-63-2P 155589-64-3P
 155589-65-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (prepn. of, as cardiovascular agent)RN 155589-56-3 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(5-butyl-2,3-dihydro-3-oxo-1H-pyrazol-4-yl)methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)


RN 155589-57-4 CAPLUS
 CN 3H-Pyrazol-3-one, 5-butyl-1,2-dihydro-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)RN 155589-58-5 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(5-butyl-2,3-dihydro-1-methyl-5-oxo-1H-pyrazol-4-yl)methyl- (9CI) (CA INDEX NAME)

09899322

L6 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
 RN 155589-59-6 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid,
 4'-(3-butyl-2,5-dihydro-5-oxo-1-phenyl-
 1H-pyrazol-4-yl)methyl)- (9CI) (CA INDEX NAME)




RN 155589-60-9 CAPLUS
 CN 3H-Pyrazol-3-one, 5-butyl-1,2-dihydro-2-methyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 155589-61-0 CAPLUS
 CN 3H-Pyrazol-3-one, 5-butyl-1,2-dihydro-2-phenyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)


L6 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 155589-62-1 CAPLUS
 CN 3H-Pyrazol-3-one, 5-butyl-1,2-dihydro-1-methyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 155589-63-2 CAPLUS
 CN 3H-Pyrazol-3-one, 1,5-dibutyl-1,2-dihydro-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 155589-64-3 CAPLUS
 CN 1H-Pyrazol-3-ol, 5-butyl-1-(1-oxopropyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, propanoate (ester) (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 155589-65-4 CAPLUS
 CN 1H-Tetrazole, 5-[(5-butyl-3-methoxy-1-methyl-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 11 OF 28 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1994:323592 CAPLUS
 DOCUMENT NUMBER: 120:323592
 TITLE: (Biphenylmethyl)pyrazolo[1,5-a]pyrimidine angiotensin II receptor antagonists
 INVENTOR(S): Bru-Magniez, Nicole; Nicolai, Eric; Teulon, Jean Marie
 PATENT ASSIGNEE(S): Upas Laboratoires, Fr.
 SOURCE: Fr. Demande, 22 pp.
 CODEN: FRXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2690442	A1	19931029	PR 1992-5182	19920427 <- GI
OTHER SOURCE(S):		MARPAT 120:323592		



AB The title compds. (I; 1 R1 = C1-6 alkyl, C3-7 cycloalkyl; R3-R4 = H, halogen, Cl-6 alkyl etc.; R5 = acid substituent, ester substituent, CN, tetrazolyl substituent), useful in the treatment of hypertension, are prepd. by the cyclization of pyrazole II with .beta.-dicarbonyl compd. R2COC(R3)HCOR4 (when R5 = CN or ester functionality). Thus, pyrazolopyrimidine I (R1 = Pr, R2 = R4 = Me, R3 = H, R5 = tetrazol-5-yl) hydrochloride, m.p. 230-232.degree., was prepd. and demonstrated 63% radio

ligand displacement from rat-isolated angiotensin receptors at 1 .times. 10-5 M.

IT 155056-41-0P 155056-42-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(prepn. and reaction of, in prepn. of (biphenylmethyl)pyrazolopyrimidin

e angiotensin II receptor antagonists)


RN 155056-41-0 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 4'-(3-amino-5-propyl-1H-pyrazol-4-yl)methyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Kamal Saeed




RN 154057-12-2 CAPLUS
 CN Benzamide, N-butyl-3-(3-butyl-4-[(2-chlorobenzoyl)amino]sulfonyl)-3-fluoro[1,1'-biphenyl]-4-ylmethyl-5-cyano-1H-pyrazol-1-yl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 154057-24-6 CAPLUS
 CN Benzamide, N-[(4'-(3-butyl-5-cyano-1-(5-(methoxyacetyl)amino)-2-(trifluoromethyl)phenyl)-1H-pyrazol-4-yl)methyl]-3'-fluoro[1,1'-biphenyl]-2-ylsulfonyl)-2-chloro- (9CI) (CA INDEX NAME)




RN 154057-35-9 CAPLUS
 CN Benzamide, N-[(4'-(3-butyl-5-cyano-1-[5-((1-oxopropyl)amino)-2-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl)methyl]-3'-fluoro[1,1'-biphenyl]-2-ylsulfonyl)-2-chloro- (9CI) (CA INDEX NAME)




RN 154057-37-1 CAPLUS
 CN Benzamide, N-[(4'-(3-butyl-5-cyano-1-(5-(methoxyacetyl)amino)-2-(trifluoromethyl)phenyl)-1H-pyrazol-4-yl)methyl]-3'-fluoro[1,1'-biphenyl]-2-ylsulfonyl)-2-fluoro- (9CI) (CA INDEX NAME)




RN 154057-36-0 CAPLUS




RN 154057-38-2 CAPLUS
 CN Benzamide, N-[(4'-(3-butyl-5-cyano-1-[(ethoxyacetyl)amino]-2-(trifluoromethyl)phenyl)-1H-pyrazol-4-yl)methyl]-3'-fluoro[1,1'-biphenyl]-2-ylsulfonyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 154057-39-3 CAPLUS
 CN Benzamide, N-butyl-3-[3-butyl-5-cyano-4-[(3-fluoro-2-[(1,1'-biphenyl)-4-yl]methyl)-1H-pyrazol-1-yl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 154057-40-6 CAPLUS
 CN Benzamide, N-[(4'-(5-cyano-1-[(methoxyacetyl)amino]-2-(trifluoromethyl)phenyl)-3-propyl-1H-pyrazol-4-yl)methyl]-3'-fluoro[1,1'-biphenyl]-2-ylsulfonyl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 154057-42-8 CAPLUS
 CN Benzamide,
 N-butyl-4-chloro-3-[(2-[(2-chlorobenzoyl)amino]sulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl)methyl]-5-cyano-3-propyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 154057-41-7 CAPLUS
 CN Benzamide, N-[(4-[(5-cyano-1-[(ethoxyacetyl)amino]-2-(trifluoromethyl)phenyl)-3-propyl-1H-pyrazol-4-yl)methyl]-3'-fluoro[1,1'-biphenyl]-2-ylsulfonyl]-2-fluoro- (9CI) (CA INDEX NAME)




09899322

L6 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)

RN 154057-43-9 CAPLUS


CN Benzamide, N-butyl-4-chloro-3-[5-cyano-4-[(3-fluoro-2'-{[(2-fluorobenzoyl)amino]sulfonyl}[1,1'-biphenyl]-4-yl)methyl]-3-propyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 154057-44-0 CAPLUS


CN Benzamide, N-butyl-3-[4-[(2-chlorobenzoyl)amino]sulfonyl]-3-fluoro[1,1'-biphenyl]-4-yl]-5-cyano-3-propyl-1H-pyrazol-1-yl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 154057-45-1 CAPLUS


CN Benzamide, N-butyl-3-[5-cyano-4-[(3-fluoro-2'-{[(2-fluorobenzoyl)amino]sulfonyl}[1,1'-biphenyl]-4-yl)methyl]-3-propyl-1H-pyrazol-1-yl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)

RN 154057-46-2 CAPLUS


CN Benzamide, N-[(4'-(1-[5-(acetylamino)-2-chlorophenyl]-3-butyl-5-cyano-1H-pyrazol-4-yl)methyl)-3'-fluoro-5-propyl[1,1'-biphenyl]-2-yl]sulfonyl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 154057-47-3 CAPLUS


CN Carbamic acid, [(4'-(1-[5-(acetylamino)-2-chlorophenyl]-3-butyl-5-cyano-1H-pyrazol-4-yl)methyl)-3'-fluoro-5-propyl[1,1'-biphenyl]-2-yl]sulfonyl]-ethyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 154057-48-4 CAPLUS

CN Benzamide, N-[(4'-(1-[5-(butylamino)-2-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl)methyl)-3,3'-difluoro[1,1'-biphenyl]-2-yl]sulfonyl]-2-fluoro- (9CI) (CA INDEX NAME)




IT 154056-92-5 154056-96-9 154056-97-0
154056-98-1 154057-09-7 154057-10-0
154057-11-1 154057-12-2 154057-24-6
154057-30-4

Kamal Saeed


09899322

L6 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
 RL: RCT (Reactant), RACT (Reactant or reagent)
 (prep. as angiotensin II antagonist)
 RN 154056-92-5 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-(2-chlorobenzoyl)amino)sulfonyl][1,1'-biphenyl]-4-yl)methyl]-1-(2-chloro-5-[(1-oxopentyl)amino]phenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 154056-96-9 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-(2-chlorobenzoyl)amino)sulfonyl][1,1'-biphenyl]-4-yl)methyl]-1-(2-chloro-5-[(1-oxopentyl)amino]phenyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 154056-97-0 CAPLUS
 CN 1H-Pyrazole-5-carboxamide, 3-butyl-4-[(2'-(2-chlorobenzoyl)amino)sulfonyl][1,1'-biphenyl]-4-yl)methyl]-1-(2-chloro-5-[(1-oxopentyl)amino]phenyl)-N-methyl-, (9CI) (CA INDEX NAME)


L6 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)

RN 154056-98-1 CAPLUS
 CN Benzamide, N-[(4'-(3-butyl-1-[2-chloro-5-[(1-oxopropyl)aminophenyl]-5-cyano-1H-pyrazol-4-yl)methyl]-3'-fluoro[1,1'-biphenyl]-2-yl)sulfonyl]-2-chloro- (9CI) (CA INDEX NAME)




RN 154057-09-7 CAPLUS
 CN Benzamide, N-[(4'-(3-butyl-1-[2-chloro-5-[(1-oxopentyl)amino]phenyl]-5-

L6 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
 cyano-1H-pyrazol-4-yl)methyl]-3'-fluoro[1,1'-biphenyl]-2-yl)sulfonyl]-2-chloro- (9CI) (CA INDEX NAME)



RN 154057-10-0 CAPLUS
 CN Carbamic acid, [(4'-(3-butyl-1-[2-chloro-5-[(1-oxopropyl)aminophenyl]-5-cyano-1H-pyrazol-4-yl)methyl]-3'-fluoro[1,1'-biphenyl]-2-yl)sulfonyl]-1,1-dimethyl-ethyl ester (9CI) (CA INDEX NAME)




Kamal Saeed

09899322

L6 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)


RN 154057-11-1 CAPLUS
 CN Carbamic acid, 4-[(3-butyl-1-[2-chloro-5-((1-oxopropyl)amino)phenyl]-5-cyano-1H-pyrazol-4-yl)methyl]-3'-fluoro[1,1'-biphenyl]-2-yl)sulfonyl]-butyl ester (9CI) (CA INDEX NAME)



RN 154057-12-2 CAPLUS

CN Benzamide, N-butyl-3-[3-butyl-4-[(2-chlorobenzoyl)amino]sulfonyl]-3-fluoro[1,1'-biphenyl]-4-yl)methyl]-5-cyano-1H-pyrazol-1-yl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 154057-24-6 CAPLUS

CN Benzonamide, N-[(4'-[(3-butyl-5-cyano-1-[5-((methoxyacetyl)amino)-2-(trifluoromethyl)phenyl)-1H-pyrazol-4-yl)methyl]-3'-fluoro[1,1'-biphenyl]-2-yl)sulfonyl]-2-chloro- (9CI) (CA INDEX NAME)

L6 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 154057-30-4 CAPLUS

CN Acetamide, N-[(3-butyl-5-cyano-4-[(3-fluoro-2'-{[(2-fluorophenyl)amino]sulfonyl}-5'-propyl[1,1'-biphenyl]-4-yl)methyl]-1H-pyrazol-1-yl)-4-chlorophenyl]- (9CI) (CA INDEX NAME)


L6 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)

RN 154057-22-4 154057-23-5 154057-25-7
 154057-27-9 154057-28-0 154057-29-1
 154057-32-6 154057-33-7 154057-34-8
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. as intermediate in prepn. of (biphenylmethyl)pyrazole angiotensin II antagonists)
 RN 154056-93-6 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 4-[(2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl)methyl]-3-butyl-1-(2-chloro-5-nitrophenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 154056-94-7 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-(2-chlorobenzoyl)amino)sulfonyl][1,1'-biphenyl]-4-yl)methyl]-1-(2-chloro-5-nitrophenyl)-, ethyl ester (9CI) (CA INDEX NAME)




IT 154056-93-6 154056-94-7 154056-95-8
 154057-00-8 154057-01-9 154057-02-0
 154057-03-1 154057-04-2 154057-05-3
 154057-06-4 154057-07-5 154057-08-6


Kamal Saeed




RN 154056-95-8 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 1-(5-amino-2-chlorophenyl)-3-butyl-4-[(2-[(2-chlorobenzoyl)amino]sulfonyl)[1,1'-biphenyl]-4-yl]methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 154057-00-8 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 4-[(4-bromo-2-fluorophenyl)methyl]-3-butyl-




RN 154057-01-9 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 4-[(4-bromo-2-fluorophenyl)methyl]-3-butyl-1-(2-chloro-5-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 154057-02-0 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 4-[(4-bromo-2-fluorophenyl)methyl]-3-butyl-1-(2-chloro-5-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 154057-03-1 CAPLUS
 CN 1H-Pyrazole-5-carboxamide, 4-[(4-bromo-2-fluorophenyl)methyl]-3-butyl-1-(2-chloro-5-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 154057-04-2 CAPLUS
 CN 1H-Pyrazole-5-carbonitrile, 4-[(4-bromo-2-fluorophenyl)methyl]-3-butyl-1-(2-chloro-5-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 154057-05-3 CAPLUS
 CN 1H-Pyrazole-5-carbonitrile, 1-(5-amino-2-chlorophenyl)-4-[(4-bromo-2-fluorophenyl)methyl]-3-butyl- (9CI) (CA INDEX NAME)




RN 154057-06-4 CAPLUS
 CN Propanamide, N-[3-[(4-bromo-2-fluorophenyl)methyl]-3-butyl-5-cyano-1H-pyrazol-1-yl]-4-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 154057-07-5 CAPLUS
 CN Propanamide, N-[3-[(3-butyl-5-cyano-4-[(2-[(1,1-dimethylethyl)amino]sulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]methyl)-1H-pyrazol-1-yl]-4-chlorophenyl)- (9CI) (CA INDEX NAME)


09899322

L6 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 154057-08-6 CAPLUS

CN Propanamide, N-[3-[(2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl)methyl]-3-butyl-5-cyano-1H-pyrazol-1-yl]-4-chlorophenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)


RN 154057-22-4 CAPLUS
CN Benzoic acid, 3-[(2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl)methyl]-3-butyl-5-cyano-1H-pyrazol-1-yl]-4-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 154057-23-5 CAPLUS


CN Benzamide,
3-[(2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl)methyl]-3-butyl-5-cyano-1H-pyrazol-1-yl]-N-butyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 154057-25-7 CAPLUS


CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[(1-(2-bromo-5-nitrophenyl)-3-butyl-5-cyano-1H-pyrazol-4-yl)methyl]-3'-fluoro- (9CI) (CA INDEX NAME)



RN 154057-27-9 CAPLUS


CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[(3-butyl-5-cyano-1-[5-nitro-2-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl)methyl]-3'-fluoro- (9CI) (CA INDEX NAME)

L6 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 154057-28-0 CAPLUS

CN Benzamide,
N-[(4'-(3-butyl-5-cyano-1-[5-nitro-2-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl)methyl)-3'-fluoro[1,1'-biphenyl]-2-yl]sulfonyl-2-chloro- (9CI) (CA INDEX NAME)




RN 154057-29-1 CAPLUS

CN Benzamide,
N-[(4'-(1-[5-amino-2-(trifluoromethyl)phenyl]-3'-fluoro[1,1'-biphenyl]-2-yl)sulfonyl)-2-chloro- (9CI) (CA INDEX NAME)


Kamal Saeed

09899322

L6 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 154057-32-6 CAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, 4'-{[3-butyl-1-(2-chloro-5-nitrophenyl)-5-cyano-1H-pyrazol-4-yl)methyl]-3'-fluoro-5-propyl- (9CI) (CA INDEX NAME)




RN 154057-33-7 CAPLUS
CN Benzamide,
N-{[4'-(3-butyl-1-(2-chloro-5-nitrophenyl)-5-cyano-1H-pyrazol-

L6 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
4-yl)methyl]-3'-fluoro-5-propyl[1,1'-biphenyl]-2-yl)sulfonyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 154057-34-8 CAPLUS
CN Benzamide,
N-{[4'-(1-(4-amino-2-chlorophenyl)-3-butyl-5-cyano-1H-pyrazol-4-yl)methyl]-3'-fluoro-5-propyl[1,1'-biphenyl]-2-yl)sulfonyl]-2-fluoro- (9CI) (CA INDEX NAME)

L6 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




L6 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1994-235329 CAPLUS
DOCUMENT NUMBER: 120:235329
TITLE: C-linked pyrazole biaryl tetrazoles as antagonists of angiotensin II. Part II: Pharmacokinetics and an efficient regioselective synthesis
AUTHOR(S): Watson, S. P.; Middlemiss, D.; Pase, M.; Hubbard, T.; Panchal, T. A.; Heron, N. M.; Paton, J. M. S.; Butt, A.; Dean, A. W.; et al.
CORPORATE SOURCE: Glaxo Group Res., Ware/Hertfordshire, SG12 0DP, UK
SOURCE: Bioorganic & Medicinal Chemistry Letters (1994), 4(1), 151-6
DOCUMENT TYPE: CODEN: BMCLB8; ISSN: 0960-894X
Journal
LANGUAGE: English
AB C-linked N-alkyl pyrazole biaryl tetrazoles are highly potent antagonists of angiotensin II. Pharmacokinetics parameters in the rat are reported for two of these compds. The N-cyclopropylmethyl pyrazole has an oral bioavailability of 58%. In addn. an efficient regioselective synthesis of pyrazoles is described.
IT 153359-86-5P 154266-18-9P 154266-19-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and oxidn. and tetrazole deriv. formation from)
RN 153359-86-5 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 4'-{[3-butyl-5-(hydroxymethyl)-1-(1-methylethyl)-1H-pyrazol-4-yl)methyl}- (9CI) (CA INDEX NAME)




RN 154266-18-9 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 4'-{[3-butyl-1-(cyclopropylmethyl)-5-(hydroxymethyl)-1H-pyrazol-4-yl)methyl}- (9CI) (CA INDEX NAME)


Kamal Saeed




RN 154266-19-0 CAPLUS
 CN [1,1'-Biphenyl]-2-carbonitrile, 4'-'-[(1,3-dibutyl-5-(hydroxymethyl)-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




IT 137646-07-2P 137646-19-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and pharmacokinetics of)
 RN 137646-07-2 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid,
 1,3-dibutyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-19-6 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(cyclopropylmethyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




IT 153359-89-8P 153359-90-1P 154266-16-7P
 154266-17-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 153359-89-8 CAPLUS
 CN 1H-Pyrazole-5-methanol, 1,3-dibutyl-4-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 153359-90-1 CAPLUS
 CN 1H-Pyrazole-5-methanol, 3-butyl-1-(1-methylethyl)-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 154266-16-7 CAPLUS
 CN 1H-Pyrazole-3-methanol, 1,5-dibutyl-4-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 154266-17-8 CAPLUS
 CN 1H-Pyrazole-3-methanol, 5-butyl-1-(1-methylethyl)-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1994:191713 CAPLUS
 DOCUMENT NUMBER: 120:191713
 TITLE: Furanone intermediates in pharmaceutical pyrazole preparation
 INVENTOR(S): Watson, Stephen Paul
 PATENT ASSIGNEE(S): Glaxo Group Ltd., UK
 SOURCE: Brit. UK Pat. Appl., 30 pp.
 CODEN: BAXXDU
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2265900	A1	19931013	GB 1993-7342	19930407 --
PRIORITY APPLN. INFO.:			GB 1992-7591	19920407
OTHER SOURCE(S):	MARPAT	120:191713		
GI				




AB Title compds. I (R1 = H, C1-6 alkyl, C2-6 alkenyl; R2a = H, C1-6 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-4 alkyl, C3-6 alkenyl-F-C1-6 alkyl, F-C3-6 alkenyl; X = H, halo, R4CH6H4 wherein R4 = H2N, NC, protectant of CO2H or NH2, optionally protected C-linked tetrazolyl) useful for prepn. of pharmaceuticals (no data), are prepnd. 2-Hexane was added to 1-[1,1-((dimethylethyl)dimethylsilyl)oxy]acetate (prepns. given) to give 1-[1,1-((dimethylethyl)dimethylsilyl)oxy]-3,4-octanedione which was reacted with 5-(4'-(bromomethyl)[1,1'-biphenyl]-2-yl)-2-(triphenylmethyl)-2H-tetrazole to give the tetrazole deriv. which was treated with Bu4N+PF6- to give the desilylated furanone deriv. which in turn was treated with Me2CHNNHMe to give the title compd. II.

IT 153359-86-5P 153360-06-6P 153360-07-7P
 153360-08-8P 153360-09-9P 153360-10-2P
 153360-11-3P 153360-12-4P 153360-13-5P
 153360-15-7P 153360-16-8P 153360-17-9P
 153360-18-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepns. and reaction of, in prepn. of pyrazole pharmaceuticals)

RN 153359-86-5 CAPLUS
 CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[(3-butyl-5-(hydroxymethyl)-1-(methylethyl)-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)


L6 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 153360-06-6 CAPLUS
 CN 1H-Pyrazole-5-carboxaldehyde, 3-butyl-1-(1-methylethyl)-4-[(2'-(2-(triphenylmethyl)-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 153360-07-7 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(1-methylethyl)-4-[(2'-(2-(triphenylmethyl)-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




L6 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
 CN 1H-Pyrazole-5-carboxaldehyde, 1-(1-methylethyl)-3-propyl-4-[(2'-(2-(triphenylmethyl)-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 153360-12-4 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 1-(1-methylethyl)-3-propyl-4-[(2'-(2-(triphenylmethyl)-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 153360-13-5 CAPLUS
 CN [1,1'-Biphenyl]-2-carbonitrile,
 4-[(3-butyl-5-formyl-1-(1-methylethyl)-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




L6 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)


RN 153360-08-8 CAPLUS
 CN 1H-Pyrazole-5-carboxaldehyde, 1,3-dibutyl-4-[(2'-(2-(triphenylmethyl)-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 153360-09-9 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid,
 1,3-dibutyl-4-[(2'-(2-(triphenylmethyl)-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 153360-10-2 CAPLUS
 CN 1H-Pyrazole-5-carboxaldehyde,
 3-butyl-1-methyl-4-[(2'-(2-(triphenylmethyl)-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 153360-11-3 CAPLUS

L6 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)


RN 153360-15-7 CAPLUS
 CN 1H-Pyrazole-5-carboxaldehyde, 3-butyl-1-(cyclopropylmethyl)-4-[(2'-(2-(triphenylmethyl)-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 153360-16-8 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(cyclopropylmethyl)-4-[(2'-(2-(triphenylmethyl)-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 153360-17-9 CAPLUS
 CN 1H-Pyrazole-5-carboxaldehyde,
 3-butyl-1-propyl-4-[(2'-(2-(triphenylmethyl)-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 153360-18-0 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-propyl-4-[(2'-(2-

L6 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
 (triphenylmethyl)-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl)methyl]- (9CI)
 (CA INDEX NAME)




IT 137645-95-5P 137646-06-1P 137646-07-2P
 137646-19-6P 137646-21-0P 153359-41-0P
 153359-82-1P 153359-83-2P 153359-84-3P
 153359-85-4P 153359-87-6P 153359-88-7P
 153359-89-8P 153359-90-1P 153360-14-6P
 RL BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of, as pharmaceutical)
 RN 137645-95-5 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(1-methylethyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-06-1 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 1-(1-methylethyl)-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)


L6 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 137646-07-2 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid,
 1,3-dibutyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-
 biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-19-6 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(cyclopropylmethyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-21-0 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)


L6 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 153359-81-0 CAPLUS
 CN 1H-Pyrazole-5-methanol, 3-butyl-1-(1-methylethyl)-4-[(2'-(triphenylmethyl)-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 153359-82-1 CAPLUS
 CN 1H-Pyrazole-5-methanol, 1,3-dibutyl-4-[(2'-(triphenylmethyl)-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 153359-83-2 CAPLUS
 CN 1H-Pyrazole-5-methanol, 3-butyl-1-methyl-4-[(2'-(2-(triphenylmethyl)-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)


L6 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 153359-84-3 CAPLUS
 CN 1H-Pyrazole-5-methanol, 3-butyl-4-[(4-iodophenyl)methyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 153359-85-4 CAPLUS
 CN 1H-Pyrazole-5-methanol, 1-(1-methylethyl)-3-propyl-4-[(2'-(triphenylmethyl)-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 153359-87-6 CAPLUS
 CN 1H-Pyrazole-5-methanol, 3-butyl-1-(cyclopropylmethyl)-4-[(2'-(triphenylmethyl)-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)


L6 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 153359-88-7 CAPLUS
 CN 1H-Pyrazole-5-methanol, 3-butyl-1-propyl-4-[(2'-(2-(triphenylmethyl)-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 153359-89-8 CAPLUS
 CN 1H-Pyrazole-5-methanol, 1,3-dibutyl-4-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 153359-90-1 CAPLUS
 CN 1H-Pyrazole-5-methanol, 3-butyl-1-(1-methylethyl)-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)

RN 153360-14-6 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1-(1-methylethyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1994134381 CAPLUS


DOCUMENT NUMBER: 120:134381

TITLE: Nonpeptide angiotensin II antagonists derived from 1H-pyrazole-5-carboxylates and 4-aryl-1H-imidazole-5-carboxylates

AUTHOR(S): Ashton, Wallace T.; Hutchins, Steven M.; Greenlee, William J.; Dose, George A.; Chang, Raymond S. L.; Lotti, Victor J.; Faust, Kristie A.; Chen, Tsing Bau; Zingaro, Gloria J.; et al.

CORPORATE SOURCE: Merck Res. Lab., Rahway, NJ, 07065, USA
 SOURCE: Journal of Medicinal Chemistry (1993), 36(23), 3595-605DOCUMENT TYPE: CODEN: JMCMAR; ISSN: 0022-2623
 LANGUAGE: English

GI



AB Two series of potential angiotensin II antagonists derived from carboxyl-functionalized "diazole" heterocycles have been prepd. and evaluated. Initially, limited investigation of 4-arylimidazole-5-carboxylates led to 2-n-butyl-4-(2-chlorophenyl)-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-1H-imidazole-5-carboxylic acid (I), which was found to be a highly potent antagonist of the rabbit aorta AT1 receptor (IC50 0.55 nM). In conscious, normotensive rats, I at 0.1 mg/kg i.v. inhibited the pressor response to AII by 88% with a duration of ~6 h. More extensively studied was an isosteric series of 3-alkyl-4-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-1H-pyrazole-5-carboxylates bearing aryl, alkyl, or aralkyl substituents at N1. These compds. were available in highly regioselective fashion via condensation of a substituted hydrazine hydrochloride with a 2-(methoxyimino)-4-oxoalkanoate intermediate. In vitro, the most potent pyrazolecarboxylic acids were II (R = Bu; R1 = 2,6-dichlorophenyl, 2-(trifluoromethyl)phenyl, benzyl, and phenethyl), all with IC50 values of 0.18-0.24 nM. Although less potent in the receptor assay, 3-n-propylpyrazolecarboxylic acids were at least as effective as their Bu counterpart in vivo. Several of the pyrazolecarboxylic acid deriva. demonstrated potent, long-lasting oral activity in rats. At 1 mg/kg po, the II (R = Bu; R1 = benzyl; R = Pr, R1 = 2,6-dichlorophenyl, 2,2,2-trifluoroethyl, and benzyl) analogs all gave >95% inhibition of the AII pressor response in the rat model, with duration of action >23 h.

L6 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)

IT 137645-69-3P 137645-94-4P 138717-62-1P

138717-63-2P 138717-64-3P 138717-65-4P

138717-66-5P 138717-67-6P 138717-68-7P

138717-69-8P 138717-70-1P 138717-71-2P

138717-72-3P 138717-73-4P 138717-74-5P

138732-94-2P 138732-98-6P 138732-99-7P

138733-00-3P 138733-01-4P 138733-02-5P

138733-03-6P 138733-04-7P 138733-06-9P

138733-07-0P 138733-08-1P 138733-09-2P

138733-10-5P 138733-11-6P 138762-13-7P

149050-56-6P 150282-42-1P 150282-43-2P

150282-44-3P 150282-45-4P 150282-46-5P

150282-47-6P 150282-48-7P 152713-35-5P

152713-36-5P 152713-37-6P 152713-38-7P

152713-39-8P 152713-43-4P 152713-44-5P

152713-45-6P 152713-46-7P 152713-47-8P


152713-48-9P 152713-49-0P 152713-50-3P

152713-51-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepns. and angiotensin II antagonist activity of)


RN 137645-69-3 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 137645-94-4 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-ethyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 138717-62-1 CAPLUS


CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-chlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 138717-63-2 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-phenyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 138717-64-3 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-phenyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 138717-65-4 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-chlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 138717-66-5 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-methylphenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 138717-67-6 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-methylphenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2,6-dichlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 138717-69-8 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2,6-dichlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 138717-70-1 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-[2-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 138717-72-3 CAPLUS
 CN 1H-Pyrazole-3-carboxylic acid, 5-butyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 138717-73-4 CAPLUS
 CN 1H-Pyrazole-3-carboxylic acid, 5-butyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)





RN 138717-74-5 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-(2,2,2-trifluoroethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 138732-94-2 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-propyl-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]-1-[2-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 138732-98-6 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(4-methoxyphenyl)-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 138733-02-5 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(4-methoxyphenyl)-2-nitrophenyl-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 138733-03-6 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-pyridinyl)-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 138733-04-7 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(phenylmethyl)-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)


RN 138732-99-7 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(4-methoxyphenyl)-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 138733-00-3 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-nitrophenyl)-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 138733-01-4 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-nitrophenyl)-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 138733-06-9 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 1-(2,6-dichlorophenyl)-3-propyl-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 138733-07-0 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-propyl-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]-1-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 138733-08-1 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-propyl-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]-1-(2,2,2-trifluoroethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 138733-09-2 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 138733-10-5 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 138733-11-6 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-propyl-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 138762-13-7 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid,
 3-butyl-1-(4-methoxy-2-nitrophenyl)-4-[(2'-
 (1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA
 INDEX NAME)




RN 149050-56-6 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-ethyl-4-[(1H-tetrazol-5-yl)methyl]-






RN 150282-42-1 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2,4-dichlorophenyl)-4-[(2'-(1H-




RN 150282-43-2 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2,5-dichlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 150282-44-3 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl-4-yl)methyl]-1-(2,4,6-trichlorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 150282-46-5 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(4-chlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)





RN 150282-47-6 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2,3-dichlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 150282-48-7 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(phenylmethyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 152713-35-4 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 1-[1,1'-biphenyl]-2-yl-3-butyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 152713-39-8 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 1-(phenylmethyl)-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 152713-43-4 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(3-chlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 152713-44-5 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(4-chlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)


RN 152713-36-5 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2'-[1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl)methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 152713-37-6 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-phenylethyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 152713-38-7 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 1-(2,6-dichlorophenyl)-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 152713-45-6 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2,3-dichlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 152713-46-7 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2,4-dichlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 152713-47-8 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2,5-dichlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 152713-48-9 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-(2,4,6-trichlorophenyl)- (9CI) (CA INDEX NAME)




RN 152713-49-0 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 1-[(1,1'-biphenyl)-2-yl]-3-butyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 152713-50-3 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-phenylethyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 138733-44-5 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-chlorophenyl)-4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 138733-45-6 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-((2'-cyano[1,1'-biphenyl]-4-yl)methyl)-1-(2-methylphenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 152713-51-4 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 1-(phenylmethyl)-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




IT 138733-43-4P 138733-44-5P 138733-45-6P
 138733-46-7P 138733-47-8P 138733-49-0P
 152713-57-0P 152713-58-1P 152713-59-2P
 152713-60-5P 152713-61-6P 152713-62-7P
 152713-63-8P 152713-64-9P 152713-65-0P
 152713-66-1P 152713-67-2P 152713-68-3P
 152713-69-4P 152713-70-7P 152713-71-8P
 152713-72-9P 152713-73-0P 152713-74-1P
 152713-75-2P 152713-76-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and cyclization of, with azide, triazole deriv. from)
 RN 138733-43-4 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 138733-46-7 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1-(2,6-dichlorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 138733-47-8 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1-(2-(trifluoromethyl)phenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 138733-49-0 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1-(2,2,2-trifluoroethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 152713-57-0 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(3-chlorophenyl)-4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 152713-58-1 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(4-chlorophenyl)-4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 152713-59-2 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1-(2,4-dichlorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 152713-60-5 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1-(2,4,6-trichlorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 152713-61-6 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1-(2,5-dichlorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 152713-62-7 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1-(2,5-dichlorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)







RN 152713-63-8 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-((2'-cyano[1,1'-biphenyl]-4-yl)methyl)-1-(2-nitrophenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 152713-64-9 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-((2'-cyano[1,1'-biphenyl]-4-yl)methyl)-1-(4-methoxyphenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 152713-65-0 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-((2'-cyano[1,1'-biphenyl]-4-yl)methyl)-1-(4-methoxy-2-nitrophenyl)-, ethyl ester (9CI) (CA INDEX NAME)




L6 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
 RN 152713-66-1 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 1-[1,1'-biphenyl]-2-yl-3-butyl-4-((2'-cyano[1,1'-biphenyl]-4-yl)methyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 152713-67-2 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-((2'-cyano[1,1'-biphenyl]-4-yl)methyl)-1-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 152713-68-3 CAPLUS
 CN 1H-Pyrazole-3-carboxylic acid, 5-butyl-4-((2'-cyano[1,1'-biphenyl]-4-yl)methyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 152713-69-4 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-((2'-cyano[1,1'-biphenyl]-4-yl)methyl)-1-ethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 152713-70-7 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-((2'-cyano[1,1'-biphenyl]-4-yl)methyl)-1-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 152713-71-8 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1-(2-phenylethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 152713-72-9 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid,
 4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-3-
 (2,6-dichlorophenyl)-3-propyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 152713-73-0 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid,
 4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-3-
 propyl-1-(2-(trifluoromethyl)phenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 152713-74-1 CAPLUS
 CN 1H-Pyrazole-3-carboxylic acid,
 4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-5-
 propyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 152713-75-2 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid,
 4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-3-
 propyl-1-(2,2,2-trifluoroethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 152713-76-3 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid,
 4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1-
 (phenylmethyl)-3-propyl-, ethyl ester (9CI) (CA INDEX NAME)




L6 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1993:580772 CAPLUS
 DOCUMENT NUMBER: 119:180772
 TITLE: (Bisphenylmethyl)pyrazoles for treatment of hypertension and cognitive disorders
 INVENTOR(S): Ross, Barry Clive; Middlemiss, David; Eldred, Colin David; Montana, John Gary; Shah, Pritom
 PATENT ASSIGNEE(S): Glaxo Group Ltd., UK
 SOURCE: PCT Int. Appl., 89 pp.
 CODEN: PIKXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

Patent No. Kind Date Application No. Date
 WO 9305025 A1 19930318 WO 1991-GB1521 19910906 --
 W: BG, CS, HU, LK, PL, RO, SU
 RW: BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG
 OTHER SOURCE(S): MARPAT 119:180772
 GI



I




II

AB The title angiotensin II-inhibiting compds. I [R1 = H, C1-6 alkyl, C2-6 alkenyl; R2 = H, (un)substituted C1-6 alkyl, (un)substituted C3-7 cycloalkyl, (un)substituted C1-6 alkenyl, Ph, etc.; R3 = H, (un)substituted C1-6 alkyl, C2-6 alkenyl, (un)substituted alkylamide, alkylcarbonyl, etc.; R4 = CO2H, NHCO2CF3, C atom-linked tetrazolyl groups], useful for the treatment or prophylaxis of hypertension, cognitive disorders, renal failure, hyperaldosteronism, cardiac insufficiency, congestive heart failure, post myocardial infarction,

L6 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
 glaucoma, etc. (no data), are prep'd. and formulation data presented. Thus, tetrazole deriv. II was prep'd. from 2-hexanone in 9 steps.


IT 137645-63-7P 137645-65-9P 137645-66-0P
 137645-67-1P 137645-73-7P 137645-72-8P
 137645-78-4P 137645-81-9P 137645-82-0P
 137645-87-5P 137645-88-6P 137645-89-7P
 137645-90-0P 137645-91-1P 137645-93-3P
 137646-03-8P 137646-04-9P 137646-12-9P
 137646-14-1P 137646-15-2P 137646-17-4P
 137646-18-5P 137646-28-7P 137646-33-4P
 137646-34-5P 137646-35-6P 137646-36-7P
 137646-37-8P 137646-38-9P 137646-39-0P
 137646-40-3P 137659-84-8P 137659-85-9P
 137659-86-0P 137659-87-1P 137659-88-2P
 137659-89-3P 137659-90-6P 137659-91-7P
 137659-92-8P 137659-93-9P 137659-97-3P
 137660-00-5P 137660-01-6P 137660-02-7P
 137660-03-8P 137660-04-9P 137660-05-0P
 137660-06-1P 137660-07-2P 137660-08-3P
 137660-09-4P 137660-10-7P 137660-11-8P
 137660-12-9P 137660-13-0P 137660-14-1P
 137660-15-2P 137660-16-3P 137660-17-4P
 137660-18-5P 137660-21-0P 137660-22-1P
 137660-23-2P 137660-25-4P 137660-26-5P
 137660-27-6P 137660-28-7P 137660-29-8P
 137660-30-1P 137660-31-2P 137660-35-6P
 137660-36-7P 137660-37-8P 137660-38-9P
 137660-39-0P 137660-40-3P 137660-41-4P
 137660-42-5P 137660-43-6P 137660-45-0P
 137660-48-1P 137660-49-2P 137660-50-5P
 137660-52-7P 137660-54-9P 137660-55-0P
 137660-56-1P 137660-57-2P 137661-64-2P
 137661-66-4P 137661-67-5P 137661-68-6P

RN RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prep'n. and reaction of, antihypertensive intermediates from)
 RN 137645-63-7 CAPLUS
 CN 1H-Tetrazole, 5-[4-[(3-butyl-5-[(phenylmethoxy)methyl]-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl] - (9CI) (CA INDEX NAME)




RN 137645-65-9 CAPLUS


L6 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
 CN 1H-Pyrazole-5-methanol,
 3-butyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-(2,2,2-trifluoroethyl) - (9CI) (CA INDEX NAME)



RN 137645-66-0 CAPLUS
 CN 1H-Pyrazole-3-methanol,
 5-butyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-(2,2,2-trifluoroethyl) - (9CI) (CA INDEX NAME)




RN 137645-67-1 CAPLUS
 CN 1H-Pyrazole-5-carboxaldehyde, 3-butyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-(2,2,2-trifluoroethyl) - (9CI) (CA INDEX NAME)




RN 137645-71-7 CAPLUS
 CN 1H-Pyrazole-5-methanol, 3-butyl-1-ethyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl] - (9CI) (CA INDEX NAME)

L6 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)


RN 137645-72-8 CAPLUS
 CN 1H-Pyrazole-5-methanol, 3-butyl-1-(1-methylethyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl] - (9CI) (CA INDEX NAME)




RN 137645-78-4 CAPLUS
 CN 1H-Pyrazole-5-methanol, 3-butyl-1-methyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl] - (9CI) (CA INDEX NAME)




RN 137645-81-9 CAPLUS
 CN 1H-Pyrazole-3-methanol, 1,5-dibutyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl] - (9CI) (CA INDEX NAME)




RN 137645-82-0 CAPLUS
 CN 1H-Pyrazole-5-methanol, 1-ethyl-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-87-5 CAPLUS
 CN 1H-Pyrazole-5-carboxaldehyde, 3-butyl-1-(1-methylethyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-88-6 CAPLUS
 CN 1H-Pyrazole-3-carboxaldehyde, 5-butyl-1-(1-methylethyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-93-3 CAPLUS
 CN 1H-Pyrazole-5-carboxaldehyde, 1-(1-methylethyl)-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-03-8 CAPLUS
 CN 1H-Pyrazole-5-methanol, 3-butyl-1-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-04-9 CAPLUS
 CN 1H-Pyrazole-5-carboxaldehyde, 1-ethyl-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-89-7 CAPLUS
 CN 1H-Pyrazole-5-carboxaldehyde, 3-butyl-1-(2-methylpropyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-90-0 CAPLUS
 CN 1H-Pyrazole-5-carboxaldehyde, 3-butyl-1-(cyclopropylmethyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-91-1 CAPLUS
 CN 1H-Pyrazole-5-carboxaldehyde, 3-butyl-1-cyclobutyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-12-9 CAPLUS
 CN 1H-Pyrazole-5-methanol, 1-(2-methylpropyl)-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-14-1 CAPLUS
 CN 1H-Pyrazole-5-methanol, 1-(2,2-dimethylpropyl)-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-15-2 CAPLUS
 CN 1H-Pyrazole-5-carboxaldehyde, 3-butyl-1-methyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-17-4 CAPLUS
 CN 1H-Pyrazole-5-carboxaldehyde, 1-(2-methylpropyl)-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-18-5 CAPLUS
 CN 1H-Pyrazole-5-carboxaldehyde, 1-(2,2-dimethylpropyl)-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-28-7 CAPLUS
 CN Methanesulfonamide,
 N-[4'-(3-butyl-1-ethyl-5-(hydroxymethyl)-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)




RN 137646-33-4 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-{[(3-butyl-5-(methoxymethyl)-1H-pyrazol-4-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137646-34-5 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid,
 4'-{[(5-butyl-3-(methoxymethyl)-1-phenyl-1H-pyrazol-4-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137646-35-6 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid,
 4'-{[(3-butyl-5-(methoxymethyl)-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137646-36-7 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid,
 4'-{[(5-butyl-3-(methoxymethyl)-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 137646-37-8 CAPLUS
 CN 2H-Tetrazole, 5-[(4'-(3-butyl-5-(methoxymethyl)-1H-pyrazol-4-yl)methyl)[1,1'-biphenyl]-2-yl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 137646-38-9 CAPLUS
 CN 2H-Tetrazole, 5-[(4'-(3-butyl-5-(methoxymethyl)-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl)[1,1'-biphenyl]-2-yl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 137646-39-0 CAPLUS
 CN 2H-Tetrazole, 5-[(4'-(3-butyl-5-(methoxymethyl)-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl)[1,1'-biphenyl]-2-yl]-2-(trifluoromethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
 1H-pyrazol-4-yl)methyl]1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI)
 (CA INDEX NAME)




RN 137646-40-3 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(1-(2-amino-2-oxoethyl)-5-butyl-3-(methoxymethyl)-1H-pyrazol-4-yl)methyl]-, 1,1-dimethylethyl ester (9CI)
 (CA INDEX NAME)




RN 137659-84-8 CAPLUS
 CN Methanesulfonamide,
 N-[4'-(1-ethyl-5-(hydroxymethyl)-3-propyl-1H-pyrazol-4-yl)methyl]1,1'-biphenyl]-2-yl]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)

L6 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137659-85-9 CAPLUS
 CN Methanesulfonamide, N-[4'-(1-ethyl-5-formyl-3-propyl-1H-pyrazol-4-yl)methyl]1,1'-biphenyl]-2-yl]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)




RN 137659-86-0 CAPLUS
 CN Methanesulfonamide, N-[4'-(3-butyl-1-ethyl-5-formyl-1H-pyrazol-4-yl)methyl]1,1'-biphenyl]-2-yl]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)

L6 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137659-87-1 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid,
 4'-(3-butyl-5-(methoxymethyl)-1-phenyl-1H-pyrazol-4-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137659-88-2 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(1-(2-amino-2-oxoethyl)-3-butyl-5-(methoxymethyl)-1H-pyrazol-4-yl)methyl]-, 1,1-dimethylethyl ester (9CI)
 (CA INDEX NAME)


L6 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137659-89-3 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid,
 4'-(15-butyl-3-(methoxymethyl)-1-methyl-1H-pyrazol-4-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137659-90-6 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid,
 4'-(13-butyl-5-(methoxymethyl)-1-methyl-1H-pyrazol-4-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137659-91-7 CAPLUS
 CN 2H-Tetrazole, 5-[(3-butyl-1-[(dimethylamino)sulfonyl]-5-(methoxymethyl)-1H-pyrazol-4-yl)methyl]-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137659-92-8 CAPLUS
 CN 2H-Tetrazole, 5-[(3-butyl-1-ethyl-5-(methoxymethyl)-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-01-6 CAPLUS
 CN 2H-Tetrazole, 5-[(3-butyl-1-ethyl-5-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-02-7 CAPLUS
 CN 2H-Tetrazole, 5-[(3-butyl-1-ethyl-3-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-03-8 CAPLUS
 CN 2H-Tetrazole, 5-[(3-butyl-1-(1-methylethyl)-5-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)





RN 137659-93-9 CAPLUS
 CN 2H-Tetrazole, 5-[(3-butyl-1-ethyl-3-(methoxymethyl)-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137659-97-3 CAPLUS
 CN 2H-Tetrazole, 5-[(3-butyl-5-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-00-5 CAPLUS
 CN 2H-Tetrazole, 5-[(3-[(phenylmethoxy)methyl]-5-propyl-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-04-9 CAPLUS
 CN 2H-Tetrazole, 5-[(3-butyl-1-(1-methylethyl)-3-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-05-0 CAPLUS
 CN 2H-Tetrazole, 5-[(3-butyl-1-(3-methylpropyl)-5-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-06-1 CAPLUS
 CN 2H-Tetrazole, 5-[(3-butyl-1-(cyclopropylmethyl)-5-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-07-2 CAPLUS
 CN 2H-Tetrazole, 5-[4'-[(5-butyl-1-(cyclopropylmethyl)-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-08-3 CAPLUS
 CN 2H-Tetrazole, 5-[4'-[(3-butyl-1-cyclobutyl-5-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-09-4 CAPLUS
 CN 2H-Tetrazole, 5-[4'-[(3-butyl-1-methyl-5-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-10-7 CAPLUS
 CN 2H-Tetrazole, 5-[4'-[(5-butyl-1-methyl-3-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-11-8 CAPLUS
 CN 2H-Tetrazole, 5-[4'-[(3-butyl-5-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-12-9 CAPLUS
 CN 2H-Tetrazole, 5-[4'-[(5-butyl-3-[(phenylmethoxy)methyl]-1-propyl-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-13-0 CAPLUS
 CN 2H-Tetrazole, 5-[4'-[(1,3-dibutyl-5-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-14-1 CAPLUS
 CN 2H-Tetrazole, 5-[4'-[(1,5-dibutyl-3-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-15-2 CAPLUS
 CN 2H-Tetrazole, 5-[4'-[(1-ethyl-5-[(phenylmethoxy)methyl]-3-propyl-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 137660-16-3 CAPLUS
 CN 2H-Tetrazole, 5-[4'-[(1-ethyl-3-[(phenylmethoxy)methyl]-5-propyl-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-17-4 CAPLUS
 CN 2H-Tetrazole, 5-[4'-[(1-(1-methylethyl)-5-[(phenylmethoxy)methyl]-3-propyl-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-18-5 CAPLUS
 CN 2H-Tetrazole, 5-[4'-[(1-(1-methylethyl)-3-[(phenylmethoxy)methyl]-5-propyl-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)

09899322


L6 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 137660-21-0 CAPLUS
CN 2H-Tetrazole, 5-[4'-(3-ethyl-5-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-22-1 CAPLUS
CN 2H-Tetrazole, 5-[4'-(1,3-diethyl-5-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-23-2 CAPLUS
CN 2H-Tetrazole, 5-[4'-(1,5-diethyl-3-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137660-25-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-5-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137660-26-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-1-ethyl-5-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137660-27-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(5-butyl-1-ethyl-3-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L6 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137660-29-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(5-butyl-1-(1-methylethyl)-3-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137660-28-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-1-(1-methylethyl)-5-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 137660-30-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-1-ethyl-5-(hydroxymethyl)-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137660-31-2 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-5-(hydroxymethyl)-1-(1-methylethyl)-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137660-35-6 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(1-(2-methylpropyl)-5-[(phenylmethoxy)methyl]-3-propyl-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl) (9CI) (CA INDEX NAME)



RN 137660-38-9 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(1-(2,2-dimethylpropyl)-5-[(phenylmethoxy)methyl]-3-propyl-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl) (9CI) (CA INDEX NAME)




RN 137660-39-0 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(1-(2,2-dimethylpropyl)-3-[(phenylmethoxy)methyl]-5-propyl-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl) (9CI) (CA INDEX NAME)




RN 137660-40-3 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(3-butyl-5-(methoxymethyl)-1-(2-propenyl)-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl) (9CI) (CA INDEX NAME)




RN 137660-36-7 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(1-(2-methylpropyl)-3-[(phenylmethoxy)methyl]-5-propyl-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl) (9CI) (CA INDEX NAME)




RN 137660-37-8 CAPLUS
 CN 1H-Pyrazole-6-carboxylic acid, 3-butyl-4-[(2'-(1,1-dimethylethoxy)carbonyl)[1,1'-biphenyl]-4-yl)methyl]-1-(1-methylethyl) (9CI) (CA INDEX NAME)




RN 137660-41-4 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(1-(2-butyl-3-(methoxymethyl)-1-(2-propenyl)-1H-pyrazol-4-yl)methyl)[1,1'-biphenyl]-2-yl]-2-(triphenylmethyl) (9CI) (CA INDEX NAME)




RN 137660-42-5 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(5-butyl-1-methyl-3-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137660-43-6 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-5-(hydroxymethyl)-1-methyl-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137660-45-8 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-((2'-(1,1-dimethylethoxy)carbonyl)[1,1'-biphenyl]-4-yl)methyl)-1-methyl- (9CI) (CA INDEX NAME)




RN 137660-48-1 CAPLUS
 CN 1H-Pyrazole, 4-((2'-(1,1'-biphenyl)-4-yl)methyl)-3-((phenylmethoxy)methyl)-5-propyl- (9CI) (CA INDEX NAME)




RN 137660-49-2 CAPLUS
 CN 1H-Pyrazole, 3-butyl-4-((2'-(1,1'-biphenyl)-4-yl)methyl)-5-((phenylmethoxy)methyl)- (9CI) (CA INDEX NAME)




RN 137660-50-5 CAPLUS
 CN 1H-Pyrazole, 1-ethyl-4-((2'-(1,1'-biphenyl)-4-yl)methyl)-5-((phenylmethoxy)methyl)-3-propyl- (9CI) (CA INDEX NAME)




RN 137660-52-7 CAPLUS
 CN 1H-Pyrazole, 3-butyl-1-ethyl-4-((2'-(1,1'-biphenyl)-4-yl)methyl)-5-((phenylmethoxy)methyl)- (9CI) (CA INDEX NAME)




RN 137660-54-9 CAPLUS
 CN [1,1'-Biphenyl]-2-amine, 4'--((1-ethyl-5-((phenylmethoxy)methyl)-3-propyl-1H-pyrazol-4-yl)methyl)- (9CI) (CA INDEX NAME)




RN 137660-55-0 CAPLUS
 CN [1,1'-Biphenyl]-2-amine,
 4'--((1-ethyl-1-ethyl-5-((phenylmethoxy)methyl)-1H-pyrazol-4-yl)methyl)- (9CI) (CA INDEX NAME)




RN 137660-56-1 CAPLUS
 CN Methanesulfonamide,
 N-[(1-ethyl-5-((phenylmethoxy)methyl)-3-propyl-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)




RN 137660-57-2 CAPLUS
 CN Methanesulfonamide, N-[4'-(3-butyl-1-ethyl-5-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)




RN 137681-64-2 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(5-butyl-1-[(dimethylamino)sulfonyl]-3-(methoxymethyl)-1H-pyrazol-4-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137681-66-4 CAPLUS
 CN 2H-Tetrazole,
 5-[4'-(5-butyl-1-(2-methylpropyl)-3-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 137681-67-5 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(5-butyl-1-cyclobutyl)-3-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 137681-68-6 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-5-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 137645-46-6P 137645-47-7P 137645-48-8P
 137645-49-9P 137645-50-2P 137645-59-3P
 137645-70-6P 137645-73-9P 137645-74-0P
 137645-75-1P 137645-76-2P 137645-77-3P
 137645-79-5P 137645-80-8P 137645-82-1P
 137645-84-2P 137645-85-3P 137645-86-4P
 137645-92-2P 137645-94-4P 137645-95-5P
 137645-96-6P 137645-97-7P 137645-98-8P
 137645-99-9P 137646-00-5P 137646-01-6P
 137646-02-7P 137646-05-0P 137646-06-1P
 137646-07-2P 137646-08-3P 137646-09-4P
 137646-10-7P 137646-11-8P 137646-13-0P
 137646-16-3P 137646-19-6P 137646-20-9P
 137646-21-0P 137646-22-1P 137646-23-2P
 137646-24-3P 137646-25-4P 137646-26-5P
 137646-27-6P 137646-29-8P 137646-30-1P
 137659-82-6P 137659-83-7P 137660-32-3P
 137660-33-4P 137660-34-5P 137660-44-7P
 137660-51-6P 137660-53-8P 137660-54-3P

RL: SPN (Synthetic preparation); PRP (Preparation)
 (prepn. of, as angiotensin II inhibitor)

RN 137645-46-6 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-5-(methoxymethyl)-1H-pyrazol-4-yl)methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 137645-45-5
 CMF C23 H26 N2 O3




CM 2


CRN 76-05-1
 CMF C2 H F3 O2




RN 137645-47-7 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid,
 4'-(5-butyl-3-(methoxymethyl)-1-phenyl-1H-pyrazol-4-yl)methyl- (9CI) (CA INDEX NAME)




RN 137645-48-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid,
4'-([3-butyl-5-(methoxymethyl)-1-phenyl-
1H-pyrazol-4-yl]methyl)- (9CI) (CA INDEX NAME)




RN 137645-49-9 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid,
 4'-(3-butyl-5-(methoxymethyl)-1-(2,2,2-
 trifluoroethyl)-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-68-2 CAPLUS
CN 1H-Pyrazole-3-carboxaldehyde, 5-butyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-(2,2,2-trifluoroethyl) (9CI) (CA INDEX NAME)




RN 137645-69-3 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




BN 137645-70-6 CAPLUS




RN 137645-73-9 CAPLUS
CN 1H-Pyrazole-3-methanol, 5-butyl-1-(1-methylethyl)-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl-4-yl]methyl]- (9CI) (CA INDEX NAME)




RN 137645-74-0 CAPLUS
CN 1H-Pyrazole-5-methanol,
3-butyl-1-(cyclopropylmethyl)-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]-(9CI) (CA INDEX NAME)




RN 137645-75-1 CAPLUS
CN 1H-Pyrazole-3-methanol, 5-butyl-1-ethyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-76-2 CAPLUS
CN 1H-Pyrazole-5-methanol, 3-butyl-1-cyclobutyl-4-[(2'-(1H-tetrazol-5-yl)1-phenylvinyl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-77-3 CAPLUS
CN 1H-Pyrazole-3-methanol, 5-butyl-1-cyclobutyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-79-5 CAPLUS
CN 1H-Pyrazole-3-methanol, 5-butyl-1-methyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-80-8 CAPLUS
 CN 1H-Pyrazole-5-methanol, 1,3-dibutyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-83-1 CAPLUS
 CN 1H-Pyrazole-3-methanol, 1-ethyl-5-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-84-2 CAPLUS
 CN 1H-Pyrazole-5-methanol, 1-(1-methylethyl)-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-94-4 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-ethyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-95-5 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(1-methylethyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-96-6 CAPLUS
 CN 1H-Pyrazole-3-carboxylic acid, 5-butyl-1-(1-methylethyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-85-3 CAPLUS
 CN 1H-Pyrazole-3-methanol, 1-(1-methylethyl)-5-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-86-4 CAPLUS
 CN 1H-Pyrazole-5-carboxaldehyde, 3-butyl-1-ethyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-92-2 CAPLUS
 CN 1H-Pyrazole-5-carboxaldehyde, 1,3-dibutyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-97-7 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-methylpropyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-98-8 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-cyclobutyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-99-9 CAPLUS
 CN 1H-Tetrazole, 5-[(3-butyl-1-phenyl-1H-pyrazol-4-yl)methyl]-2-yl- (9CI) (CA INDEX NAME)




RN 137646-00-5 CAPLUS
CN 1H-Pyrazole-5-methanol, 1,3-diethyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-01-6 CAPLUS
CN 1H-Pyrazole-3-methanol, 1,5-diethyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-02-7 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-carboxy[1,1'-biphenyl]-4-yl)methyl]-1-ethyl- (9CI) (CA INDEX NAME)




RN 137646-05-0 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 1-ethyl-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-06-1 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 1-((1-methylethyl)-3-propyl-4-([2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl)- (9CI) (CA INDEX NAME)





RN 137646-07-2 CAPLUS




RN 137646-08-3 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-carboxy[1,1'-biphenyl]-4-yl)methyl]-1-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 137646-09-4 CAPLUS
CN 1H-Pyrazole-3-methanol, 5-butyl-1-(2-methylpropyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-11-8 CAPLUS
CN 1H-Pyrazole-3-methanol, 5-butyl-1-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-13-0 CAPLUS
CN 1H-Pyrazole-3-methanol,
1-(2-methylpropyl)-5-propyl-4-([2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl)- (9CI) (CA INDEX NAME)




RN 137646-16-3 CAPLUS
CN 1H-Pyrazole-5-carboxaldehyde, 3-butyl-1-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-19-6 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(cyclopropylmethyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-20-9 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-methyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)





RN 137646-21-0 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-22-1 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 1-(2-methylpropyl)-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-23-2 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 1-(2-dimethylpropyl)-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-25-4 CAPLUS
 CN 1H-Pyrazole-3-carboxylic acid, 1,5-dibutyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-26-5 CAPLUS
 CN 1H-Tetrazole, 5-[(4-[(5-butyl-1-(methoxymethyl)-1-(2-propenyl)-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl)- (9CI) (CA INDEX NAME)



RN 137646-27-6 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-carboxy[1,1'-biphenyl]-4-yl)methyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 137646-29-8 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 1-ethyl-3-propyl-4-[(2'-(trifluoromethyl)sulfonyl)amino][1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-30-1 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-ethyl-4-[(2'-(trifluoromethyl)sulfonyl)amino][1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)

09899322


L6 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137659-82-6 CAPLUS
CN 1H-Pyrazole-3-methanol, 1-(2,2-dimethylpropyl)-5-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137659-83-7 CAPLUS
CN 1H-Tetrazole,
5-[(4-[(3-butyl-5-(methoxymethyl)-1-(2-propenyl)-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]- (9CI) (CA INDEX NAME)



L6 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137660-44-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-5-formyl-1-methyl-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137660-51-6 CAPLUS
CN 1H-Pyrazole, 1-ethyl-4-[(2'-nitro[1,1'-biphenyl]-4-yl)methyl]-3-[(phenylmethoxy)methyl]-5-propyl- (9CI) (CA INDEX NAME)

L6 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
RN 137660-32-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-1-ethyl-5-formyl-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137660-33-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid,
4'-(3-butyl-5-formyl-1-(1-methylethyl)-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137660-34-5 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-(1,1-dimethylethoxy)carbonyl)[1,1'-biphenyl]-4-yl)methyl]-1-ethyl- (9CI) (CA INDEX NAME)


L6 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137660-53-8 CAPLUS
CN 1H-Pyrazole, 5-butyl-1-ethyl-4-[(2'-nitro[1,1'-biphenyl]-4-yl)methyl]-3-[(phenylmethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 137660-58-3 CAPLUS
CN 1H-Pyrazole-5-methanol, 3-butyl-1-(2-methylpropyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




IT 137645-50-2P 137645-51-3P 137645-52-4P
 137645-53-5P 137645-54-6P 137645-56-8P
 137645-57-9P 137645-58-0P 137645-59-1P
 137645-60-4P 137645-61-5P 137645-62-6P
 137645-64-8P 137659-80-4P 137659-81-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as angiotensin II inhibitor)
 RN 137645-50-2 CAPLUS
 CN 1H-Tetrazole, 5-[4'-(3-butyl-5-(methoxymethyl)-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl] [1,1'-biphenyl]-2-yl] - (9CI) (CA INDEX NAME)




RN 137645-51-3 CAPLUS
 CN 1H-Tetrazole, 5-[4'-(5-butyl-3-(methoxymethyl)-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl] [1,1'-biphenyl]-2-yl] - (9CI) (CA INDEX NAME)




RN 137645-52-4 CAPLUS



RN 137645-53-5 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(1-(2-amino-2-oxoethyl)-3-butyl-5-(methoxymethyl)-1H-pyrazol-4-yl)methyl] - (9CI) (CA INDEX NAME)




RN 137645-54-6 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid,
 4'-(15-butyl-3-(methoxymethyl)-1-methyl-1H-pyrazol-4-yl)methyl] - (9CI) (CA INDEX NAME)



RN 137645-56-8 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid,
 4'-(3-butyl-5-(methoxymethyl)-1-methyl-1H-pyrazol-4-yl)methyl], mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 137645-55-7
 CMF C24 H28 N2 O3




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 137645-57-9 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(5-butyl-1-[(dimethylamino)sulfonyl]-3-(methoxymethyl)-1H-pyrazol-4-yl)methyl] - (9CI) (CA INDEX NAME)




RN 137645-58-0 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-1-[(dimethylamino)sulfonyl]-5-(methoxymethyl)-1H-pyrazol-4-yl)methyl] - (9CI) (CA INDEX NAME)

09899322


L6 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137645-59-1 CAPLUS
CN 1H-Tetrazole, 5-[4'-[(3-butyl-1-ethyl-5-(methoxymethyl)-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]- (9CI) (CA INDEX NAME)




RN 137645-60-4 CAPLUS
CN 1H-Tetrazole, 5-[4'-[(5-butyl-1-ethyl-3-(methoxymethyl)-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]- (9CI) (CA INDEX NAME)




L6 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 137659-80-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid,
4'-[(5-butyl-3-(methoxymethyl)-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137659-81-5 CAPLUS
CN 1H-Tetrazole, 5-[4'-[(3-butyl-5-(methoxymethyl)-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]- (9CI) (CA INDEX NAME)




IT 137659-94-0P 137681-65-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L6 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)

RN 137645-61-5 CAPLUS
CN 1H-Pyrazole-1-sulfonamide, 3-butyl-5-(methoxymethyl)-N,N-dimethyl-4-[(2-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-62-6 CAPLUS
CN 1H-Pyrazole-1-sulfonamide, 5-butyl-3-(methoxymethyl)-N,N-dimethyl-4-[(2-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-64-8 CAPLUS
CN 1H-Tetrazole, 5-[4'-[(5-butyl-3-((phenylmethoxy)methyl)-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]- (9CI) (CA INDEX NAME)

L6 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
(prepn. of, as antihypertensive)

RN 137659-94-0 CAPLUS
CN 1H-Pyrazole-1-sulfonamide, 5-butyl-3-(methoxymethyl)-N,N-dimethyl-4-[(2-(2-(triphenylmethyl)-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137681-65-3 CAPLUS
CN 1H-Pyrazole-1-sulfonamide, 3-butyl-5-(methoxymethyl)-N,N-dimethyl-4-[(2-(2-(triphenylmethyl)-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)



Kamal Saeed

L6 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1993:574814 CAPLUS
 DOCUMENT NUMBER: 119:174814
 TITLE: Substituted pyrazoles, isoxazoles and isothiazoles as
 neurotensin antagonists
 INVENTOR(S): Chakravarty, Prasun K.; Ransom, Richard W.
 PATENT ASSIGNEE(S): Merck and Co., Inc., USA
 SOURCE: Brit. UK Pat. Appl., 51 pp.
 CODEN: BAXXDU
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2263638	A1	19930804	GB 1993-1003	19930120 <-
PRIORITY APPLN. INFO.:			US 1992-827126	19920128
GI				




AB Substituted pyrazoles, isoxazoles, and isothiazoles, as disclosed in patent application WO91/15479-A1, are neurotensin antagonists useful for the treatment of certain central nervous system and gastrointestinal disorders. The compds. have the general formula I [$K = O, S, NR_7$ ($R_7 = H, (substituted) Cl-10 alkyl, aryl, etc.$); $R_1 = NH_2O_2R_{23}, NH_2O_2NHCOR_{23}, SO_2NH_2R_{23}$, etc. ($R_{23} = aryl, heteroaryl, C_3-7 cycloalkyl, etc.$); $R_{2a}, R_{2b} = H, Cl, Br, I, F, CF_3, Cl-4 alkyl, Cl-4 alkoxy, Cl-4 alkyl, Cl-4 alkoxy; R_{3a} = H, Cl, Br, I, F, Cl-6 alkyl, Cl-6 alkoxy, Cl-6 aryl-C_1-4 alkyl; R_{3b} = H, Cl, Br, I, F, CF_3, Cl-6 alkyl, etc.; R_6 = H, (substituted) Cl-6 alkyl, aryl, etc.; R_8 = H, OH, NH_2, CH_2OH, Cl, Br, I, F, etc.; $r = 1, 2$; E = single bond, O, CO, etc.; X = C-C single bond, CO, O, S, etc.]. Representative compds. of the invention were tested with a neurotensin binding assay using human frontal cortex.$


IT 138732-72-6 150282-42-1 150282-43-2
 150282-44-3 150282-45-4 150282-46-5
 150282-47-6 150282-48-7 150282-49-8
 150282-50-1 150282-51-2 150282-52-3
 150282-53-4 150282-54-5 150282-55-6
 150282-56-7 150282-57-8 150282-59-9
 RL: BIOL (Biological study)

L6 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
 (as neurotensin antagonist, for treatment of central nervous system disorder or gastrointestinal disorder)

RN 138732-72-6 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-(1-(cyclopropylcarbonyl)amino)sulfonyl)[1,1'-biphenyl]-4-yl)methyl]-1-[2-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 150282-42-1 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2,4-dichlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 150282-43-2 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2,5-dichlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)


L6 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 150282-44-3 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-(2,4,6-trichlorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 150282-45-4 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(3-chlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




L6 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)

RN 150282-46-5 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(4-chlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 150282-47-6 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2,3-dichlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 150282-48-7 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(phenylmethyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)

09899322

L6 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 150282-49-8 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-(cyclopropylcarbonyl)amino)sulfonyl](1,1'-biphenyl)-4-yl)methyl]-1-(2,6-dichlorophenyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 150282-50-1 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-[(2'-(cyclopropylcarbonyl)amino)sulfonyl](1,1'-biphenyl)-4-yl)methyl]-1-(2,2,2-trifluoroethyl)-, ethyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 150282-51-2 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-chlorophenyl)-4-[(2'-(cyclopropylcarbonyl)amino)sulfonyl](1,1'-biphenyl)-4-yl)methyl ester (9CI) (CA INDEX NAME)




RN 150282-52-3 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-chlorophenyl)-4-[(2'-(6-[(1,1-dimethyllethoxy)carbonyl]amino)-1-oxohexyl)amino)sulfonyl](1,1'-biphenyl)-4-yl)methyl]-ethyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 150282-53-4 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2,4-dichlorophenyl)-4-[(2'-(6-[(1,1-dimethyllethoxy)carbonyl]amino)-1-oxohexyl)amino)sulfonyl](1,1'-biphenyl)-4-yl)methyl]-ethyl ester (9CI) (CA INDEX NAME)



RN 150282-54-5 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-(6-[(1,1-dimethyllethoxy)carbonyl]amino)-1-oxohexyl)amino)sulfonyl](1,1'-biphenyl)-4-yl)methyl]-1-(2,4,6-trichlorophenyl)-ethyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 1-A




PAGE 2-A



RN 150282-55-6 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 4-[(2'-(6-amino-1-oxohexyl)amino)sulfonyl](1,1'-biphenyl)-4-yl)methyl]-3-butyl-1-(2,4,6-trichlorophenyl)-ethyl ester (9CI) (CA INDEX NAME)



PAGE 1-A




RN 150282-57-8 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 4-[(2'-(6-amino-1-oxohexyl)amino)sulfonyl][1,1'-biphenyl]-4-yl)methyl]-3-butyl-1-(2-chlorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)




PAGE 2-A

RN 150282-56-7 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 4-[(2'-(6-amino-1-oxohexyl)amino)sulfonyl][1,1'-biphenyl]-4-yl)methyl]-3-butyl-1-(2,4-dichlorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 150282-58-9 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-chlorophenyl)-4-[(2'-(6-amino-1-oxohexyl)amino)sulfonyl][1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI)



DOCUMENT NUMBER: 119:85413
 TITLE: C-Linked pyrazole biaryl tetrazoles as antagonists of angiotensin II

AUTHOR(S): Middlemiss, D.; Ross, B. C.; Eldred, C.; Montana, J. G.; Shah, P.; Hirst, G. C.; Watson, S. P.; Panchal, T.

CORPORATE SOURCE: A.; Paton, J. M. S.; et al.
 SOURCE: Glaxo Group Res., Ware/Hertfordshire, SG12 0DP, UK
 Bioorganic & Medicinal Chemistry Letters (1992)

1), 2(10), 1243-6
 CODEN: BMCLB8; ISSN: 0960-894X


DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The identification of a novel series of C-linked pyrazole biaryl tetrazoles as antagonists of angiotensin II is described. These compds. are highly potent in vitro (pKB ca. 10) and some of the compds. cause significant redns. in blood pressure at 1 mg kg⁻¹ p.o. in renal hypertensive rats. Structure-activity relations are described.


IT 137645-69-3 137645-70-0 137645-71-7
 137645-94-4 137645-95-5 137645-97-7
 137645-98-8 137646-02-7 137646-07-2
 137646-19-6 137646-20-9 137646-21-0
 137646-30-1 138773-73-4 149050-56-6
 149050-57-7 149050-58-8

RL: BIOL (Biological study)
 (angiotensin II antagonist activity of, antihypertensive activity and structure in relation to)


RN 137645-69-3 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 137645-70-6 CAPLUS
 CN 1H-Pyrazole-3-carboxylic acid, 5-butyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 137645-71-7 CAPLUS
 CN 1H-Pyrazole-5-methanol, 3-butyl-1-ethyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-94-4 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-ethyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-95-5 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(1-methylethyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-97-7 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-methylpropyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-98-8 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-cyclobutyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-02-7 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-carboxy[1,1'-biphenyl]-4-yl)methyl]-1-ethyl- (9CI) (CA INDEX NAME)




RN 137646-07-2 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 1,3-dibutyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-19-6 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(cyclopropylmethyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-20-9 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-methyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-21-0 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-30-1 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-ethyl-4-[(2'-(trifluoromethyl)sulfonyl)amino][1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 138717-73-4 CAPLUS
 CN 1H-Pyrazole-3-carboxylic acid, 5-butyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 149050-56-6 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-ethyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 149050-57-7 CAPLUS
 CN 1H-Pyrazole-5-carboxamide, 3-butyl-1-ethyl-N-methyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 149050-58-8 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2,2-dimethylpropyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1993:101948 CAPLUS
 DOCUMENT NUMBER: 118:101948
 TITLE: Preparation of 3-pyrazolone derivatives as
 angiotensin
 II antagonists and antihypertensives.
 INVENTOR(S): Hoornaeert, Christian; Daumas, Marc; Aletru, Michel;
 Muller, Jean Claude
 PATENT ASSIGNEE(S): Synthelabo S. A., Fr.
 SOURCE: Fr. Demande, 27 pp.
 CODEN: FRXXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2672891	A1	19920821	FR 1991-2031	19910220 --
FR 2672891	B1	19940218		

OTHER SOURCE(S): MARPAT 118:101948
 GI



AB 3-Pyrazolones I [X = bond, O, S, OCH2, CH2O, CO; R1 = linear or branched C1-7 alkyl, C3-9 alkenyl, or cyclo(C3-7)alkyl(C1-6)alkyl; R2 = linear or branched C1-7 alkyl, C3-9 alkenyl, or C3-9 alkynyl, (un)substituted aryl, aryl(C1-3)alkyl, aryoxy(C1-3)alkyl, arylthio(C1-3)alkyl, cyclo(C3-7)alkyl(C1-3)alkyl, heteroaryl(C1-3)alkyl; R3 = CO2H, SO3H, PO3H2, 1H-tetrazol-5-yl, NHCOR11, NHOSO2R11, CONHSO2R11 (R11 = Me, CF3, (un)substituted Ph), CONHOR12, SO2NHR12 (R12 = halo, Me, (un)substituted Ph, tetrazolyl derivs., oxadiazolyl and thiadiazolyl derivs.), their tautomers, and pharmaceutically acceptable salts with acids, are prepd. Reaction of 16 g Me 3-oxoheptanoate with 40.12 g Me 4'- (bromomethyl)biphenyl-2-carboxylate and 5.57 g NaOMe in MeOH gave 42.2 g ester II, which (4 g) was heated with 1.52 g PhCH2NNH2 at 90 degree. under Ar to give 1.8 g I (R1 = Bu, R2 = PhCH2, R3 = CO2Me, X = bond) (III). Sapon. of 1.6 g III followed by acidification gave 0.69 acid I (R3 = CO2H, others remain unchanged). I had IC50 of 10 nM to 10 .mu.M against angiotensin II binding at rabbit adrenal cortex prepn. in vitro.

IT 145822-20-4P 145822-21-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 RN: 145821-88-1 CAPLUS
 CN: (1,1'-Biphenyl)-2-carboxylic acid, 4-[(3-butyl-4,5-dihydro-1-methyl-5-oxo-



RN 149050-56-6 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-ethyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 149050-57-7 CAPLUS
 CN 1H-Pyrazole-5-carboxamide, 3-butyl-1-ethyl-N-methyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 149050-58-8 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2,2-dimethylpropyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
 (Reactant or reagent)
 (prepn. and hydrolysis of)

RN 145822-20-4 CAPLUS
 CN (1,1'-Biphenyl)-2-carboxylic acid, 4-[(3-butyl-4,5-dihydro-1-methyl-5-oxo-1-phenylmethyl)-1H-pyrazol-4-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 145822-21-5 CAPLUS
 CN 3H-Pyrazol-3-one, 5-butyl-2,4-dihydro-2-(phenylmethyl)-4-[(2'-(1-triphenylmethyl)-1H-tetrazol-5-yl)-1,1'-biphenyl]- (9CI) (CA INDEX NAME)




IT 145821-88-1P 145821-89-2P 145821-90-5P
 145821-91-6P 145821-92-7P 145821-93-8P
 145821-94-9P 145821-95-0P 145821-96-1P
 145821-97-2P 145821-98-3P 145821-99-4P
 145822-00-0P 145822-01-1P 145822-02-2P
 145822-03-3P 145822-04-4P 145822-05-5P
 145822-06-6P 145822-07-7P 145822-08-8P
 145822-09-9P 145822-10-0P 145822-11-3P
 145822-12-4P 145822-13-5P 145822-14-6P
 145822-15-7P 145822-16-8P 145822-17-9P
 145822-18-0P 145822-19-1P 145850-35-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as antagonist of angiotensin II)


RN 145821-88-1 CAPLUS
 CN (1,1'-Biphenyl)-2-carboxylic acid, 4-[(3-butyl-4,5-dihydro-1-methyl-5-oxo-

09899322

L6 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
1H-pyrazol-4-yl)methyl] - (9CI) (CA INDEX NAME)




RN 145821-89-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-4,5-dihydro-1-(3-methoxyphenyl)-5-oxo-1H-pyrazol-4-yl)methyl] - (9CI) (CA INDEX NAME)




RN 145821-90-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-1-(4-chlorophenyl)-4,5-dihydro-5-oxo-1H-pyrazol-4-yl)methyl] - (9CI) (CA INDEX NAME)

L6 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 145821-91-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-4,5-dihydro-5-oxo-1-(phenylmethyl)-1H-pyrazol-4-yl)methyl] - (9CI) (CA INDEX NAME)




RN 145821-92-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-4,5-dihydro-5-oxo-1-(2-phenylethyl)-1H-pyrazol-4-yl)methyl] - (9CI) (CA INDEX NAME)

L6 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 145821-93-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-4,5-dihydro-5-oxo-1-(3-phenylpropyl)-1H-pyrazol-4-yl)methyl] - (9CI) (CA INDEX NAME)


L6 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 145821-95-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-1-(cyclohexylmethyl)-4,5-dihydro-5-oxo-1H-pyrazol-4-yl)methyl] - (9CI) (CA INDEX NAME)




RN 145821-94-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-4,5-dihydro-5-oxo-1-(2-phenoxyethyl)-1H-pyrazol-4-yl)methyl] - (9CI) (CA INDEX NAME)



RN 145821-96-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(1,3-dibutyl-4,5-dihydro-5-oxo-1H-pyrazol-4-yl)methyl] - (9CI) (CA INDEX NAME)


09899322

L6 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 145821-97-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid,
4'-(3-butyl-1-(2-cyclohexylethyl)-4,5-
dihydro-5-oxo-1H-pyrazol-4-yl)methyl- (9CI) (CA INDEX NAME)

PAGE 1-A




L6 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




PAGE 2-A

RN 145821-98-3 CAPLUS
CN 3H-Pyrazol-3-one,
5-butyl-2,4-dihydro-2-(phenylmethyl)-4-[(2'-(1H-tetrazol-
5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 145821-99-4 CAPLUS
CN 3H-Pyrazol-3-one, 5-butyl-2,4-dihydro-2-(2-phenylethyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 145822-00-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid,
4'-(3-butyl-1-[(4-chlorophenyl)methyl]-
4,5-dihydro-5-oxo-1H-pyrazol-4-yl)methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




L6 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




PAGE 1-A

RN 145822-01-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-4,5-dihydro-5-oxo-1-[(4-
(trifluoromethyl)phenyl)methyl]-1H-pyrazol-4-yl)methyl- (9CI) (CA INDEX
NAME)

PAGE 2-A



RN 145822-02-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-4,5-dihydro-1-[(4-
methylphenyl)methyl]-5-oxo-1H-pyrazol-4-yl)methyl- (9CI) (CA INDEX
NAME)



PAGE 2-A



Kamal Saeed

09899322

L6 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



L6 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A



PAGE 1-A

PAGE 2-A





PAGE 2-A

RN 145822-03-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[[3-butyl-4,5-dihydro-1-[(4-methoxyphenyl)methyl]-5-oxo-1H-pyrazol-4-yl]methyl]- (9CI) (CA INDEX NAME)

RN 145822-04-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[[3-butyl-1-[(3-chlorophenyl)methyl]-4,5-dihydro-5-oxo-1H-pyrazol-4-yl]methyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)

L6 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 145822-05-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[[3-butyl-4,5-dihydro-1-[(3-methoxyphenyl)methyl]-5-oxo-1H-pyrazol-4-yl]methyl]- (9CI) (CA INDEX NAME)

RN 145822-07-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[[3-butyl-1-[(3-fluorophenyl)methyl]-4,5-dihydro-5-oxo-1H-pyrazol-4-yl]methyl]- (9CI) (CA INDEX NAME)




RN 145822-06-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[[3-butyl-4,5-dihydro-5-oxo-1-[(3-trifluoromethyl)phenyl)methyl]-1H-pyrazol-4-yl]methyl]- (9CI) (CA INDEX NAME)

RN 145822-08-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[[3-butyl-1-[(2-fluorophenyl)methyl]-

Kamal Saeed


09899322

L6 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
4,5-dihydro-5-oxo-1H-pyrazol-4-yl)methyl] - (9CI) (CA INDEX NAME)




RN 145822-09-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-{[3-butyl-4,5-dihydro-1-{(2-methylphenyl)methyl}-5-oxo-1H-pyrazol-4-yl]methyl}- (9CI) (CA INDEX NAME)


L6 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 145822-10-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-{[3-butyl-1-((2-chlorophenyl)methyl)-4,5-dihydro-5-oxo-1H-pyrazol-4-yl]methyl}- (9CI) (CA INDEX NAME)




L6 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
RN 145822-11-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-{[3-butyl-4,5-dihydro-1-(3-methylbutyl)-5-oxo-1H-pyrazol-4-yl]methyl}- (9CI) (CA INDEX NAME)




RN 145822-12-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-{[3-butyl-1-[(3,4-difluorophenyl)methyl]-4,5-dihydro-5-oxo-1H-pyrazol-4-yl]methyl}- (9CI) (CA INDEX NAME)

L6 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 2-A




RN 145822-13-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-{[3-butyl-1-[(3,5-difluorophenyl)methyl]-4,5-dihydro-5-oxo-1H-pyrazol-4-yl]methyl}- (9CI) (CA INDEX NAME)





RN 145822-14-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-{[3-butyl-1-[(3,4-dichlorophenyl)methyl]-4,5-dihydro-5-oxo-1H-pyrazol-4-yl]methyl}- (9CI) (CA INDEX NAME)

PAGE 1-A




Kamal Saeed

PAGE 1-A




RN 145822-16-8 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-1-[(3,5-dimethoxyphenyl)methyl]-4,5-dihydro-5-oxo-1H-pyrazol-4-yl)methyl)- (9CI) (CA INDEX NAME)


PAGE 2-A




RN 145822-15-7 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-1-[(3,5-dichlorophenyl)methyl]-4,5-dihydro-5-oxo-1H-pyrazol-4-yl)methyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
 RN 145822-17-9 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-4,5-dihydro-1-[(3-methoxyphenyl)methyl]-5-oxo-1H-pyrazol-4-yl)methyl)- (9CI) (CA INDEX NAME)




RN 145822-18-0 CAPLUS
 CN 3H-Pyrazol-3-one, 5-butyl-2-(cyclohexylmethyl)-2,4-dihydro-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 145822-19-1 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-(2-cyclopentylethyl)-4,5-dihydro-5-oxo-1-(phenylmethyl)-1H-pyrazol-4-yl)methyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 145850-35-7 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-1-[(4-fluorophenyl)methyl]-4,5-dihydro-5-oxo-1H-pyrazol-4-yl)methyl)- (9CI) (CA INDEX NAME)

PAGE 1-A







L6 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1992:162413 CAPLUS
 DOCUMENT NUMBER: 116:162413
 TITLE: Silver halide color photographic material with improved processing stability
 INVENTOR(S): Keguchi, Hiroyuki; Hirabayashi, Shigeto
 PATENT ASSIGNEE(S): Konica Co., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 44 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03160442	A2	19910710	JP 1989-299771	19891120 <--

GI




AB A Ag halide color photog. material contains a pyrazolaoazole magenta coupler [I; Z = a nonmetal at. group leaving upon reaction with the oxidized form of a color developing agent; R = H, a substituent] and Coup[Time]eSc [Coup = a coupler residue releasing (Time)eSc upon reaction with an oxidized color developing agent; Time = a timing group releasing Sc after (Time)eSc being released from Coup; Sc = a scavenger or its precursor for the oxidized color developing agent which can be scavenged by redox or coupling reaction of the oxidized color developing agent; e = 0, 1] and a binder crosslinked by a hardening agent L(SO2A)m (L = a m-valent linking group contg. an ether bond; A = CH:CH2, CH2CH2B; B = a group releasing by a base in the form of BH). The color photog. material provides high coloration and excellent color reprodn. and shows little change in the photog. properties when the pH of a color developing soln. fluctuates.
 IT 139600-53-6
 RL: DEV (Device component use); USES (Uses)
 (color photog. films contg., for scavenging oxidized color developing agents)
 RN 139600-53-6 CAPLUS
 CN Benzoic acid, 3-[[5-[[3-[(2-carboxyethyl)amino]carbonyl]-4-hydroxy-1-naphthalenyl]oxy]-1-(4-nitrophenyl)-3-undecyl-1H-pyrazol-4-yl)methyl]-4,5-dihydroxy-, propyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1992:106284 CAPLUS
 DOCUMENT NUMBER: 116:106284
 TITLE: Preparation of substituted pyrazoles, isoxazoles and isothiazoles as angiotensin II antagonists
 INVENTOR(S): Allen, Eric E.; Greenlee, William J.; MacCoss, Malcolm; Ashton Co., Inc., USA
 PATENT ASSIGNEE(S): Merck and Co., Inc., USA
 SOURCE: PCT Int. Appl., 171 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9115479	A1	19911017	WO 1991-US1952	19910327 <--
W: CA, JP RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, Iu, NL, SE CA 2079343	AA	19911001	CA 1991-2079343	19910327 <--
EP 523141	A1	19930120	EP 1991-907490	19910327 <--
R: CH, DE, FR, GB, IT, Iu, NL JP 05505822	T2	19930826	JP 1991-507326	19910327 <--
PRIORITY APPLN. INFO.:			US 1990-501469	19900330
			WO 1991-US1952	19910327

OTHER SOURCE(S): MARPAT 116:106284
 GI



AB Title compds. I [I = bond, (substituted) amino, (alkyl)thio, (alkyl)sulfinyl, (alkyl)sulfonyl, CH(OH), O, CO, K = O, S, NH, (substituted)alkylamino, etc.; X = bond, CO, O, S, NH, etc.; R1 = HO2C, HO3S, Cl-4 polyfluorosulfonylaminos, H2NSO2, (HO)2P(O), (substituted)heterocyclyl, etc.; R2a, R2b = H, halo, H2N, O2N, Cl-4 alkyl, Cl-4 alkoxy, etc.; R3a = H, halo, Cl-6 alkyl, Cl-6 alkoxy, etc.; R3b = H, halo, O2N, Cl-6 alkyl, hydroxy-Cl-4-alkyl, etc.; R6 = Cl-3 alkyl, Cl-5

L6 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
 alkenyl, C₂-5 alkynyl which can be substituted, R₈ = H, HO, (alkyl)(dialkyl)amino, etc.; κ = 1, 2) and their salts, as angiotensin II antagonists useful in treatment of hypertension, ocular hypertension, on certain CNS disorders (no data) are prep'd. 5-Amino-3-butyl-1-(2-chlorophenyl)-4-[(2-tetrazol-5-ylbiphenyl-4-yl)methyl]pyrazole (prepn. given) in CCl_4 was diazotized to give the pyrazole deriv. which was heated


with NaCN in DMSO to give the nitrilepyrazole which was dild. with brine and extd. with ether to give the title pyrazole II. Pharmaceutical formulations comprising II are given.

IT 138733-40-19 138733-43-4P 138733-44-5P
 138733-45-6P 138733-46-7P 138733-47-8P
 138733-49-0P 138733-54-7P 138733-55-8P
 138733-57-0P 138733-58-1P 138733-59-2P
 138733-60-5P 138733-61-6P 138762-16-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); (prepn. and reaction of, in prepn. of angiotensin II inhibitors)

RN 138733-40-1 CAPLUS


CN 1H-Tetrazole, 5-[(3-butyl-5-chloro-1-(2-chlorophenyl)-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]- (9CI) (CA INDEX NAME)



RN 138733-43-4 CAPLUS


CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1-phenyl-, ethyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 138733-44-5 CAPLUS


CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-chlorophenyl)-4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 138733-45-6 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1-(2-methylphenyl)-, ethyl ester (9CI) (CA INDEX NAME)


L6 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 138733-46-7 CAPLUS


CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1-(2,6-dichlorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 138733-49-0 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1-(2,2,2-trifluoroethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 138733-47-8 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1-(2-trifluoromethylphenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 138733-54-7 CAPLUS


CN 1H-Pyrazole-5-carboxylic acid, 4-[(2'-aminosulfonyl)[1,1'-biphenyl]-4-yl)methyl]-3-butyl-1-(2-chlorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 138733-55-8 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 4-[(2'-(aminosulfonyl)(1,1'-biphenyl)-4-yl)methyl]-3-butyl-1-(2-chlorophenyl)-, (9CI) (CA INDEX NAME)




RN 138733-57-0 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-chlorophenyl)-4-[(2'-nitro[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 138733-58-1 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 4-[(2'-(aminobiphenyl-4-yl)methyl)-3-butyl-1-(2-chlorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 138733-59-2 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 4-[(2'-(bis(trifluoromethyl)sulfonyl)amino)[1,1'-biphenyl]-4-yl)methyl]-3-butyl-1-(2-chlorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 138733-60-5 CAPLUS
 CN 1H-Pyrazole-5-amine, 3-butyl-1-(2-chlorophenyl)-4-[(2'-(2-(triphenylmethyl)-2H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-, (9CI) (CA INDEX NAME)



RN 138733-61-6 CAPLUS
 CN Methanesulfonamide, N-(3-butyl-1-(2-chlorophenyl)-4-[(2'-(2-phenylmethyl)-2H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-1H-pyrazole-5-yl)-1,1,1-trifluoro- (9CI) (CA INDEX NAME)



RN 138762-16-0 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-chlorophenyl)-4-[(2'-(trifluoroacetyl)amino)sulfonyl][1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)



IT 137645-69-3P 138531-94-9P 138717-61-0P
 138717-62-1P 138717-63-2P 138717-64-3P
 138717-65-4P 138717-66-5P 138717-67-6P
 138717-68-7P 138717-69-8P 138717-70-1P
 138717-71-2P 138717-72-3P 138717-73-4P
 138717-74-5P 138717-75-6P 138717-76-7P
 138717-77-8P 138718-04-4P 138718-05-5P
 138732-46-5P 138732-49-7P 138732-50-0P
 138732-51-1P 138732-52-2P 138732-53-3P
 138732-54-4P 138732-55-5P 138732-56-6P
 138732-57-7P 138732-58-8P 138732-59-9P
 138732-60-2P 138732-61-3P 138732-62-4P
 138732-63-5P 138732-64-6P 138732-65-7P
 138732-66-8P 138732-67-9P 138732-68-0P
 138732-69-1P 138732-70-2P 138732-71-3P
 138732-72-6P 138732-73-7P 138732-74-8P


L6 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)

138732-75-9 138732-76-0P 138732-77-1P
 138732-78-2P 138732-79-3P 138732-80-6P
 138732-81-7P 138732-82-8P 138732-83-9P
 138732-84-0P 138732-85-1P 138732-86-2P
 138732-87-3P 138732-88-4P 138732-89-5P
 138732-90-6P 138732-91-9P 138732-92-0P
 138732-93-1P 138732-94-2P 138732-95-3P
 138732-96-4P 138732-97-5P 138732-98-6P
 138732-99-7P 138733-00-3P 138733-01-4P
 138733-02-5P 138733-03-6P 138733-04-7P
 138733-05-8P 138733-06-9P 138733-07-0P
 138733-08-1P 138733-09-2P 138733-10-5P
 138733-11-6P 138733-12-7P 138733-13-8P
 138733-14-9P 138733-15-0P 138733-16-1P
 138733-17-2P 138733-18-3P 138733-19-4P
 138733-20-7P 138733-21-8P 138733-22-9P
 138733-23-0P 138733-24-1P 138733-25-2P
 138733-26-3P 138733-27-4P 138733-28-5P
 138733-29-6P 138733-30-9P 138733-31-0P
 138733-32-1P 138733-33-2P 138733-34-3P
 138733-35-4P 138733-36-5P 138733-37-6P
 138733-38-7P 138762-09-1P 138762-10-4P
 138762-11-5P 138762-12-6P 138762-13-7P
 138762-14-8P 138762-15-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prep. of, as angiotensin II inhibitor)

RN: 137645-69-3 CAPLUS


CN: 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN: 138531-94-9 CAPLUS


CN: Pyridineisulfonamide,
 N-(3-butyl-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN: 138717-61-0 CAPLUS


CN: 1H-Pyrazol-5-amine, 3'-butyl-1-(2-chlorophenyl)-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN: 138717-62-1 CAPLUS


CN: 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-chlorophenyl)-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN: 138717-63-2 CAPLUS

CN: 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-phenyl-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN: 138717-64-3 CAPLUS


CN: 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-phenyl-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN: 138717-65-4 CAPLUS


CN: 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-chlorophenyl)-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN: 138717-66-5 CAPLUS

CN: 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-methylphenyl)-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN: 138717-67-6 CAPLUS

CN: 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-methylphenyl)-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN: 138717-68-7 CAPLUS


CN: 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2,6-dichlorophenyl)-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 138717-69-8 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2,6-dichlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 138717-70-1 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-[2-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-(2,2,2-trifluoroethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 138717-75-6 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 4-[(2'-(benzoylamino)sulfonyl)[1,1'-biphenyl]-4-yl)methyl]-3-butyl-1-(2-chlorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 138717-76-7 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-chlorophenyl)-4-[(2'-(trifluoroacetyl)amino)sulfonyl][1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)


RN 138717-71-2 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 138717-72-3 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 5-butyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 138717-73-4 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 5-butyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 138717-74-5 CAPLUS




RN 138717-77-8 CAPLUS
CN Methanesulfonamide, N-[3-butyl-1-(2-chlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-pyrazol-5-yl]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)




RN 138718-04-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-[(5-amino-3-butyl-1-phenyl-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)

09899322

L6 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 138718-05-5 CAPLUS
CN 1H-Pyrazol-5-amine, 3-butyl-1-phenyl-4-((2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl)- (9CI) (CA INDEX NAME)




RN 138732-48-6 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 4-((2'-(benzoylamino)sulfonyl)[1,1'-biphenyl]-4-yl)methyl-3-butyl-1-(2-chlorophenyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 138732-49-7 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-chlorophenyl)-4-((2'-(trifluoromethyl)sulfonyl)amino)[1,1'-biphenyl]-4-yl)methyl- (9CI) (CA INDEX NAME)




RN 138732-50-0 CAPLUS
CN 1H-Pyrazole-5-ol, 3-butyl-1-phenyl-4-((2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 138732-51-1 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-phenyl-4-((2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 138732-52-2 CAPLUS
CN 1H-Pyrazole-5-methanol, 3-butyl-1-phenyl-4-((2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl)- (9CI) (CA INDEX NAME)




RN 138732-53-3 CAPLUS
CN 1H-Pyrazole-5-methanol, 3-butyl-1-(2-chlorophenyl)-4-((2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 138732-54-4 CAPLUS
CN 1H-Pyrazole-5-methanol, 1-(2-chlorophenyl)-3-propyl-4-((2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl)- (9CI) (CA INDEX NAME)



RN 138732-55-5 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-methylphenyl)-4-((2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 138732-56-6 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-nitrophenyl)-4-((2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl)-, methyl ester (9CI) (CA INDEX NAME)


Kamal Saeed

09899322

L6 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
NAME)




RN 138732-57-7 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-1-[2-(trifluoromethyl)phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 138732-58-8 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-chloro-4-methoxyphenyl)-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)


L6 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 138732-59-9 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-propyl-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 138732-60-2 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-methylpropyl)-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 138732-61-3 CAPLUS


L6 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(pentafluoroethyl)-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 138732-62-4 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(cyclohexylmethyl)-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 138732-63-5 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-[(dimethylamino)methyl]-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




L6 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)


RN 138732-64-6 CAPLUS
CN Acetamide, N-[3-butyl-1-(2-chlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 138732-65-7 CAPLUS
CN 1H-Pyrazole-5-amine, 3-butyl-1-(2-chlorophenyl)-N,N-dimethyl-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 138732-66-8 CAPLUS
CN 1H-Pyrazole-5-amine, 3-butyl-1-(2-chlorophenyl)-N-propyl-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 138732-67-9 CAPLUS
CN 1H-Tetrazole, 5-[(4-[(3-butyl-1-(2-chlorophenyl)-5-methoxy-1H-pyrazol-4-yl)methyl]-1,1'-biphenyl)-2-yl]- (9CI) (CA INDEX NAME)


Kamal Saeed




RN 138732-68-0 CAPLUS
 CN 1H-Tetrazole, 5-[(4'-[(3-butyl-1-(2-chlorophenyl)-5-propoxy-1H-pyrazol-4-yl)methyl]biphenyl)-2-yl]- (9CI) (CA INDEX NAME)




RN 138732-69-1 CAPLUS
 CN 1H-Tetrazole, 5-[(4'-[(3-butyl-1-(2-chlorophenyl)-5-(methoxymethyl)biphenyl)-2-yl]- (9CI) (CA INDEX NAME)




RN 138732-70-4 CAPLUS
 CN 1H-Tetrazole, 5-[(4'-[(3-butyl-1-(2-chlorophenyl)-5-(methylsulfinyl)biphenyl)-2-yl]- (9CI) (CA INDEX NAME)




RN 138732-71-5 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2-[(cyclopropylcarbonyl)amino]sulfonyl)biphenyl]-4-yl)methyl]-1-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 138732-72-6 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2-[(cyclopropylcarbonyl)amino]sulfonyl)biphenyl]-4-yl)methyl]-1-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 138732-73-7 CAPLUS
 CN Cyclopropanecarboxamide, N-[(4'-[(3-butyl-1-[2-(trifluoromethyl)phenyl]-5-[(trifluoromethyl)sulfonyl]amino)-1H-pyrazol-4-yl)methyl]biphenyl)-2-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 138732-75-9 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 4-[(2-[(cyclopropylcarbonyl)amino]sulfonyl)biphenyl]-4-yl)methyl]-3-propyl-1-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 138732-74-8 CAPLUS
 CN Cyclopropanecarboxamide, N-[(4'-[(3-butyl-5-[(pentafluoroethyl)sulfonyl]amino)-1H-pyrazol-4-yl)methyl]biphenyl)-2-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 138732-76-0 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 4-[(2-[(cyclopropylcarbonyl)amino]sulfonyl)biphenyl]-4-yl)methyl]-3-propyl-1-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)


09899322

L6 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 138732-77-1 CAPLUS
CN Cyclopropanecarboxamide,
N-[(4'-(3-propyl-1-(2-(trifluoromethyl)phenyl)-5-
[(trifluoromethyl)sulfonyl]amino)-1H-pyrazol-4-yl)methyl](1,1'-biphenyl)-
2-yl)sulfonyl] - (9CI) (CA INDEX NAME)


L6 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
propyl-1-(2-(trifluoromethyl)phenyl)-1H-pyrazol-4-yl)methyl](1,1'-
biphenyl)-2-yl)sulfonyl] - (9CI) (CA INDEX NAME)



RN 138732-79-3 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-butyl-4-[(2'-
[(cyclopropylcarboxylamino)sulfonyl](1,1'-biphenyl)-4-yl)methyl]-
(9CI) (CA INDEX NAME)




RN 138732-78-2 CAPLUS
CN Cyclopropanecarboxamide,
N-[(4'-(5-[(pentafluoroethyl)sulfonyl]amino)-3-




RN 138732-80-6 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-
[(cyclopropylcarboxylamino)sulfonyl](1,1'-biphenyl)-4-yl)methyl]-1-(2,6-
dichlorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 138732-81-7 CAPLUS
CN Cyclopropanecarboxamide, N-[(4'-(3-butyl-1-(2,6-dichlorophenyl)-5-
[(trifluoromethyl)sulfonyl]amino)-1H-pyrazol-4-yl)methyl](1,1'-biphenyl)-
2-yl)sulfonyl] - (9CI) (CA INDEX NAME)


L6 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 138732-83-9 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-{[(1-
oxobutyl)amino]sulfonyl}(1,1'-biphenyl)-4-yl)methyl]-1-(2-
(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)



RN 138732-82-8 CAPLUS
CN Cyclopropanecarboxamide, N-[(4'-(3-butyl-1-(2,6-dichlorophenyl)-5-
[(pentafluoroethyl)sulfonyl]amino)-1H-pyrazol-4-yl)methyl](1,1'-biphenyl)-
2-yl)sulfonyl] - (9CI) (CA INDEX NAME)




RN 138732-84-0 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-{[(1-
oxobutyl)amino]sulfonyl}(1,1'-biphenyl)-4-yl)methyl]-1-(2-
(trifluoromethyl)phenyl)-, ethyl ester (9CI) (CA INDEX NAME)


Kamal Saeed

09899322

L6 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 138732-85-1 CAPLUS
 CN Butanamide, N-[(4'-(3-butyl-1-(2-(trifluoromethyl)phenyl)-5-((trifluoromethyl)sulfonyl)amino)-1H-pyrazol-4-yl)methyl](1,1'-biphenyl)-2-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 138732-86-2 CAPLUS
 CN Butanamide, N-[(4'-(3-butyl-5-((pentafluoroethyl)sulfonyl)amino)-1-(2-(trifluoromethyl)phenyl)-1H-pyrazol-4-yl)methyl](1,1'-biphenyl)-2-yl)sulfonyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 138732-87-3 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 4-[(2'-(1-oxobutyl)amino)sulfonyl][1,1'-biphenyl]-4-yl)methyl]-3-propyl-1-(2-(trifluoromethyl)phenyl)-1H-pyrazole-5-carboxylic acid, 4-[(2'-(1-oxobutyl)amino)sulfonyl][1,1'-biphenyl]-2-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 138732-88-4 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2,6-dichlorophenyl)-4-[(2'-(1-oxobutyl)amino)sulfonyl][1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 138732-89-5 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2,6-dichlorophenyl)-4-[(2'-(1-oxobutyl)amino)sulfonyl][1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 138732-90-8 CAPLUS
 CN Butanamide, N-[(4'-(3-butyl-1-(2,6-dichlorophenyl)-5-((trifluoromethyl)sulfonyl)amino)-1H-pyrazol-4-yl)methyl](1,1'-biphenyl)-2-yl)sulfonyl]- (9CI) (CA INDEX NAME)


L6 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 138732-91-9 CAPLUS
 CN Butanamide, N-[(4'-(3-butyl-1-(2,6-dichlorophenyl)-5-((2'-(1H-tetrazol-5-yl)amino)sulfonyl)-1H-pyrazol-4-yl)methyl](1,1'-biphenyl)-2-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 138732-92-0 CAPLUS
 CN Methanesulfonamide, N-(3-butyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-[2-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl)-1,1,1-trifluoro- (9CI) (CA INDEX NAME)




RN 138732-93-1 CAPLUS
 CN Ethanesulfonamide, N-(3-butyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-[2-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl)-1,1,2,2,2-pentafluoro- (9CI) (CA INDEX NAME)




RN 138732-94-2 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-[2-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 138732-95-3 CAPLUS
 CN Methanesulfonamide, 1,1,1-trifluoro-N-[3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-[2-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)




RN 138732-96-4 CAPLUS
 CN Methanesulfonamide, N-[3-butyl-1-(2,6-dichlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-pyrazol-5-yl]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)




RN 138732-97-5 CAPLUS
 CN Ethanesulfonamide, N-[3-butyl-1-(2,6-dichlorophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-pyrazol-5-yl]-1,1,2,2,2-pentafluoro- (9CI) (CA INDEX NAME)




RN 138732-98-6 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-[(4-methoxyphenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-pyrazol-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)




L6 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
 RN 138732-99-7 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(4-methoxyphenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 138733-00-3 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-nitrophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 138733-01-4 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-nitrophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 138733-02-5 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-[(4-methoxy-2-nitrophenyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-pyrazol-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)

09899322


L6 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)- (9CI) (CA INDEX NAME)



RN 138733-03-6 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-pyridinyl)-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 138733-04-7 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(phenylmethyl)-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 138733-05-8 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 1-(2-chlorophenyl)-3-propyl-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]- (9CI) (CA INDEX NAME)


L6 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 138733-06-9 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 1-(2,6-dichlorophenyl)-3-propyl-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 138733-07-0 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-propyl-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-1-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 138733-08-1 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-propyl-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]- (9CI) (CA INDEX NAME)


L6 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
biphenyl)-4-yl)methyl)-1-(2,2,2-trifluoroethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 138733-09-2 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-propyl-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 138733-10-5 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 5-propyl-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 138733-11-6 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 5-propyl-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 138733-12-7 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-chlorophenyl)-4-[(2'-(cyclopropylcarbonyl)amino)sulfonyl](1,1'-biphenyl)-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 138733-13-8 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2,6-dichlorophenyl)-4-[(2'-(2-methyl-1-oxopropyl)amino)sulfonyl](1,1'-biphenyl)-4-yl)methyl]- (9CI) (CA INDEX NAME)


Kamal Saeed




RN 138733-14-9 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-(3-cyclopentyl-1-oxopropyl)amino)sulfonyl](1,1'-biphenyl)-4-yl)methyl]-1-[(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 138733-15-0 CAPLUS
 CN 1H-Pyrazole-3-carboxylic acid, 5-butyl-4-[(2'-(diphenylacetyl)amino)sulfonyl](1,1'-biphenyl)-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 138733-16-1 CAPLUS
 CN 1H-Pyrazole-3-carboxylic acid, 4-[(2'-(diphenylamino)carbonyl)amino]sulfonyl](1,1'-biphenyl)-4-yl)methyl]-5-propyl- (9CI) (CA INDEX NAME)




RN 138733-17-2 CAPLUS
 CN 1H-Pyrazole-3-carboxylic acid, 4-[(2'-(diphenylacetyl)amino)sulfonyl](1,1'-biphenyl)-4-yl)methyl]-5-propyl- (9CI) (CA INDEX NAME)




RN 138733-18-3 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 4-[(2'-(benzoylamino)sulfonyl)(1,1'-biphenyl)-4-yl)methyl]-1-(2-chlorophenyl)-3-propyl- (9CI) (CA INDEX NAME)




RN 138733-19-4 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 1-(2,6-dichlorophenyl)-3-propyl-4-[(2'-(trifluoromethyl)amino)sulfonyl](1,1'-biphenyl)-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 138733-20-7 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-(2-pyrimidinylamino)sulfonyl)(1,1'-biphenyl)-4-yl)methyl]-1-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 138733-21-8 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 4-[(2'-(4-nitrophenyl)amino)sulfonyl](1,1'-biphenyl)-4-yl)methyl]-3-propyl-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 138733-22-9 CAPLUS
 CN 1H-Pyrazole-3-carboxylic acid, 4-[(2'-(diphenylacetyl)amino)sulfonyl] [1,1'-biphenyl]-4-yl)methyl]-5-ethyl- (9CI) (CA INDEX NAME)




RN 138733-23-0 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-carboxy[1,1'-biphenyl]-4-yl)methyl]-1-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)




RN 138733-24-1 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-chlorophenyl)-4-[(2'-(phenylsulfonyl)amino)carbonyl] [1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 138733-25-2 CAPLUS
 CN 1H-Pyrazole-5-carboxamide, 3-butyl-N-(phenylsulfonyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 138733-26-3 CAPLUS
 CN Ethanesulfonamide, N-[(3-butyl-1-(2-chlorophenyl)-4-[(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-pyrazol-5-yl]-1,1,2,2,2-pentafluoro- (9CI) (CA INDEX NAME)




RN 138733-27-4 CAPLUS
 CN Benzamide, N-[(4'-(3-butyl-1-(2-chlorophenyl)-5-((trifluoromethyl)sulfonyl)amino)-1H-pyrazol-4-yl)methyl]-1,1'-biphenyl]-2-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 138733-28-5 CAPLUS
 CN Benzamide, N-[(4'-(3-butyl-1-(2-(trifluoromethyl)phenyl)-5-((trifluoromethyl)sulfonyl)amino)-1H-pyrazol-4-yl)methyl]-1,1'-biphenyl]-2-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 138733-29-6 CAPLUS
 CN Cyclopropanecarboxamide, N-[(4'-(3-butyl-1-(2-chlorophenyl)-5-((trifluoromethyl)sulfonyl)amino)-1H-pyrazol-4-yl)methyl]-1,1'-biphenyl]-2-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 138733-30-9 CAPLUS
 CN Cyclopropanecarboxamide, N-[(4'-(3-butyl-1-(2-chlorophenyl)-5-[(trifluoromethyl)sulfonyl]amino)-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]sulfonyl- (9CI) (CA INDEX NAME)




RN 138733-31-0 CAPLUS
 CN Methanesulfonamide, N-[(2-(2-chlorophenyl)-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-pyrazol-5-yl)-1,1,1-trifluoro- (9CI)




RN 138733-32-1 CAPLUS
 CN Benzamide, N-[(4'-(1-(2-chlorophenyl)-3-propyl-5-[(trifluoromethyl)sulfonyl]amino)-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]sulfonyl- (9CI) (CA INDEX NAME)




RN 138733-33-2 CAPLUS
 CN Benzamide, N-[(4'-(3-propyl-1-(2-(trifluoromethyl)phenyl)-5-[(trifluoromethyl)sulfonyl]amino)-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]sulfonyl- (9CI) (CA INDEX NAME)




RN 138733-34-3 CAPLUS
 CN Cyclopropanecarboxamide, N-[(4'-(1-(2-chlorophenyl)-3-propyl-5-[(trifluoromethyl)sulfonyl]amino)-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]sulfonyl- (9CI) (CA INDEX NAME)




RN 138733-35-4 CAPLUS
 CN Ethanesulfonamide, N-[(1-(2-chlorophenyl)-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-pyrazol-5-yl)-1,1,2,2,2-pentafluoro- (9CI) (CA INDEX NAME)




RN 138733-36-5 CAPLUS
 CN Methanesulfonamide, N-[(3-butyl-1-(2-chlorophenyl)-4-[(2'-(trifluoromethyl)sulfonyl)amino]-1H-pyrazol-5-yl)-1,1,1-trifluoro- (9CI) (CA INDEX NAME)




RN 138733-37-6 CAPLUS
 CN 1H-Pyrazole-5-carboxamide, 3-butyl-N-[(1-methylethyl)sulfonyl]-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 138733-38-7 CAPLUS
 CN 1H-Pyrazole-5-carboxamide, 3-butyl-N-(cyclopropylsulfonyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 138762-09-1 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 4-[(2'-{[(1-oxobutyl)amino]sulfonyl}[1,1'-biphenyl]-4-yl)methyl]-3-propyl-1-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 138762-10-4 CAPLUS
 CN Butanamide, N-[4'-(3-propyl-1-[2-(trifluoromethyl)phenyl]-5-[(trifluoromethyl)sulfonyl]amino)-1H-pyrazol-4-yl]methyl]-1,1'-biphenyl]-2-ylsulfonyl]- (9CI) (CA INDEX NAME)




RN 138762-11-5 CAPLUS
 CN Butanamide, N-[4'-(5-[(pentafluoroethyl)sulfonyl]amino)-3-propyl-1-[2-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]methyl]-1,1'-biphenyl]-2-ylsulfonyl]- (9CI) (CA INDEX NAME)




RN 138762-12-6 CAPLUS
 CN Ethanesulfonamide, 1,1,2,2,2-pentafluoro-N-[3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)




RN 138762-13-7 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-[(4-methoxy-2-nitrophenyl)-4-ylmethyl]-1H-pyrazol-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 138762-14-8 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 1-(2-chlorophenyl)-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 138762-15-9 CAPLUS
 CN Cyclopropanecarboxamide, N-[4'-(1-(2-chlorophenyl)-5-[(pentafluoroethyl)sulfonyl]amino)-3-propyl-1H-pyrazol-4-yl]methyl]-1,1'-biphenyl]-2-ylsulfonyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 23 OF 28 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1992:41353 CAPLUS
 DOCUMENT NUMBER: 116:41353
 TITLE: A new method for synthesis of 1H-pyrazol-3(2H)-ones
 AUTHOR(S): Magedov, I. V.; Smushkevich, Yu. I.
 CORPORATE SOURCE: Dep. Org. Chem., D. I. Mendelev Chem. Technol.
 Inst., Moscow, 125820, USSR
 SOURCE: Synthesis (1991), (10), 845-8
 CODEN: SYNTBF; ISSN: 0039-7881
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 116:41353
 GI



AB Dimethylpyrazolones I (R1 = Ph, 1-naphthyl, H, Me, 1-benzyl-3-indolyl, R2 = H, Me, Et, CHMe2, Ph, CH2Ph, CH2CH2Ph) were prep'd. by the intramol. cyclization of R1CH2CONMeMeCOR2 (II) in presence of LiN(SiMe3)2 and TMEDA. II were prep'd. by the methylation of R1CH2CONHNHCOR2 with PhSO3Me in presence of NaOH. This provides a new method synthesis of I.
 IT 138211-97-9
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 138211-97-9 CAPLUS
 CN 3H-Pyrazol-3-one, 5-ethyl-1,2-dihydro-1,2-dimethyl-4-(phenylmethyl)-(9CI)
 (CA INDEX NAME)




L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1992:6554 CAPLUS
 DOCUMENT NUMBER: 116:6554
 TITLE: Pyrazole derivatives as angiotensin II-receptor antagonists, process for their preparation, and pharmaceutical compositions containing them
 INVENTOR(S): Bru-Magniez, Nicole; Nicolai, Eric; Teulon, Jean
 Marie
 PATENT ASSIGNEE(S): Laboratoires UPSA S. A., Fr.
 SOURCE: Eur. Pat. Appl., 93 pp.
 CODEN: EPXXDW

DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 449699	A2	1991002	EP 1991-400717	19910318 <--
EP 449699	A3	19930407		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
FR 2659655	A1	19910920	FR 1990-3485	19900319 <--
FR 2659655	B1	19920724		
ZA 9101925	A	19920325	ZA 1991-1925	19910315 <--
AU 9173591	A1	19910919	AU 1991-73591	19910318 <--
CA 2038428	AA	19910920	CA 1991-2038428	19910318 <--
JP 04234851	A2	19920824	JP 1991-78251	19910319 <--

PRIORITY APPLN. INFO.: FR 1990-3485 19900319
 OTHER SOURCE(S): MARPAT 116:6554
 GI




AB Pyrazoles I [R1 = alkyl, alkenyl, cycloalkyl; R2 = H, alkyl, haloalkyl, cycloalkyl, etc.; A = hydroxylalkyl, alkoxyalkyl, haloalkyl, CHO, CO2H, CONH2, etc.; R4 = NO2, NH2, CO2H, alkoxyacetyl, various substituted Ph and thiényl groups] were prep'd. as cardiovascular agents, esp. for treatment of hypertension or cardiac insufficiency. Thus, Et [1-methyl-3-butyl-4-(4-nitrobenzyl)pyrazol-5-yl]oxyacetate (prepn. given) was hydrogenated over Raney Ni, and the resultant aminobenzyl compd. condensed with 3,6-dichlorophthalic anhydride in MeCN, to give title compd. II (isolated as dicyclohexylamine salt). II gave 96% displacement of [125I]-[Sar1,Tyr4,Ile8]-angiotensin II from rat suprarenal angiotensin II receptors in vitro at 10-5 M.
 IT 137860-94-7P

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 137860-94-7 CAPLUS
 CN 1H-Pyrazole-1-acetic acid, 2,3-dihydro-2-methyl-4-[(4-nitrophenyl)methyl]-3-oxo-5-propyl-, ethyl ester (9CI) (CA INDEX NAME)




IT 137645-50-2P 137645-65-9P 137645-78-4P
 137860-95-8P 137860-96-9P 137860-97-0P
 137860-98-1P 137860-99-2P 137861-00-8P
 137861-01-9P 137861-02-0P 137861-03-1P
 137861-04-2P 137861-05-3P 137861-06-4P
 137861-07-5P 137861-08-6P 137861-09-7P
 137861-10-0P 137861-11-1P 137861-12-2P
 137861-13-3P 137861-14-4P 137861-15-5P
 137861-16-6P 137861-17-7P 137861-18-8P
 137861-19-9P 137861-21-2P 137861-22-4P
 137861-23-5P 137861-24-6P 137861-25-7P
 137861-26-8P 137861-27-9P 137861-28-0P
 137861-29-1P 137861-30-4P 137861-31-5P
 137861-32-6P 137861-34-8P 137861-35-9P
 137861-36-0P 137861-37-1P 137861-38-2P
 137861-39-3P 137861-40-5P 137861-41-7P
 137861-42-8P 137861-43-9P 137861-44-0P
 137861-45-1P 137861-46-2P 137861-47-3P
 137861-48-4P 137861-49-5P 137861-50-6P
 137861-51-9P 137861-52-0P 137861-53-1P
 137861-54-2P 137861-55-3P 137861-56-4P
 137861-57-5P 137861-58-6P 137861-59-7P
 137861-60-0P 137861-61-1P 137861-62-2P
 137861-63-3P 137861-64-4P 137861-65-5P
 137861-66-6P 137861-67-7P 137861-68-8P
 137861-69-9P 137861-70-0P 137861-71-1P
 137861-72-4P 137861-73-5P 137861-74-6P
 137861-75-7P 137861-76-8P 137861-77-9P
 137861-78-0P 137861-79-1P 137861-80-4P
 137861-81-5P 137861-82-6P 137862-25-0P
 137862-26-9P 137862-27-0P 137862-28-1P
 137862-29-2P


L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prep. of, as drug intermediate)
 RN 137645-50-2 CAPLUS
 1H-Tetrazole, 5-[(4-[(3-butyl-5-(methoxymethyl)-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl]1,1'-biphenyl)-2-yl] - (9CI) (CA INDEX NAME)



RN 137645-65-9 CAPLUS
 CN 1H-Pyrazole-5-methanol,
 3-butyl-4-[(2-[(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 137645-78-4 CAPLUS
 CN 1H-Pyrazole-5-methanol, 3-butyl-1-methyl-4-[(2-[(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137860-95-8 CAPLUS


L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
 (1,1'-Biphenyl)-2-carbonitrile, 4'-(3-butyl-5-(1,3-dioxolan-2-yl)-1-methyl-1H-pyrazol-4-yl)methyl] - (9CI) (CA INDEX NAME)



RN 137860-96-9 CAPLUS
 CN 1H-Tetrazole,
 5-[(4-[(3-butyl-5-(1,3-dioxolan-2-yl)-1-methyl-1H-pyrazol-4-yl)methyl]1,1'-biphenyl)-2-yl] - (9CI) (CA INDEX NAME)




RN 137860-97-0 CAPLUS
 CN Acetic acid, [(4-[(4-aminophenyl)methyl]-3-butyl-1-methyl-1H-pyrazol-5-yl)oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 137860-98-1 CAPLUS

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
 CN Acetic acid, [(4-[(4-aminophenyl)methyl]-1-methyl-3-propyl-1H-pyrazol-5-yl)oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 137860-99-2 CAPLUS
 CN Acetic acid, [(4-[(4-aminophenyl)methyl]-1-methyl-3-propyl-1H-pyrazol-5-yl)oxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 137861-00-8 CAPLUS
 CN Acetic acid,
 [(4-[(4-aminophenyl)methyl]-3-propyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)oxy]-, methyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137861-01-9 CAPLUS
 CN 1H-Pyrazole-1-acetic acid, 4-[(4-aminophenyl)methyl]-5-hydroxy-3-propyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 137861-02-0 CAPLUS
 CN Acetic acid, [(4-[(4-aminophenyl)methyl]-5-propyl-1H-pyrazol-3-yl)oxy]-, ethyl ester (9CI) (CA INDEX NAME)

09899322

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137861-03-1 CAPLUS
CN 1H-Tetrazole,
5-[(4'-(5-(methoxymethyl)-3-propyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl)[1,1'-biphenyl]-2-yl]- (9CI) (CA INDEX NAME)



RN 137861-04-2 CAPLUS
CN Morpholine, 4-[(2-[(1-methyl-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-pyrazol-5-yl)oxy]ethyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137861-05-3 CAPLUS
CN Piperazine,
1-(2-methoxyphenyl)-4-[(1-methyl-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-pyrazol-5-yl)oxy]acetyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 1-A



PAGE 2-A




RN 137861-06-4 CAPLUS
CN Ethanamine, N,N-dimethyl-2-[(1-methyl-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-pyrazol-5-yl)oxy]- (9CI) (CA INDEX NAME)




L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)

RN 137861-07-5 CAPLUS
CN Thiomorpholine-4-[(3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)oxy]acetyl)- (9CI) (CA INDEX NAME)



RN 137861-08-6 CAPLUS
CN Carbamic acid, diethyl-,
1-methyl-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-pyrazol-5-yl ester (9CI) (CA INDEX NAME)




RN 137861-09-7 CAPLUS
CN Ethanol,
2-[(3-butyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)oxy]- (9CI) (CA INDEX NAME)


Kamal Saeed

09899322

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137861-10-0 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile,
4-[(3-butyl-5-formyl-1-methyl-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137861-11-1 CAPLUS
CN 1H-Pyrazole-5-methanol, 4-[(4-aminophenyl)methyl]-1-methyl-3-propyl- (9CI) (CA INDEX NAME)

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137861-12-2 CAPLUS
CN Benzenesulfonic acid,
2-[(4-[(5-[(2-[(2-methoxyethyl)amino]ethyl)amino]methyl]phenyl)amino]carbonyl)- (9CI) (CA INDEX NAME)




RN 137861-13-3 CAPLUS
CN Benzenesulfonic acid,
2-[(4-[(5-[(dimethylamino)carbonyl]oxy)-1-methyl-3-propyl-1H-pyrazol-4-yl)methyl]phenyl)amino]carbonyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137861-14-4 CAPLUS
CN Carbamic acid, diethyl-, 4-[(4-aminophenyl)methyl]-1-methyl-3-propyl-1H-pyrazol-5-yl ester (9CI) (CA INDEX NAME)


L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 137861-16-6 CAPLUS
CN Carbamic acid, dimethyl-, 4-[(4-aminophenyl)methyl]-1-methyl-3-propyl-1H-pyrazol-5-yl ester (9CI) (CA INDEX NAME)




RN 137861-15-5 CAPLUS
CN Benzenesulfonic acid, 2-[(4-[(3-butyl-5-(2-hydroxyethoxy)-1-methyl-1H-pyrazol-4-yl)methyl]phenyl)amino]carbonyl)- (9CI) (CA INDEX NAME)




RN 137861-17-7 CAPLUS
CN Morpholine, 4-[(4-[(4-aminophenyl)methyl]-3-butyl-1-methyl-1H-pyrazol-5-yl)oxy]acetyl- (9CI) (CA INDEX NAME)

09899322

16 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137861-18-8 CAPLUS
CN Benzenesulfonic acid, 2-[(4-[(3-butyl-1-methyl-5-(2-(4-morpholinyl)-2-oxoethoxy)-1H-pyrazol-4-yl)methyl]phenyl)amino]carbonyl- (9CI) (CA INDEX NAME)



RN 137861-19-9 CAPLUS
CN Ethanol, 2-[(4-[(4-aminophenyl)methyl]-3-butyl-1-methyl-1H-pyrazol-5-yl)oxy]- (9CI) (CA INDEX NAME)

16 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137861-21-3 CAPLUS
CN 1H-Pyrazole-1-acetic acid, 4-[(4-[(2-carboxy-3,6-dichlorobenzoyl)amino]phenyl)methyl]-5-(2-ethoxy-2-oxoethoxy)-3-propyl-, .alpha.-ethyl ester, compd. with N-cyclohexylcyclohexanamine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 137861-20-2
CMP C29 H31 Cl2 N3 O8

16 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




16 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 137861-23-5 CAPLUS
CN 1H-Pyrazole-1-acetic acid, 4-[(4-[(2-carboxy-3,6-dichlorobenzoyl)amino]phenyl)methyl]-5-hydroxy-3-propyl-, .alpha.-ethyl ester (9CI) (CA INDEX NAME)



CM 2

CRN 101-83-7
CMP C12 H23 N




RN 137861-22-4 CAPLUS
CN Acetic acid, [(1-methyl-3-propyl-4-[(4-[(2-sulfonylbenzoyl)amino]phenyl)methyl]-1H-pyrazol-5-yl)oxy]-, 1-ethyl ester (9CI) (CA INDEX NAME)


PAGE 2-A




Kamal Saeed




RN 137861-24-6 CAPLUS
CN 1H-Pyrazole-1-acetic acid, 4-[(4-aminophenyl)methyl]-5-(2-ethoxy-2-oxoethoxy)-3-propyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 137861-25-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-5-(carboxymethoxy)-1-methyl-1H-pyrazol-4-yl)methyl- (9CI) (CA INDEX NAME)




RN 137861-26-8 CAPLUS
CN Carbonic acid, 3-butyl-1-methyl-4-[(4-nitrophenyl)methyl]-1H-pyrazol-5-yl methyl ester (9CI) (CA INDEX NAME)




RN 137861-27-9 CAPLUS
CN Benzoic acid, 2-[[4-[(3-butyl-5-hydroxy-1-methyl-1H-pyrazol-4-yl)methyl]phenyl]amino]carbonyl-3,6-dichloro- (9CI) (CA INDEX NAME)




RN 137861-28-0 CAPLUS
CN Acetic acid, [[1-methyl-3-propyl-4-[(4-[(2-sulfonylbenzoyl)amino]phenyl)methyl]-1H-pyrazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 137861-29-1 CAPLUS
CN Benzoic acid, 2-[[4-[(5-(carboxymethoxy)-3-propyl-1H-pyrazol-4-yl)methyl]phenyl]amino]carbonyl- (9CI) (CA INDEX NAME)




RN 137861-30-4 CAPLUS
CN Benzoic acid, 2-[[4-[(5-(2-methoxy-2-oxoethoxy)-3-propyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl]phenyl]amino]carbonyl- (9CI) (CA INDEX NAME)




RN 137861-31-5 CAPLUS
CN Benzoic acid, 3,6-dichloro-2-[[4-[(5-(2-methoxy-2-oxoethoxy)-3-propyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl]phenyl]amino]carbonyl- (9CI) (CA INDEX NAME)

09899322

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 137861-32-6 CAPLUS
CN Benzoic acid, 3,6-dichloro-2-[[4-[[5-(2-methoxy-2-oxoethoxy)-1-methyl-3-propyl-1H-pyrazol-4-yl]methyl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)

RN 137861-34-8 CAPLUS
CN Benzoic acid, 3,6-dichloro-2-[[4-[[5-(2-ethoxy-2-oxoethoxy)-1-methyl-3-propyl-1H-pyrazol-4-yl]methyl]phenyl]amino]carbonyl]-, compd. with N-cyclohexylcyclohexanamine (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 137861-33-7
CMF C26 H27 Cl2 N3 O6



CM 2


CRN 101-83-7
CMF C12 H23 N




RN 137861-35-9 CAPLUS

CN Benzoic acid, 2-[[4-[[5-(2-ethoxy-2-oxoethoxy)-1-methyl-3-propyl-1H-pyrazol-4-yl]methyl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137861-36-0 CAPLUS
CN Benzenamine, 4-[[5-(methoxymethyl)-1-methyl-3-propyl-1H-pyrazol-4-yl]methyl]- (9CI) (CA INDEX NAME)




RN 137861-37-1 CAPLUS
CN Benzenamine, 4-[[3-(methoxymethyl)-5-propyl-1H-pyrazol-4-yl]methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137861-38-2 CAPLUS
CN Benzenesulfonic acid, 2-[[4-[[5-(methoxymethyl)-1-methyl-3-propyl-1H-pyrazol-4-yl]methyl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 137861-39-3 CAPLUS
CN Benzenesulfonic acid, 2-[[4-[[5-[(diethylamino)carbonyloxy]-1-methyl-3-propyl-1H-pyrazol-4-yl]methyl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

09899322

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137861-40-6 CAPLUS
CN 1H-Pyrazole-3-methanol, 4-[(4-aminophenyl)methyl]-5-propyl- (9CI) (CA INDEX NAME)




RN 137861-41-7 CAPLUS
CN Carbamic acid, dimethyl-, 4-[(4-aminophenyl)methyl]-3-propyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl ester (9CI) (CA INDEX NAME)

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137861-42-8 CAPLUS
CN Benzenesulfonic acid, 2-[(4-[(5-[(dimethylamino)carbonyl]oxy)-3-propyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl]methyl)phenyl]amino]carbonyl- (9CI) (CA INDEX NAME)




RN 137861-43-9 CAPLUS
CN Ethanol, 2-[(4-[(4-aminophenyl)methyl]-3-propyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)oxy]- (9CI) (CA INDEX NAME)

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137861-44-0 CAPLUS
CN Benzenesulfonic acid, 2-[(4-[(5-(2-hydroxyethoxy)-3-propyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl]phenyl)amino]carbonyl- (9CI) (CA INDEX NAME)




RN 137861-45-1 CAPLUS
CN Acetic acid, [(1-methyl-3-propyl-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]-1H-pyrazol-5-yl)oxy]-, ethyl ester (9CI) (CA INDEX NAME)


L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137861-46-2 CAPLUS
CN 1H-Pyrazol-5-ol, 1-methyl-3-propyl-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137861-47-3 CAPLUS
CN 1H-Pyrazol-5-ol, 3-butyl-1-methyl-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137861-48-4 CAPLUS
CN 1H-Pyrazol-5-ol, 3-propyl-4-[(2'-(1H-tetrazol-5-yl){1,1'-biphenyl}-4-yl)methyl]-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 137861-49-5 CAPLUS
 CN Ethanol, 2-[(3-butyl-1-methyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-pyrazol-5-yl)oxy]- (9CI) (CA INDEX NAME)




RN 137861-50-8 CAPLUS
 CN 1H-Tetrazole, 5-[(4-[(3-butyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl)- (9CI) (CA INDEX NAME)




RN 137861-51-9 CAPLUS
 CN Carbamic acid, dimethyl-, 3-butyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl ester (9CI) (CA INDEX NAME)




RN 137861-55-3 CAPLUS
 CN Ethanol,
 2-[(1-methyl-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-pyrazol-5-yl)oxy]- (9CI) (CA INDEX NAME)




RN 137861-56-4 CAPLUS
 CN Acetic acid,
 [(3-butyl-1-methyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-pyrazol-5-yl)oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 137861-57-5 CAPLUS
 CN Ethanol, 2-[(3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)oxy]- (9CI) (CA INDEX NAME)




RN 137861-52-0 CAPLUS
 CN Carbamic acid, dimethyl-, 3-butyl-1-methyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-pyrazol-5-yl ester (9CI) (CA INDEX NAME)




RN 137861-53-1 CAPLUS
 CN Acetic acid, [(3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 137861-54-2 CAPLUS
 CN Carbamic acid, dimethyl-, 1-methyl-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-pyrazol-5-yl ester (9CI) (CA INDEX NAME)




RN 137861-58-6 CAPLUS
 CN Benzenesulfonic acid, 2-[(4-[(3-(methoxymethyl)-5-propyl-1H-pyrazol-4-yl)methyl]phenyl)amino]carbonyl- (9CI) (CA INDEX NAME)




RN 137861-59-7 CAPLUS
 CN 1H-Pyrazole, 5-(bromomethyl)-1-methyl-4-[(4-nitrophenyl)methyl]-3-propyl- (9CI) (CA INDEX NAME)




RN 137861-60-0 CAPLUS
CN 1H-Pyrazole, 3-[(bromomethyl)-4-[(4-nitrophenyl)methyl]-5-propyl]- (9CI) (CA INDEX NAME)




RN 137861-61-1 CAPLUS
CN Morpholine, 4-[[[1-methyl-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-pyrazol-5-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)



RN 137861-62-2 CAPLUS
CN 1H-Pyrazole-5-methanol, 3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 137861-63-3 CAPLUS
CN 1H-Pyrazole-5-methanol, 1-methyl-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137861-64-4 CAPLUS
CN Piperazine, 1-[(3-butyl-1-methyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-pyrazol-5-yl)oxy]acetyl]-4-(2-methoxyphenyl)- (CA INDEX NAME)



PAGE 1-A




RN 137861-66-6 CAPLUS
CN Morpholine, 4-[[[3-butyl-1-methyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1H-pyrazol-5-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)




RN 137861-65-5 CAPLUS
CN Thiomorpholine, 4-[[[1-methyl-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-


PAGE 2-A




RN 137861-67-7 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 4-[[[5-(bromomethyl)-3-butyl-1-methyl-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 137861-68-8 CAPLUS
 CN 1H-Pyrazol-5-ol, 3-butyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 137861-69-9 CAPLUS
 CN Morpholine, 4-[(3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)oxy]acetyl- (9CI) (CA INDEX NAME)



RN 137861-70-2 CAPLUS
 CN Piperazine, 1-[(2-methoxyphenyl)-4-[[3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl]oxy]acetyl- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 137861-71-3 CAPLUS
 CN 2-Thiophenecarboxylic acid, 3-[(5-(2-hydroxyethoxy)-1-methyl-3-propyl-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137861-72-4 CAPLUS
 CN [(1,1'-Biphenyl)-2-carboxylic acid, 4'-[(5-(2-hydroxyethoxy)-1-methyl-3-propyl-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 137861-73-5 CAPLUS
 CN Acetic acid, [(1-methyl-3-propyl-4-[(2-(1H-tetrazol-5-yl)-3-phenyl)phenyl]methyl)-1H-pyrazol-5-yl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 137861-74-6 CAPLUS
 CN Acetic acid, [(1-methyl-3-propyl-4-[(2-[(trifluoromethyl)sulfonyl]amino)-1,1'-biphenyl]-4-yl)methyl]-1H-pyrazol-5-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 137861-75-7 CAPLUS
 CN Benzamide, N-[(3-butyl-1-methyl-5-[(2-(4-morpholinyl)-2-oxoethoxy)-1H-pyrazol-4-yl)methyl]phenyl)-2-[(trifluoromethyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)


09899322

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 137861-76-8 CAPLUS

CN Acetic acid, [[4-[(2'-amino[1,1'-biphenyl]-4-yl)methyl]-1-methyl-3-propyl-1H-pyrazol-5-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 137861-77-9 CAPLUS

CN Ethanol, 2-[(3-(2-methylpropyl)-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl]oxy]- (CA INDEX NAME)

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)


RN 137861-80-4 CAPLUS

CN 1H-Tetrazole, 5-[(4'-[(3-butyl-5-(methoxymethyl)-1-methyl-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl)- (9CI) (CA INDEX NAME)



RN 137861-81-5 CAPLUS


CN 1H-Tetrazole, 5-[(4'-[(5-(methoxymethyl)-1-methyl-3-propyl-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl)- (9CI) (CA INDEX NAME)



RN 137861-82-6 CAPLUS


CN Benzenesulfonic acid, 2-[[4-[(3-(hydroxymethyl)-5-propyl-1H-pyrazol-4-yl)methyl]phenyl]amino]carbonyl- (9CI) (CA INDEX NAME)

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137861-78-0 CAPLUS

CN Acetic acid, [[1-methyl-3-(2-methylpropyl)-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-1H-pyrazol-5-yl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 137861-79-1 CAPLUS

CN Acetic acid, [[3-(2-methylpropyl)-4-[(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137882-25-8 CAPLUS

CN Benzoic acid, 2-[[4-[(5-(2-methoxy-2-oxoethoxy)-1-methyl-3-propyl-1H-pyrazol-4-yl)methyl]phenyl]amino]carbonyl-, compd. with N-cyclohexylcyclohexanamine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 137882-24-7

CMF C25 H27 N3 O6




CM 2


Kamal Saeed

CRN 101-83-7
CMF C12 H23 N


RN 137882-26-9 CAPLUS
CN Benzoic acid, 2-[[4-[(3-butyl-5-(2-ethoxy-2-oxoethoxy)-1-methyl-1H-pyrazol-4-yl)methyl]phenyl]amino]carbonyl- (9CI) (CA INDEX NAME)




RN 137882-27-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(3-butyl-5-hydroxy-1-methyl-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 137882-28-1 CAPLUS
CN Piperazine, 1-[[4-[(4-aminophenyl)methyl]-1-methyl-3-propyl-1H-pyrazol-5-yl]oxylacetyl]-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 137882-29-2 CAPLUS
CN Benzenesulfonic acid, 2-[[4-[(5-(hydroxymethyl)-1-methyl-3-propyl-1H-pyrazol-4-yl)methyl]phenyl]amino]carbonyl- (9CI) (CA INDEX NAME)




IT 137860-03-8P 137860-04-9P 137860-05-0P
137860-06-1P 137860-07-2P 137860-08-3P
137860-09-4P 137860-10-7P 137860-11-0P
137860-12-9P 137860-13-0P 137860-14-1P
137860-15-2P 137860-16-3P 137860-17-4P
137860-18-5P 137860-19-6P 137860-20-9P
137860-21-0P 137860-22-1P 137860-23-2P
137860-24-3P 137860-25-4P 137860-27-6P
137860-28-7P 137860-29-8P 137860-30-1P
137860-31-2P 137860-32-3P 137860-33-4P
137860-34-5P 137860-35-6P 137860-39-0P
137860-40-3P 137860-41-4P 137860-42-5P
137860-43-6P 137860-44-7P 137860-45-8P
137860-46-9P 137860-47-0P 137860-49-2P
137860-50-5P 137860-51-6P 137860-52-7P
137860-53-8P 137860-54-9P 137860-55-0P
137860-56-1P 137860-58-3P 137860-59-4P
137860-62-8P 137860-62-9P 137860-63-0P
137860-64-1P 137860-65-2P 137860-66-3P
137860-68-5P 137860-69-6P 137860-70-9P
137860-71-0P 137860-72-1P 137860-73-2P
137860-74-3P 137860-75-4P 137860-76-5P
137860-77-6P 137860-78-7P 137860-79-8P
137860-80-1P 137860-21-4P 137860-22-5P
137882-23-6P
RL: SPA (Synthetic preparation); PREP (Preparation)
(prep. of, as intermediate for cardiovascular agents)


RN 137860-03-8 CAPLUS
CN 1H-Pyrazol-5-ol, 3-butyl-1-methyl-4-[(4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 137860-04-9 CAPLUS
CN 1H-Pyrazol-5-ol, 1-methyl-4-[(4-nitrophenyl)methyl]-3-propyl- (9CI) (CA INDEX NAME)




RN 137860-05-0 CAPLUS
CN 3H-Pyrazol-3-one, 1,2-dihydro-4-[(4-nitrophenyl)methyl]-5-propyl- (9CI) (CA INDEX NAME)




09899322

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)

RN 137860-06-1 CAPLUS
CN 1H-Pyrazole-1-acetic acid, 5-hydroxy-4-[(4-nitrophenyl)methyl]-3-propyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 137860-07-2 CAPLUS
CN 1H-Pyrazol-5-ol, 4-[(4-nitrophenyl)methyl]-3-propyl-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 137860-08-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[{(3-butyl-5-hydroxy-1-methyl-1H-pyrazol-4-yl)methyl}-, methyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137860-09-4 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[{(3-butyl-5-hydroxy-1-methyl-1H-pyrazol-4-yl)methyl}- (9CI) (CA INDEX NAME)



RN 137860-10-7 CAPLUS
CN Acetic acid, [(1-methyl-4-[(4-nitrophenyl)methyl]-3-propyl-1H-pyrazol-5-yloxy)-, ethyl ester (9CI) (CA INDEX NAME)


L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137860-11-8 CAPLUS
CN Acetic acid, [(3-butyl-1-methyl-4-[(4-nitrophenyl)methyl]-1H-pyrazol-5-yloxy)-, ethyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)

RN 137860-13-0 CAPLUS
CN Acetic acid, [(1-methyl-4-[(4-nitrophenyl)methyl]-3-propyl-1H-pyrazol-5-yloxy)-, methyl ester (9CI) (CA INDEX NAME)




RN 137860-14-1 CAPLUS
CN Acetic acid, [(4-[(4-nitrophenyl)methyl]-3-propyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yloxy)-, methyl ester (9CI) (CA INDEX NAME)



RN 137860-12-9 CAPLUS
CN Acetic acid, [(4-[(4-nitrophenyl)methyl]-5-propyl-1H-pyrazol-3-yloxy)-, ethyl ester (9CI) (CA INDEX NAME)


RN 137860-15-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[{(3-butyl-5-(2-ethoxy-2-oxoethoxy)-1-methyl-1H-pyrazol-4-yl)methyl}-, methyl ester (9CI) (CA INDEX NAME)




Kamal Saeed

09899322

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137860-16-3 CAPLUS
CN Acetic acid, [3-butyl-4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1-methyl-1H-pyrazol-5-yl]oxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 137860-17-4 CAPLUS
CN Carbonic acid, 4-[(4-aminophenyl)methyl]-3-butyl-1-methyl-1H-pyrazol-5-yl methyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137860-18-5 CAPLUS
CN 1H-Pyrazole-1-acetic acid, 5-(2-ethoxy-2-oxoethoxy)-4-[(4-nitrophenyl)methyl]-3-propyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 137860-19-6 CAPLUS
CN Morpholine, 4-[(3-butyl-1-methyl-1H-pyrazol-5-yl)oxy]acetyl- (9CI) (CA INDEX NAME)

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137860-20-9 CAPLUS
CN Ethanol, 2-[(3-butyl-1-methyl-4-[(4-nitrophenyl)methyl]-1H-pyrazol-5-yl)oxy]- (9CI) (CA INDEX NAME)


L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 137860-22-1 CAPLUS
CN Carbamic acid, diethyl-, 1-methyl-4-[(4-nitrophenyl)methyl]-3-propyl-1H-pyrazol-5-yl ester (9CI) (CA INDEX NAME)




RN 137860-21-0 CAPLUS
CN Carbamic acid, dimethyl-, 1-methyl-4-[(4-nitrophenyl)methyl]-3-propyl-1H-pyrazol-5-yl ester (9CI) (CA INDEX NAME)




RN 137860-23-2 CAPLUS
CN Carbamic acid, dimethyl-, 4-[(4-nitrophenyl)methyl]-3-propyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl ester (9CI) (CA INDEX NAME)

09899322

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137860-24-3 CAPLUS
CN Ethanol, 2-[(4-[(4-nitrophenyl)methyl]-3-propyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)oxy]- (9CI) (CA INDEX NAME)




RN 137860-25-4 CAPLUS
CN Piperazine, 1-(2-methoxyphenyl)-4-[[[1-methyl-4-[(4-nitrophenyl)methyl]-3-propyl-1H-pyrazol-5-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137860-27-6 CAPLUS
CN Acetic acid, [[4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1-methyl-3-propyl-1H-pyrazol-5-yl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 137860-28-7 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 4'--[[5-hydroxy-3-propyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137860-29-8 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 4'--[[3-butyl-5-(2-hydroxyethoxy)-1-methyl-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)


L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 137860-31-2 CAPLUS
CN Carbamic acid, dimethyl-, 3-butyl-4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1-methyl-1H-pyrazol-5-yl ester (9CI) (CA INDEX NAME)



RN 137860-30-1 CAPLUS
CN Carbamic acid, dimethyl-, 3-butyl-4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl ester (9CI) (CA INDEX NAME)




RN 137860-32-3 CAPLUS
CN Acetic acid, [[4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-3-propyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)


Kamal Saeed

09899322

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137860-33-4 CAPLUS
CN Carbamic acid, dimethyl-, 4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1-methyl-3-propyl-1H-pyrazol-5-yl ester (9CI) (CA INDEX NAME)




RN 137860-34-5 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile,
4'-(5-(2-hydroxyethoxy)-1-methyl-3-propyl-
1H-pyrazol-4-yl)methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137860-35-6 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile,
4'-(5-(2-hydroxyethoxy)-3-propyl-1-(2,2,2-
trifluoroethyl)-1H-pyrazol-4-yl)methyl- (9CI) (CA INDEX NAME)




RN 137860-39-0 CAPLUS
CN 1H-Pyrazole, 3-(methoxymethyl)-4-[(4-nitrophenyl)methyl]-5-propyl- (9CI)
(CA INDEX NAME)

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137860-40-3 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile,
4'-(3-(methoxymethyl)-5-propyl-1H-pyrazol-
4-yl)methyl- (9CI) (CA INDEX NAME)




RN 137860-41-4 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile,
4'-(3-butyl-5-(methoxymethyl)-1H-pyrazol-
4-yl)methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 137860-42-5 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 4'-(3-butyl-5-(methoxymethyl)-1-(2,2,2-
trifluoroethyl)-1H-pyrazol-4-yl)methyl- (9CI) (CA INDEX NAME)




RN 137860-43-6 CAPLUS
CN 1H-Pyrazole,
5-(methoxymethyl)-1-methyl-4-[(4-nitrophenyl)methyl]-3-propyl-
(9CI) (CA INDEX NAME)


Kamal Saeed

09899322

16 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137860-44-7 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 4'-(3-(4-nitrophenyl)methyl)-1-methyl-3-propyl-1H-pyrazol-4-yl)methyl- (9CI) (CA INDEX NAME)




RN 137860-45-8 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile,
4'-(3-butyl-5-(methoxymethyl)-1-methyl-1H-pyrazol-4-yl)methyl- (9CI) (CA INDEX NAME)

16 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137860-46-9 CAPLUS
CN 1H-Pyrazole-5-methanol, 1-methyl-4-(4-nitrophenyl)methyl-3-propyl- (9CI) (CA INDEX NAME)




RN 137860-47-0 CAPLUS
CN 1H-Pyrazole-3-methanol, 4-(4-nitrophenyl)methyl-5-propyl- (9CI) (CA INDEX NAME)

16 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137860-49-2 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile,
4'-(3-hydroxy-1-methyl-3-(2-methylpropyl)-1H-pyrazol-4-yl)methyl- (9CI) (CA INDEX NAME)




RN 137860-50-5 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile,
4'-(3-hydroxy-3-(2-methylpropyl)-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl- (9CI) (CA INDEX NAME)

16 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137860-51-6 CAPLUS
CN Acetic acid, [4-(2'-cyano[1,1'-biphenyl]-4-yl)methyl-1-methyl-3-(2-methylpropyl)-1H-pyrazol-5-yl]oxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 137860-52-7 CAPLUS
CN Acetic acid,
[4-(2'-cyano[1,1'-biphenyl]-4-yl)methyl-3-(2-methylpropyl)-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl]oxy-, ethyl ester (9CI) (CA INDEX NAME)


Kamal Saeed




RN 137860-53-8 CAPLUS
 CN [1,1'-Biphenyl]-2-carbonitrile, 4'-(5-(2-hydroxyethoxy)-3-(2-methylpropyl)-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl- (9CI)
 (CA INDEX NAME)




RN 137860-54-9 CAPLUS
 CN 1H-Pyrazol-5-ol, 1-methyl-4-[(2'-nitro[1,1'-biphenyl]-4-yl)methyl]-3-propyl- (9CI) (CA INDEX NAME)




RN 137860-55-0 CAPLUS
 CN Acetic acid, [(1-methyl-4-[(2'-nitro[1,1'-biphenyl]-4-yl)methyl]-3-propyl-1H-pyrazol-5-yl)oxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 137860-56-1 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(5-(2-hydroxyethoxy)-1-methyl-3-propyl-1H-pyrazol-4-yl)methyl- ethyl ester (9CI) (CA INDEX NAME)




RN 137860-58-3 CAPLUS
 CN 2-Thiophenecarbonitrile, 3-[(4-[(5-hydroxy-1-methyl-3-propyl-1H-pyrazol-4-yl)methyl]phenyl)- (9CI) (CA INDEX NAME)




RN 137860-59-4 CAPLUS
 CN Acetic acid, [(4-[(4-(2-cyano-3-thienyl)phenyl)methyl]-1-methyl-3-propyl-1H-pyrazol-5-yl)oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 137860-61-8 CAPLUS
 CN 2-Thiophenecarboxylic acid, 3-[(4-[(5-hydroxy-1-methyl-3-propyl-1H-pyrazol-4-yl)methyl]phenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 137860-62-9 CAPLUS
 CN 2-Thiophenecarboxylic acid, 3-[(5-(2-hydroxyethoxy)-1-methyl-3-propyl-1H-pyrazol-4-yl)methyl]phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 137860-63-0 CAPLUS
 CN Piperazine, 1-[(4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-3-propyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)oxy]acetyl]-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 137860-64-1 CAPLUS
 CN Morpholine, 4-[(4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-3-propyl-1-

09899322

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl]oxy]acetyl)- (9CI) (CA INDEX NAME)




RN 137860-65-2 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile,
4'-[(3-butyl-5-(hydroxymethyl)-1-methyl-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137860-66-3 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile,
4'-[(3-butyl-5-(2-hydroxyethoxy)-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137860-68-5 CAPLUS
CN 3-Thiophene-carbonitrile, 2-[4-((3-butyl-5-hydroxy-1-methyl-1H-pyrazol-4-yl)methyl)phenyl]- (9CI) (CA INDEX NAME)




RN 137860-69-6 CAPLUS
CN Carboxamic acid, diethyl-,
4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1-methyl-3-propyl-1H-pyrazol-5-yl ester (9CI) (CA INDEX NAME)

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137860-70-9 CAPLUS
CN Thiomorpholine, 4-[[4-((2'-cyano[1,1'-biphenyl]-4-yl)methyl)-3-propyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137860-72-1 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile,
4'-[(1-methyl-5-[2-(4-morpholinyl)ethoxy]-3-propyl-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137860-71-0 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile,
4'-[(5-[2-(dimethylamino)ethoxy]-1-methyl-3-propyl-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)


RN 137860-73-2 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[(3-butyl-5-(hydroxymethyl)-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137860-74-3 CAPLUS
 CN [1,1'-Biphenyl]-2-carbonitrile, 4'-(5-(methoxymethyl)-3-propyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl- (9CI) (CA INDEX NAME)




RN 137860-75-4 CAPLUS
 CN Morpholine, 4-[(3-butyl-4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1-methyl-1H-pyrazol-5-yl)oxy]acetyl- (9CI) (CA INDEX NAME)




RN 137860-76-5 CAPLUS
 CN Morpholine, 4-[(4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1-methyl-3-propyl-1H-pyrazol-5-yl)oxy]acetyl- (9CI) (CA INDEX NAME)




RN 137860-77-6 CAPLUS
 CN [1,1'-Biphenyl]-2-carbonitrile, 4'-(5-(hydroxymethyl)-3-propyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl- (9CI) (CA INDEX NAME)




RN 137860-78-7 CAPLUS
 CN [1,1'-Biphenyl]-2-carbonitrile, 4'-(5-(hydroxymethyl)-1-methyl-3-propyl-1H-pyrazol-4-yl)methyl- (9CI) (CA INDEX NAME)




RN 137860-79-8 CAPLUS
 CN Piperazine, 1-[(3-butyl-4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1-methyl-1H-pyrazol-5-yl)oxy]acetyl- (9CI) (CA INDEX NAME)




RN 137860-80-1 CAPLUS
 CN Thiomorpholine, 4-[(4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1-methyl-3-propyl-1H-pyrazol-5-yl)oxy]acetyl- (9CI) (CA INDEX NAME)




RN 137882-21-4 CAPLUS
 CN [1,1'-Biphenyl]-2-carbonitrile, 4'-(5-hydroxy-1-methyl-3-propyl-1H-pyrazol-4-yl)methyl- (9CI) (CA INDEX NAME)



RN 137882-22-5 CAPLUS
 CN Acetic acid, [3-butyl-4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl]oxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 137882-23-6 CAPLUS
 CN Piperazine, 1-[[[4-((2'-cyano[1,1'-biphenyl]-4-yl)methyl)-1-methyl-3-propyl-1H-pyrazol-5-yl]oxy]acetyl]-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1991:680018 CAPLUS
 DOCUMENT NUMBER: 115:280018
 TITLE: Preparation of (pyrazolylmethyl)biphenylcarboxylates and related compounds as angiotensin II antagonists
 INVENTOR(S): Ross, Barry Clive; Middlemiss, David; Eldred, Colid
 David; Montana, John Gary; Shah, Pitom
 PATENT ASSIGNEE(S): Glaxo Group Ltd., UK
 SOURCE: Eur. Pat. Appl., 58 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 446062	A1	19910911	EP 1991-301923	19910308 <<
FI 9101161	A	19910910	FI 1991-1161	19910300 <<
NO 9100935	A	19910910	NO 1991-935	19910308 <<
CA 2037872	AA	19910910	CA 1991-2037872	19910308 <<
AU 9172736	A1	19910912	AU 1991-72736	19910308 <<
AU 636720	B2		19930506	
ZA 9101721	A	19920226	ZA 1991-1721	19910308 <<
JP 06205175	A2	19940201	JP 1991-69159	19910308 <<
US 5389659	A	19950214	US 1991-666746	19910308 <<
PRIORITY APPLN. INFO.:		GB 1990-5354		19900309
OTHER SOURCE(S):		MARPAT 115:280018		

GI



AB Title compds. [I; R1 = H, alky, alkenyl; R2 = R1, cycloalkyl, fluorooalkyl, fluoroalkenyl, Ph, (modified) carboxyalkyl, carbonylaminoalkyl; R3 = H, (substituted) alky, alkenyl, phenoxyalkyl, benzyloxyalkyl, (modified) carboxyalkyl, carbonylaminoalkyl; R4 = CO2H, NHCO2CF3, tetrazole] were prep'd. as angiotensin II antagonists (no data). Thus, MeCO(CH2)3Me and MeOCH2CO2Me were condensed using NaNH2 in Et2O to give MeOCH2COCH2CO(CH2)3Me. The latter was condensed with


L6 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
 1,1-dimethylethyl 4'-bromomethylbiphenyl-2-carboxylate (prepn. given) using K2CO3 in Me2CO and the product cyclocondensed with NH4.H2O in EtOH followed by hydrolysis with CF3CO2H to give title compd. II.
 IT 137645-46-6P 137645-47-7P 137645-48-8P
 137645-49-9P 137645-50-2P 137645-51-3P
 137645-52-4P 137645-53-5P 137645-54-6P
 137645-56-8P 137645-57-9P 137645-58-0P
 137645-59-1P 137645-60-4P 137645-61-5P
 137645-62-6P 137645-63-7P 137645-64-8P
 137645-65-9P 137645-66-0P 137645-67-1P
 137645-68-2P 137645-69-3P 137645-70-6P
 137645-71-7P 137645-72-8P 137645-73-9P
 137645-74-0P 137645-75-1P 137645-76-2P
 137645-77-3P 137645-78-4P 137645-79-5P
 137645-80-8P 137645-81-9P 137645-82-0P
 137645-83-1P 137645-84-2P 137645-85-3P
 137645-86-4P 137645-87-5P 137645-88-6P
 137645-89-7P 137645-90-0P 137645-91-1P
 137645-92-2P 137645-93-3P 137645-94-4P
 137645-95-5P 137645-96-6P 137645-97-7P
 137645-98-8P 137645-99-9P 137646-00-5P
 137646-01-6P 137646-02-7P 137646-03-8P
 137646-04-9P 137646-05-0P 137646-06-1P
 137646-07-2P 137646-08-3P 137646-09-4P
 137646-10-7P 137646-11-8P 137646-12-9P
 137646-13-0P 137646-14-1P 137646-15-2P
 137646-16-3P 137646-17-4P 137646-18-5P
 137646-19-6P 137646-20-7P 137646-21-0P
 137646-22-1P 137646-23-2P 137646-24-3P
 137646-25-4P 137646-26-5P 137646-27-6P
 137646-28-7P 137646-29-8P 137646-30-1P
 137659-80-4P 137659-81-5P 137659-82-6P
 137659-83-7P 137659-84-8P 137659-85-9P
 137659-86-0P 137660-58-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPP (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PRSP (Preparation); USES (Uses); (prepn. of, as angiotensin II antagonist)

RN 137645-46-6 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(3-butyl-5-(methoxymethyl)-1H-pyrazol-4-yl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 137645-45-5
 CMF C23 H26 N2 O3




CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 137645-47-7 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid,
 4'-(3-butyl-5-(methoxymethyl)-1-phenyl-
 1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-48-8 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid,
 4'-(3-butyl-5-(methoxymethyl)-1-phenyl-
 1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-49-9 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid,
 4'-(3-butyl-5-(methoxymethyl)-1-(2,2,2-
 trifluoroethyl)-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-50-2 CAPLUS
 CN 1H-Tetrazole, 5-(4'-(3-butyl-5-(methoxymethyl)-1-(2,2,2-trifluoroethyl)-
 1H-pyrazol-4-yl)methyl)-1,1'-biphenyl-2-yl]- (9CI) (CA INDEX NAME)




RN 137645-53-5 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(1-(2-amino-2-oxoethyl)-3-butyl-
 5-(methoxymethyl)-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 137645-51-3 CAPLUS
 CN 1H-Tetrazole, 5-(4'-(3-butyl-3-(methoxymethyl)-1-(2,2,2-trifluoroethyl)-
 1H-pyrazol-4-yl)methyl)-1,1'-biphenyl-2-yl]- (9CI) (CA INDEX NAME)



RN 137645-53-5 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(1-(2-amino-2-oxoethyl)-3-butyl-
 5-(methoxymethyl)-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-54-6 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(1-(2-amino-2-oxoethyl)-5-butyl-
 3-(methoxymethyl)-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)

RN 137645-52-4 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(1-(2-amino-2-oxoethyl)-5-butyl-
 3-(methoxymethyl)-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)

09899322


L6 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 137645-56-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(5-butyl-1-((dimethylamino)sulfonyl)-3-(methoxymethyl)-1H-pyrazol-4-yl)methyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 137645-55-7
CMF C24 H28 N2 O3




CM 2

CRN 76-05-1
CMF C2 H P3 O2

L6 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137645-57-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(5-butyl-1-((dimethylamino)sulfonyl)-3-(methoxymethyl)-1H-pyrazol-4-yl)methyl)- (9CI) (CA INDEX NAME)




RN 137645-58-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(5-butyl-1-((dimethylamino)sulfonyl)-5-(methoxymethyl)-1H-pyrazol-4-yl)methyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 137645-59-1 CAPLUS
CN 1H-Tetrazole, 5-[(5-butyl-1-ethyl-5-(methoxymethyl)-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl] (CA INDEX NAME)




RN 137645-60-4 CAPLUS
CN 1H-Tetrazole, 5-[(5-butyl-1-ethyl-3-(methoxymethyl)-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl] (CA INDEX NAME)




RN 137645-61-5 CAPLUS
CN 1H-Pyrazole-1-sulfonamide, 3-butyl-5-(methoxymethyl)-N,N-dimethyl-4-[(2-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)


L6 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 137645-62-6 CAPLUS
CN 1H-Pyrazole-1-sulfonamide, 5-butyl-3-(methoxymethyl)-N,N-dimethyl-4-[(2-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-63-7 CAPLUS
CN 1H-Tetrazole, 5-[(5-butyl-1-((dimethylamino)sulfonyl)-3-(methoxymethyl)-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl] (9CI) (CA INDEX NAME)




RN 137645-64-8 CAPLUS
CN 1H-Tetrazole, 5-[(5-butyl-1-((dimethylamino)sulfonyl)-3-(methoxymethyl)-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl] (9CI) (CA INDEX NAME)


Kamal Saeed




RN 137645-65-9 CAPLUS
 CN 1H-Pyrazole-3-methanol, 3-butyl-4-((2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl)-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 137645-66-0 CAPLUS
 CN 1H-Pyrazole-3-methanol, 3-butyl-4-((2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl)-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 137645-67-1 CAPLUS
 CN 1H-Pyrazole-3-carboxaldehyde, 3-butyl-4-((2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl)-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 137645-68-2 CAPLUS
 CN 1H-Pyrazole-3-carboxaldehyde, 5-butyl-4-((2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl)-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 137645-69-3 CAPLUS
 CN 1H-Pyrazole-3-carboxylic acid, 3-butyl-4-((2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl)-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 137645-70-6 CAPLUS
 CN 1H-Pyrazole-3-carboxylic acid, 5-butyl-4-((2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl)-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 137645-71-7 CAPLUS
 CN 1H-Pyrazole-5-methanol, 3-butyl-1-ethyl-4-((2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl)- (9CI) (CA INDEX NAME)




RN 137645-72-8 CAPLUS
 CN 1H-Pyrazole-5-methanol, 3-butyl-1-(1-methylethyl)-4-((2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl)- (9CI) (CA INDEX NAME)




RN 137645-73-9 CAPLUS
 CN 1H-Pyrazole-3-methanol, 5-butyl-1-(1-methylethyl)-4-((2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl)- (9CI) (CA INDEX NAME)




RN 137645-74-0 CAPLUS
 CN 1H-Pyrazole-5-methanol, 3-butyl-1-(cyclopropylmethyl)-4-((2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl)- (9CI) (CA INDEX NAME)




RN 137645-75-1 CAPLUS
 CN 1H-Pyrazole-3-methanol, 5-butyl-1-ethyl-4-((2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl)- (9CI) (CA INDEX NAME)




RN 137645-76-2 CAPLUS
 CN 1H-Pyrazole-5-methanol, 3-butyl-1-cyclobutyl-4-((2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl)- (9CI) (CA INDEX NAME)




RN 137645-77-3 CAPLUS
CN 1H-Pyrazole-3-methanol, 5-butyl-1-cyclobutyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-78-4 CAPLUS
CN 1H-Pyrazole-3-methanol, 3-butyl-1-methyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-79-5 CAPLUS
CN 1H-Pyrazole-3-methanol, 5-butyl-1-methyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-80-8 CAPLUS
CN 1H-Pyrazole-5-methanol, 1,3-dibutyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-81-9 CAPLUS
CN 1H-Pyrazole-3-methanol, 1,5-dibutyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-82-0 CAPLUS
CN 1H-Pyrazole-5-methanol, 1-ethyl-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-83-1 CAPLUS
CN 1H-Pyrazole-3-methanol, 1-ethyl-5-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-84-2 CAPLUS
CN 1H-Pyrazole-5-methanol, 1-(1-methylethyl)-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-85-3 CAPLUS
CN 1H-Pyrazole-3-methanol, 1-(1-methylethyl)-5-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-86-4 CAPLUS
CN 1H-Pyrazole-5-carboxaldehyde, 3-butyl-1-ethyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-87-5 CAPLUS
CN 1H-Pyrazole-5-carboxaldehyde, 3-butyl-1-(1-methylethyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-88-6 CAPLUS
CN 1H-Pyrazole-3-carboxaldehyde, 5-butyl-1-(1-methylethyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-89-7 CAPLUS
 CN 1H-Pyrazole-5-carboxaldehyde, 3-butyl-1-(2-methylpropyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-90-0 CAPLUS
 CN 1H-Pyrazole-5-carboxaldehyde, 3-butyl-1-(cyclopropylmethyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-91-1 CAPLUS
 CN 1H-Pyrazole-5-carboxaldehyde, 3-butyl-1-cyclobutyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-92-2 CAPLUS
 CN 1H-Pyrazole-5-carboxaldehyde, 1,3-dibutyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-93-3 CAPLUS
 CN 1H-Pyrazole-5-carboxaldehyde, 1-(1-methylethyl)-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-94-4 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-ethyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-95-5 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(1-methylethyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-96-6 CAPLUS
 CN 1H-Pyrazole-3-carboxylic acid, 5-butyl-1-(1-methylethyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-97-7 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-methylpropyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-98-8 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-cyclobutyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137645-99-9 CAPLUS
 CN 1H-Tetrazole, 5-[(3-butyl-5-(methoxymethyl)-1-phenyl-1H-pyrazol-4-yl)methyl]-2-yl (9CI) (CA INDEX NAME)




RN 137646-00-5 CAPLUS
 CN 1H-Pyrazole-5-methanol, 1,3-diethyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 137646-01-6 CAPLUS
 CN 1H-Pyrazole-3-methanol, 1,5-diethyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-02-7 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-carboxy(1,1'-biphenyl)-4-yl)methyl]-1-ethyl- (9CI) (CA INDEX NAME)




RN 137646-03-8 CAPLUS


L6 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
 CN 1H-Pyrazole-3-methanol, 3-butyl-1-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-04-9 CAPLUS
 CN 1H-Pyrazole-5-carboxaldehyde, 1-ethyl-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-05-0 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 1-ethyl-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-06-1 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 1-(1-methylethyl)-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-07-2 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 1,3-dibutyl-1-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-08-3 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-carboxy(1,1'-biphenyl)-4-yl)methyl]-1-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 137646-09-4 CAPLUS
 CN 1H-Pyrazole-3-methanol, 5-butyl-1-(2-methylpropyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-10-7 CAPLUS
 CN 1H-Pyrazole-3-methanol, 5-butyl-1-(cyclopropylmethyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-11-8 CAPLUS
 CN 1H-Pyrazole-3-methanol, 5-butyl-1-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-12-9 CAPLUS
 CN 1H-Pyrazole-5-methanol, 1-(2-methylpropyl)-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-13-0 CAPLUS
 CN 1H-Pyrazole-3-methanol, 1-(2-methylpropyl)-5-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-14-1 CAPLUS
 CN 1H-Pyrazole-5-methanol, 1-(2,2-dimethylpropyl)-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-15-2 CAPLUS
 CN 1H-Pyrazole-5-carboxaldehyde, 3-butyl-1-methyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-16-3 CAPLUS
 CN 1H-Pyrazole-5-carboxaldehyde, 3-butyl-1-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-17-4 CAPLUS
 CN 1H-Pyrazole-5-carboxaldehyde, 1-(2-methylpropyl)-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-18-5 CAPLUS
 CN 1H-Pyrazole-5-carboxaldehyde, 1-(2,2-dimethylpropyl)-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-19-6 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-methyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-20-9 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-methyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-21-0 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 137646-22-1 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 1-(2-methylpropyl)-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-23-2 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 1-(2,2-dimethylpropyl)-3-propyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-24-3 CAPLUS
 CN 1H-Tetrazole, 5-[(4-[(5-butyl-1-(1,1-dimethylethyl)-3-(methoxymethyl)-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl)- (9CI) (CA INDEX NAME)

09899322


L6 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 137646-25-4 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid,
1,5-dibutyl-4-[(2'-(1H-tetrazol-5-yl)[1,1'-
biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137646-26-5 CAPLUS
CN 1H-Tetrazole,
5-[(4-[(5-butyl-3-(methoxymethyl)-1-(2-propenyl)-1H-pyrazol-
4-yl)methyl]-1,1'-biphenyl)-2-yl]- (9CI) (CA INDEX NAME)




RN 137646-27-6 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-carboxy[1,1'-biphenyl]-4-
yl)methyl]-1-methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137646-28-7 CAPLUS
CN Methanesulfonyamide,
N-[(4-[(3-butyl-1-ethyl-5-(hydroxymethyl)-1H-pyrazol-4-
yl)methyl]-1,1'-biphenyl)-2-yl]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)




RN 137646-29-8 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 1-ethyl-3-propyl-4-[(2'-
[(trifluoromethyl)sulfonyl]amino[1,1'-biphenyl]-4-yl)methyl]-
(CA INDEX NAME)

L6 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137646-30-1 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-ethyl-4-[(2'-
[(trifluoromethyl)sulfonyl]amino[1,1'-biphenyl]-4-yl)methyl]- (9CI)
(CA INDEX NAME)




RN 137659-80-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid,
4-[(5-butyl-3-(methoxymethyl)-1-(2,2,2-
trifluoroethyl)-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)


L6 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 137659-81-5 CAPLUS
CN 1H-Tetrazole, 5-[(4-[(3-butyl-5-(methoxymethyl)-1H-pyrazol-4-
yl)methyl]-1,1'-biphenyl)-2-yl]- (9CI) (CA INDEX NAME)




RN 137659-82-6 CAPLUS
CN 1H-Pyrazole-3-methanol, 1-(2,2-dimethylpropyl)-5-propyl-4-[(2'-(1H-
tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137659-83-7 CAPLUS
CN 1H-Tetrazole,
5-[(4-[(3-butyl-5-(methoxymethyl)-1-(2-propenyl)-1H-pyrazol-
4-yl)methyl]-1,1'-biphenyl)-2-yl]- (9CI) (CA INDEX NAME)


Kamal Saeed




RN 137659-84-8 CAPLUS
 CN Methanesulfonamide, N-[4'-(1-ethyl-5-(hydroxymethyl)-3-propyl-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)




RN 137659-85-9 CAPLUS
 CN Methanesulfonamide, N-[4'-(1-ethyl-5-formyl-3-propyl-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)



RN 137659-86-0 CAPLUS
 CN Methanesulfonamide, N-[4'-(3-butyl-1-ethyl-5-formyl-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)




RN 137660-58-3 CAPLUS
 CN 1H-Pyrazole-5-methanol, 3-butyl-1-(2-methylpropyl)-4-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




IT 137646-33-4P 137646-34-5P 137646-35-6P
 137646-36-7P 137646-37-8P 137646-38-9P
 137646-39-0P 137646-40-3P 137659-87-1P
 137659-88-2P 137659-89-3P 137659-90-6P
 137659-91-7P 137659-92-8P 137659-93-9P
 137659-94-0P 137659-97-3P 137660-00-5P
 137660-01-6P 137660-02-7P 137660-03-8P
 137660-04-9P 137660-05-0P 137660-06-1P
 137660-07-2P 137660-08-3P 137660-09-4P
 137660-10-7P 137660-11-8P 137660-12-9P
 137660-13-0P 137660-14-1P 137660-15-2P
 137660-16-3P 137660-17-4P 137660-18-5P
 137660-21-0P 137660-22-1P 137660-23-2P
 137660-25-4P 137660-26-5P 137660-27-6P
 137660-28-7P 137660-29-8P 137660-30-1P
 137660-31-2P 137660-32-3P 137660-33-4P
 137660-34-5P 137660-35-6P 137660-36-7P
 137660-37-8P 137660-38-9P 137660-39-0P
 137660-40-3P 137660-41-4P 137660-42-5P
 137660-43-6P 137660-44-7P 137660-45-8P
 137660-48-1P 137660-49-2P 137660-50-5P
 137660-51-6P 137660-52-7P 137660-53-8P
 137660-54-9P 137660-55-0P 137660-56-1P
 137660-57-2P 137681-64-2P 137681-65-3P
 137681-66-4P 137681-67-5P 137681-68-6P

RL: SPP (Synthetic preparation); PREP (Preparation)
 (prepn. of, as intermediate for angiotensin II antagonists)

RN 137646-33-4 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-5-(methoxymethyl)-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137646-34-5 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-5-(methoxymethyl)-1-phenyl-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137646-35-6 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-5-(methoxymethyl)-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

09899322

L6 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137646-36-7 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(5-butyl-3-(methoxymethyl)-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137646-37-8 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(3-butyl-5-(methoxymethyl)-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137659-87-1 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(5-butyl-3-(methoxymethyl)-1-phenyl-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137659-88-2 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(1-(2-amino-2-oxoethyl)-3-butyl-5-(methoxymethyl)-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L6 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 137646-38-9 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(3-butyl-5-(methoxymethyl)-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137646-39-0 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(5-butyl-3-(methoxymethyl)-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137646-40-3 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(1-(2-amino-2-oxoethyl)-5-butyl-3-(methoxymethyl)-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137659-89-3 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(5-butyl-3-(methoxymethyl)-1-methyl-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137659-90-6 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(1-(2-amino-2-oxoethyl)-3-butyl-5-(methoxymethyl)-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Kamal Saeed




RN 137659-91-7 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-1-((dimethylamino)sulfonyl)-5-(methoxymethyl)-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137659-92-8 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(3-butyl-1-ethyl-5-(methoxymethyl)-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-00-5 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(3-[(phenylmethoxy)methyl]-5-propyl-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-01-6 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(3-butyl-1-ethyl-5-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-02-7 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(5-butyl-1-ethyl-3-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137659-93-9 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(5-butyl-1-ethyl-3-(methoxymethyl)-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137659-94-0 CAPLUS
 CN 1H-Pyrazole-1-sulfonamide, 5-butyl-3-(methoxymethyl)-N,N-dimethyl-4-[2-[2-(triphenylmethyl)-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl- (9CI) (CA INDEX NAME)




RN 137659-97-3 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(3-butyl-5-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-03-8 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(3-butyl-1-(1-methylethyl)-5-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-04-9 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(3-butyl-1-(1-methylethyl)-3-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-05-0 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(3-butyl-1-(2-methylpropyl)-5-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-06-1 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(3-butyl-1-(cyclopropylmethyl)-5-(phenylmethoxy)methyl)-1H-pyrazol-4-yl]methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-07-2 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(5-butyl-1-(cyclopropylmethyl)-3-(phenylmethoxy)methyl)-1H-pyrazol-4-yl]methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-08-3 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(3-butyl-1-cyclobutyl-5-(phenylmethoxy)methyl)-1H-pyrazol-4-yl]methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-12-9 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(5-butyl-3-(phenylmethoxy)methyl)-1H-pyrazol-4-yl]methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-13-0 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(1,3-dibutyl-5-(phenylmethoxy)methyl)-1H-pyrazol-4-yl]methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-14-1 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(1,5-dibutyl-3-(phenylmethoxy)methyl)-1H-pyrazol-4-yl]methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-09-4 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(3-butyl-1-methyl-5-(phenylmethoxy)methyl)-1H-pyrazol-4-yl]methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-10-7 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(5-butyl-1-methyl-3-(phenylmethoxy)methyl)-1H-pyrazol-4-yl]methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-11-8 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(1-ethyl-5-(phenylmethoxy)methyl)-1H-pyrazol-4-yl]methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-15-2 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(1-ethyl-3-(phenylmethoxy)methyl)-1H-pyrazol-4-yl]methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-16-3 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(1-ethyl-5-(phenylmethoxy)methyl)-1H-pyrazol-4-yl]methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-17-4 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(1-ethyl-3-(phenylmethoxy)methyl)-1H-pyrazol-4-yl]methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-18-5 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(1-(1-methylethyl)-3-((phenylmethoxy)methyl)-5-propyl-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-21-0 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(3-ethyl-5-((phenylmethoxy)methyl)-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-22-1 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(1,3-diethyl-5-((phenylmethoxy)methyl)-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-23-2 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(1,5-diethyl-3-((phenylmethoxy)methyl)-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-25-4 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-5-((phenylmethoxy)methyl)-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




L6 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)
 RN 137660-26-5 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-1-ethyl-5-((phenylmethoxy)methyl)-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137660-27-6 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-1-ethyl-3-((phenylmethoxy)methyl)-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137660-28-7 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-1-(1-methylethyl)-5-((phenylmethoxy)methyl)-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137660-29-8 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(5-butyl-1-(1-methylethyl)-3-((phenylmethoxy)methyl)-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137660-30-1 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-1-ethyl-5-(hydroxymethyl)-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137660-31-2 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-5-(hydroxymethyl)-1-(1-methylethyl)-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137660-32-3 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-1-ethyl-5-formyl-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137660-33-4 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-5-formyl-1-(1-methylethyl)-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137660-34-5 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-(1,1-dimethylethoxy)carbonyl)[1,1'-biphenyl]-4-yl)methyl]-1-ethyl-, (9CI) (CA INDEX NAME)




RN 137660-35-6 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(1-(2-methylpropyl)-5-[(phenylmethoxy)methyl]-3-propyl-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-36-7 CAPLUS
 CN 2H-Tetrazole, 5-(4'-(1-(2-methylpropyl)-3-[(phenylmethoxy)methyl]-5-propyl-1H-pyrazol-4-yl)methyl)[1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-37-8 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-(1,1-dimethylethoxy)carbonyl)[1,1'-biphenyl]-4-yl)methyl]-1-(1-methylethyl)- (9CI)



RN 137660-38-9 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(1-(2,2-dimethylpropyl)-3-[(phenylmethoxy)methyl]-5-propyl-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-39-0 CAPLUS
 CN 2H-Tetrazole, 5-[4'-(1-(2,2-dimethylpropyl)-3-[(phenylmethoxy)methyl]-5-propyl-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




09899322

L6 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)

RN 137660-40-3 CAPLUS
CN 2H-Tetrazole,
5-[4'-(3-butyl-5-(methoxymethyl)-1-(2-propenyl)-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-41-4 CAPLUS
CN 2H-Tetrazole,
5-[4'-(5-butyl-3-(methoxymethyl)-1-(2-propenyl)-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137660-42-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(5-butyl-1-methyl-3-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137660-43-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid,
4'-(5-butyl-5-(hydroxymethyl)-1-methyl-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137660-44-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(3-butyl-5-formyl-1-methyl-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137660-45-8 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-(1,1-dimethylethoxy)carbonyl)[1,1'-biphenyl]-4-yl)methyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 137660-48-1 CAPLUS
CN 1H-Pyrazole, 4-[(2'-nitro[1,1'-biphenyl]-4-yl)methyl]-3-[(phenylmethoxy)methyl]-5-propyl- (9CI) (CA INDEX NAME)


L6 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




RN 137660-49-2 CAPLUS
CN 1H-Pyrazole, 3-butyl-4-[(2'-nitro[1,1'-biphenyl]-4-yl)methyl]-5-[(phenylmethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 137660-50-5 CAPLUS
CN 1H-Pyrazole, 1-ethyl-4-[(2'-nitro[1,1'-biphenyl]-4-yl)methyl]-5-[(phenylmethoxy)methyl]-3-propyl- (9CI) (CA INDEX NAME)




RN 137660-51-6 CAPLUS
CN 1H-Pyrazole, 1-ethyl-4-[(2'-nitro[1,1'-biphenyl]-4-yl)methyl]-3-[(phenylmethoxy)methyl]-5-propyl- (9CI) (CA INDEX NAME)




RN 137660-52-7 CAPLUS
CN 1H-Pyrazole, 3-butyl-1-ethyl-4-[(2'-nitro[1,1'-biphenyl]-4-yl)methyl]-5-[(phenylmethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 137660-53-8 CAPLUS
CN 1H-Pyrazole, 5-butyl-1-ethyl-4-[(2'-nitro[1,1'-biphenyl]-4-yl)methyl]-3-[(phenylmethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 137660-54-9 CAPLUS
CN [1,1'-Biphenyl]-2-amine, 4'-{[(1-ethyl-5-[(phenylmethoxy)methyl]-3-propyl-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137660-55-0 CAPLUS
CN [1,1'-Biphenyl]-2-amine,
4'-{[(3-butyl-1-ethyl-5-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137660-57-2 CAPLUS
CN Methanesulfonamide, N-[4'-{[(3-butyl-1-ethyl-5-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137660-56-1 CAPLUS
CN Methanesulfonamide,
N-[4'-{[(1-ethyl-5-[(phenylmethoxy)methyl]-3-propyl-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)]




RN 137681-64-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-{[(5-butyl-1-[(dimethylamino)sulfonyl]-3-(methoxymethyl)-1H-pyrazol-4-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 137681-65-3 CAPLUS
 CN 2H-Tetrazole, 5-[(2-(tert-butoxycarbonyl)phenyl)-4-yl]-3-(4-methoxyphenyl)-1H-pyrazole-1-sulfonamide, 3-butyl-5-(methoxymethyl)-N,N-dimethyl-4-[(2'-(2-(tert-butoxycarbonyl)phenyl)-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 137681-66-4 CAPLUS
 CN 2H-Tetrazole, 5-[(4-[(5-butyl-1-(2-methylpropyl)-3-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl)-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 137681-67-5 CAPLUS
 CN 2H-Tetrazole, 5-[(5-butyl-1-cyclobutyl-3-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl][1,1'-biphenyl]-2-yl]-2-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 137681-68-6 CAPLUS
 CN (1,1'-Biphenyl)-2-carboxylic acid, 4'-(3-butyl-1-methyl-5-[(phenylmethoxy)methyl]-1H-pyrazol-4-yl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1983:488106 CAPLUS
 DOCUMENT NUMBER: 99:88106
 TITLE: Nonsteroidal antiinflammatory agents, XI: Antiphlogistic pyrazole derivatives, III
 AUTHOR(S): Biere, Helmut; Boettcher, Irmgard; Kapp, Joachim
 Friedrich
 CORPORATE SOURCE: Forschungslab., Schering A.-G., Berlin, 1000, Fed. Rep. Ger.
 SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1983), 316 (7), 608-16
 DOCUMENT TYPE: CODEN: ARPMAZ; ISSN: 0365-6233
 LANGUAGE: Journal
 German
 OTHER SOURCE(S): GI
 CASREACT 99:88106




AB The title pyrazoles I (R = CO₂H, CO₂Et, CH₂CO₂H; R₁ = H, F; R₂ = H, Ph, Cl, Me; R₃ = Ph, Me, p-ClC₆H₄, p-ClC₆H₄CH₂, p-ClC₆H₄CO, p-ClC₆H₄CHOH) were prepd. Thus, p-ClC₆H₄COCH₂CHNMe₂ was treated with p-FC₆H₄NNH₂CO₂Et to give 51.4% I (R = CO₂Et, R₁ = F, R₂ = H), which was converted to I (R = CH₂CO₂H, R₁ = F, R₂ = H, R₃ = p-ClC₆H₄CH₂) in 6 steps. I had antiinflammatory activity in rats and structure-activity relationships were discussed.


IT 86768-15-2
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prepn. and antiinflammatory activity of)
 RN 86768-15-2 CAPLUS
 CN 1H-Pyrazole-3-acetic acid, 4-[(4-chlorophenyl)methyl]-1-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

09899322

L6 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




L6 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1981:151890 CAPLUS
 DOCUMENT NUMBER: 94:151890
 TITLE: Pyrazolinone herbicides
 PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 16 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:
 PATENT NO. KIND DATE APPLICATION NO. DATE
 JP 55157504 A2 19801208 JP 1979-64488 19790524 <--
 JP 62009086 B4 19870226
 GI




AB I (R1 = H or alkyl; R2 = alkyl, alkoxy carbonylmethyl, or Ph; R3 = alkyl; R4 = H, acyl, or AC6H4Xn; A = CO or CH2, X = alkyl, alkoxy, halo, or NO2, and n = 0, 1, or 2) or their derivs. are herbicides. Thus, 25-50g 4-(2,4-dichlorobenzoyl)-1,2,3-trimethyl-3-pyrazolin-5-on (77007-26-2)/are controlled Echinochloa crus-galli, Scirpus pyrmaea, Sagittaria, Cyperus serotinus, Eleocharis acicularis, and annual broad-leaf weeds in rice. Synthesis of I is given.
 IT 77007-87-5 77007-88-6P 77007-89-7P
 RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. and herbicidal activity of)
 RN 77007-87-5 CAPLUS
 CN 3H-Pyrazol-3-one, 2,5-diethyl-1,2-dihydro-1-methyl-4-[(2-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)





RN 77007-88-6 CAPLUS
 CN 3H-Pyrazol-3-one, 4-[(4-chlorophenyl)methyl]-5-ethyl-1,2-dihydro-1-phenyl- (9CI) (CA INDEX NAME)




RN 77007-89-7 CAPLUS
 CN 3H-Pyrazol-3-one, 4-[(2,4-dichlorophenyl)methyl]-5-ethyl-1,2-dihydro-1-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)




Kamal Saeed

L6 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1275:16734 CAPLUS
 DOCUMENT NUMBER: 82:16734
 TITLE: Synthesis of pyrazolinone derivatives. XXIII.
 Synthesis of benzo[4,5]cyclohepta[1,2-c]pyrazolininediones
 AUTHOR(S): Ito, Isao; Nagai, Shinichi
 CORPORATE SOURCE: Fac. Pharm. Sci., Nagoya City Univ., Nagoya, Japan
 SOURCE: Chem. Pharm. Bull. (1974), 22(9), 2131-5
 CODEN: CPBTAL
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI: For diagram(s), see printed CA Issue.
 AB: Treatment of Me 4-benzyl-5-oxo-1-phenyl-3-pyrazoline-3-acetate with
 Me2SO4 followed by hydrolysis of the resulting Me 4-benzyl-2-methyl-5-oxo-1-phenyl-3-pyrazoline-3-acetate gave 4-benzyl-2-methyl-5-oxo-1-phenyl-3-pyrazoline-3-acetic acid (I). 1-Methyl-2-phenyl-3,9-dioxo-1,2,3,4,9,10-hexahydrobenzo[4,5]cyclohepta[1,2-c]pyrazole (II, X = O, Y = H2) was prepd. by cyclization of I with polyphosphoric acid. 1-Methyl-2-phenyl-3,4-dioxo-1,2,3,4,9,10-hexahydrobenzo[4,5]cyclohepta[1,2-c]pyrazole (I,
 X = H2, Y = O) was prepd. from 4-bromo-3-bromomethyl-2-methyl-1-phenyl-3-pyrazolin-5-one.
 IT 54813-83-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and cyclization of)
 RN 54813-85-3 CAPLUS
 CN 1H-Pyrazole-3-acetic acid, 2,5-dihydro-2-methyl-5-oxo-1-phenyl-4-(phenylmethyl)- (9CI) (CA INDEX NAME)




IT 54813-84-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and hydrolysis of)
 RN 54813-84-2 CAPLUS
 CN 1H-Pyrazole-3-acetic acid, 2,5-dihydro-2-methyl-5-oxo-1-phenyl-4-(phenylmethyl)-, methyl ester (9CI) (CA INDEX NAME)


L6 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)



IT 54813-82-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and methylation of)
 RN 54813-82-0 CAPLUS
 CN 1H-Pyrazole-3-acetic acid, 2,5-dihydro-5-oxo-1-phenyl-4-(phenylmethyl)-, methyl ester (9CI) (CA INDEX NAME)



IT 54813-83-1P 54813-87-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 54813-83-1 CAPLUS
 CN 1H-Pyrazole-3-acetic acid, 2,5-dihydro-5-oxo-1-phenyl-4-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)



IT 54813-83-1P 54813-87-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 54813-83-1 CAPLUS
 CN 1H-Pyrazole-3-acetic acid, 2,5-dihydro-2-methyl-5-oxo-1-phenyl-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2002 ACS (Continued)

